Akademik Bilgiler



F. RÜÇHAN USLU
PROFESÖR
Tıp Fakültesi
Dahili Tıp Bilimleri Bölümü
İç Hastalıkları Ana Bilim Dalı
Contact Information- E-posta: ruchan.uslu@ege.edu.tr
- Telefon: 0 232 390 39 06, İş Telefonu
- Telefon: 0 232 390 43 87, İş Telefonu
- Telefon: 0 232 374 73 21, Fax
- Web sayfası: http://www.ruchanuslu.net/, Kişisel Web Sayfası
Academic Degree Information- Yüksek Lisans: Ankara Üniversitesi Tıp Fakültesi, Türkiye, 1991
- Doktora: Ege Üniversitesi Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Türkiye, 1997
- Yardımcı Doçentlik: Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, Türkiye, 2000
- Doçentlik: Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, Türkiye, 2003
- Profesörlük: Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı, Türkiye, 2010

Administrative / Academic Duties (12 entries)- İzmir İl Sağlık Müdürlüğü Palyatif Bakım Kooordinasyon Kurulu Üyesi, 2013-
- İmmüno-Onkoloji Derneği Başkanı, 2013-
- Ege Üniversitesi Palyatif Bakım Uygulama ve Araştırma Merkezi Müdürü, 2011-2012
- Ege Üniversitesi Tıp Fakültesi Tıbbi Onkoloji Bilim Dalı Başkanı, 2011-
- Palyatif Bakım Derneği Başkan Yardımcısı, 2011-
- 4. Sınıf Staj Koordinatörlüğü, 2010-2012
- Ege Üniversitesi Tıp Fakültesi Eğitim Komisyonu Üyeliği, 2010-2012
- Staj Planlama Komisyonu Üyeliği, 2009-2011
- Gelişim Sınavı Komitesi Üyesi, 2003-2007
- İç Hastalıkları Ana Bilim Dalı Eğitim Komisyonu Üyeliği, 2000-
- İç Hastalıkları Ana Bilim Dalı Yazılı Sınav Komisyonu Başkanlığı, 2000-2006
- İç Hastalıkları Ana Bilim Dalı Klinik Koordinatörü, 2000-2005
Other Professional Activities (3 entries)- Doktor Dergisi Editörler Kurulu Üyeliği, 2007-2012
- Meme Sağlığı Dergisi Bilimsel Kurul Üyeliği, 2007-In Progress
- Tıp Bilimleri Dergisi Ulusal Danışmanı, 2007-In Progress
Research Interests- İç Hastalıkları (1011113)
- Onkoloji (1011210)
Indexed Journal Publications (102 entries)- Varol U, Yildiz I, Alacacioglu A, Uslu R. Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments. Asian Pac J Cancer Prev. 2014;15(4):1885-1887.
- Oktem G, Bilir A, Uslu R, Inan SV, Demiray SB, Atmaca H, Ayla S, Sercan O, Uysal A. Expression profiling of stem cell signaling alters with spheroid formation in CD133high/CD44high prostate cancer stem cells. Oncol Lett. 2014 Jun;7(6):2103-2109. Epub 2014 Mar 24.
- Varol U, Oktay E, Yildirim M, Surmeli ZG, Dirican A, Meydan N, Karaca B, Karabulut B, Uslu R. Tumor characteristics and metastatic sites may predict bevacizumab efficacy in the first line treatment of metastatic colorectal cancer. Molecular and Clinical Oncology, 2(1), 166-170, 2014.
- Goksel G, Bilir A, Uslu R, Akbulut H, Guven U, Oktem G. WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133+/CD44+ prostate cancer stem cell spheroids. J BUON. 2014 Jan-Mar;19(1):207-14.
- Varol U, Dirican A, Yildiz I, Oktay E, Degirmenci M, Alacacioglu A, Barutca S, Karabulut B, Uslu R. First-line mono-chemotherapy in frail elderly patients with metastatic colorectal cancer. Asian Pac J Cancer Prev. 2014;15(7):3157-61.
- Ozcelik H, Cakmak DE, Fadiloglu C, Yildirim Y, Uslu R. Determining the satisfaction levels of the family members of patients with advanced-stage cancer. Palliat Support Care. 2014 Jun 3:1-7. [Epub ahead of print].
- Oktem G, Sercan O, Guven U, Uslu R, Uysal A, Goksel G, Ayla S, Bilir A. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids. Oncol Rep. 2014 Jun 12. doi: 10.3892/or.2014.3252. [Epub ahead of print].
- Goksel O, Goksel T, Cok G, Karakus H, Bacakoglu F, Goker E, Uslu R, Erdinc M. Hypersensitivity to chemotherapeutics: a cross sectional study with 35 desensitisations. Int J Clin Oncol. 2014 Jul 25. [Epub ahead of print]
- Dirican A, Atmaca H, Bozkurt E, Erten C, Karaca B, Uslu R. Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway. Clin Transl Oncol. 2014 Jul 25. [Epub ahead of print].
- Pivot X, Gligorov J, Müller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; on behalf of the PrefHer Study Group; on behalf of the PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. Ann Oncol. 2014 Jul 28. pii: mdu364. [Epub ahead of print]
- Bayoglu IV, Varol U, Yildiz I, Muslu U, Alacacioglu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Cokmert S, Yildiz Y, Karabulut B, Uslu R, Tarhan MO. Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer. Asian Pac J Cancer Prev. 2014;15(17):7119-23.
- Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U, Uslu R. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract. 2014 Sep 17. pii: 1078155214551315. [Epub ahead of print]
- Varol U, Degirmenci M, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Sanli UA, Uslu R. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour Biol. 2014 Oct 9. [Epub ahead of print].
- Silbermann M, Fink RM, Min SJ, Mancuso MP, Brant J, Hajjar R, Al-Alfi N, Baider L, Turker I, ElShamy K, Ghrayeb I, Al-Jadiry M, Khader K, Kav S, Charalambous H, Uslu R, Kebudi R, Barsela G, Kuruku N, Mutafoglu K, Ozalp-Senel G, Oberman A, Kislev L, Khleif M, Keoppi N, Nestoros S, Abdalla RF, Rassouli M, Morag A, Sabar R, Nimri O, Al-Qadire M, Al-Khalaileh M, Tayyem M, Doumit M, Punjwani R, Rasheed O, Fallatah F, Can G, Ahmed J, Strode D. Evaluating Palliative Care Needs in Middle Eastern Countries. J Palliat Med. 2014 Oct 10. [Epub ahead of print].
- Varol U, Karaca B, Cakar B, Sezgin C, Karabulut B, Uslu R. Comparing Time to Disease Progression of Irinotecan and Oxaliplatin-based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. Am J Clin Oncol. 2013 Aug;36(4):388-91. doi: 10.1097/COC.0b013e318248da7c.
- Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA, Uslu R. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells. Mol Biol Rep. 2013 Jun;40(6):3925-33. doi: 10.1007/s11033-012-2469-z. Epub 2012 Dec 27.
- Arslan C, Uslu R. Secondary haematological malignancies in the BCIRG 001 study. Lancet Oncol. 2013 Mar;14(3):e87-8. doi: 10.1016/S1470-2045(13)70015-9. (Letter)
- Cirak Y, Sarsik B, Cakar B, Sen S, Simsir A, Uslu R. Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score. Med Oncol. 2013 Jun;30(2):526. doi: 10.1007/s12032-013-0526-7. Epub 2013 Mar 9.
- Ergun M, Eyigor S, Karaca B, Kisim A, Uslu R. Effects of exercise on angiogenesis and apoptosis-related molecules, quality of life, fatigue and depression in breast cancer patients. Eur J Cancer Care (Engl). 2013 Jun 3. doi: 10.1111/ecc.12068. [Epub ahead of print].
- Harika Atmaca, Emir Bozkurt, Selim Uzunoglu, Ruchan Uslu, Burcak Karaca. A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells. Toxicol Lett. 2013 Jun 20. doi:pii: S0378-4274(13)01076-X. 10.1016/j.toxlet.2013.06.213. [Epub ahead of print].
- Cakar B, Varol U, Junushova B, Muslu U, Gursoy Oner P, Gokhan Surmeli Z, Cirak Y, Karaca B, Sezgin C, Karabulut B, Uslu R. Evaluation of the efficacy of adjuvant chemotherapy in patients with high-risk stage II colon cancer. J BUON. 2013 Apr-Jun;18(2):372-376.
- Varol U, Cirak Y, Cakar B, Karaca B, Sezgin C, Uslu R, Karabulut B. Survival analysis of metastatic colorectal cancer patients who were treated with the five major therapeutic agents over the course of disease. J BUON. 2013 Jul-Sep;18(3):647-52.
- Korhan EA, Yildirim Y, Uyar M, Eyigör C, Uslu R. Examination of pain experiences of cancer patients in Western Turkey: a phenomenological study. Holist Nurs Pract. 2013 Nov-Dec;27(6):358-65. doi: 10.1097/HNP.0b013e3182a72b76.
- Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Sencan O, Kilickap S, Ozdener F, Cevik D. Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III 'Stop and Go' Study Results - A Turkish Oncology Group Trial. Oncology. 2013 Nov 12;85(6):328-335. [Epub ahead of print]
- Içli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Ustüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Ozkan M, Arican A.Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG). Breast Cancer. 2013 Dec 12. [Epub ahead of print]
- Cakar B, Karaca B, Uslu R. Sexual dysfunction in cancer patients: a review. J BUON. 2013 Oct-Dec;18(4):818-23.
- Varol U, Karaca B, Patır P, Sener A, Zekioglu O, Sanli UA, Uslu R. Association of Rac1 Expression with Trastuzumab Resistance in HER2-Positive Breast Cancer. International Journal of Hematology and Oncology, 23 (4): 219-226, 2013.
- Kisim A, Atmaca H, Cakar B, Karabulut B, Sezgin C, Uzunoglu S, Uslu R, Karaca B. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. J Cancer Res Clin Oncol. 2012 Mar 13. [Epub ahead of print].
- Varol Y, Varol U, Karaca B, Karabulut B, Sezgin C, Uslu R. The Frequency and Significance of Radiologically Detected Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer. Med Princ Pract. 2012 Apr 27. [Epub ahead of print]
- Varol U, Karaca B, Muslu U, Doganay L, Degirmenci M, Uslu R, Goker E. Undifferentiated embryonal sarcoma of the liver in an adult patient: Case report. Turk J Gastroenterol. 2012 Jun;23(3):279-283.
- Cirak Y, Varol U, Atmaca H, Kisim A, Sezgin C, Karabulut B, Uzunoglu S, Uslu R, Karaca B. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU Int. 2012 Dec;110(11 Pt C):E1147-54. doi: 10.1111/j.1464-410X.2012.11392.x. Epub 2012 Aug 9.
- Bozkurt E, Atmaca H, Kisim A, Uzunoglu S, Uslu R, Karaca B. Effects of Thymus serpyllum Extract on Cell Proliferation, Apoptosis and Epigenetic Events in Human Breast Cancer Cells. Nutr Cancer. 2012 Nov;64(8):1245-50. doi: 10.1080/01635581.2012.719658.
- Canfeza Sezgin, Erhan Gokmen, Murat Kapkac, Osman Zekioglu, Mustafa Esassolak, Bulent Karabulut, Ulus Ali Sanli, Ruchan Uslu. p53 Protein Accumulation and Presence of Visceral Metastasis Are Independent Prognostic Factors for Survival in Patients with Metastatic Inflammatory Breast Carcinoma. Medicinal Principles and Practice, 20 (2): 159-64, 2011.
- Raika Durusoy, Burcak Karaca, Bermet Junushova, Ruchan Uslu. Cancer patients' satisfaction with doctors and preferences about death in a university hospital in Turkey. Patient Education and Counseling, 85(3): e285-90, 2011.
- Cakar B, Muslu U, Karaca B, Junushova B, Uslu R, Goker E. Alveolar rhabdomyosarcoma originating from the uterine cervix. European Journal Of Gynaecological Oncology, 32 (2): 196-198, 2011.
- Selim Uzunoglu, Burçak Karaca, Harika Atmaca, Aslı Kisim, Bulent Karabulut, Ruchan Uslu. Targeting Bcl-2 Protein to Enhance Chemosensitivity of Hormone Refractory Prostate Cancer Cell Line, DU-145 by a Synergistic Combination of Docetaxel and Gossypol. Turkiye Klinikleri J Med Sci, 31(4):859-66, 2011.
- Yildirim Y, Tokem Y, Bozkurt N, Fadiloglu C, Uyar M, Uslu R. Reliability and validity of the Turkish version of the memorial symptom assessment scale in cancer patients. Asian Pac J Cancer Prev. 2011;12(12):3389-96.
- Selim Uzunoglu, Burcak Karaca, Harika Atmaca, Asli Kisim, Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu. Comparison of XTT and Alamar blue assays in the assessment of the viability of various human cancer cell lines by AT-101 (-/- gossypol). Toxicology Mechanisms and Methods, 2010: 20(8): 482–486
- Ruchan Uslu, Murat Kapkac, Burcak Karaca, Hakan Çamyar, Raika Durusoy, Necmettin Özdemir, Arif B. Aras, Aysenur Oktay, Hayal Ozkilic, Rasih Yilmaz. Screening for metastasis in primary breast cancer patients having four or more axillary lymph node involvement: is it really necessary? Journal of B.U.ON, 15: 561-567, 2010
- Eyigor C, Karaca B, Kuzeyli-Yildirim Y, Uslu R, Uyar M, Coker A. Does the tumor localization in advanced pancreatic cancer have an influence on the management of symptoms and pain? Journal of B.U.ON, 15(3): 543-6, 2010.
- Yüksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Cigdem Erten, Burcak Karaca, M. Kemal Gul, Bulent Karabulut, Ulus A. Sanlı, Ruchan Uslu. Bisphosphonate (Zoledronic Acid) Associated Adverse Events: Single Center Experience. International Journal of Hematology and Oncology, 20 (3): 135-140, 2010.
- Bulent Karabulut, Burcak Karaca, Umut Varol, Ugur Muslu, Burcu Cakar, Harika Atmaca, Asli Kisim, Selim Uzunoglu and Ruchan Uslu. Enhancing cytotoxic and apoptotic effect in OVCAR-3 and MDAH-2774 cells with all-trans retinoic acid and zoledronic acid: a paradigm of synergistic molecular targeting treatment for ovarian cancer. Journal of Experimental & Clinical Cancer Research 2010, Jul 30:29:102.
- Ozlem Akagunduz, Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus Ali Sanli, Ayfer Haydaroglu, Ruchan Uslu. Radiosensitization of Hormone-Refractory Prostate Cancer Cells by Gossypol Treatment. Journal of B.U.ON, 15(4): 763-767, 2010.
- Duygu Unuvar Purcu, Burcak Karaca, Murat Kapkac, Necmettin Ozdemir, Selim Uzunoglu, Ruchan Uslu. High-Resolution Melting Analysis for Screening of Turkish Germline Mutations in BRCA1 and BRCA2. International Journal of Hematology and Oncology, 20 (4): 235-240, 2010.
- Eyigor S, Karapolat H, Yesil H, Uslu R, Durmaz B. Effects of pilates exercises on functional capacity, flexibility, fatigue, depression and quality of life in female breast cancer patients: a randomized controlled study. Eur J Phys Rehabil Med. Dec: 46 (4): 481-7, 2010.
- Bulent Karabulut, Burcak Karaca, Harika Atmaca, Asli Kisim, Selim Uzunoglu, Canfeza Sezgin, Ruchan Uslu. Regulation of Apoptosis- Related Molecules by Synergistic Combination of All-Trans Retinoic Acid (ATRA) and Zoledronic Acid in Hormone-Refractory Prostate Cancer Cell Lines. Molecular Biology Reports, 2011 Jan: 38(1):249-59, Mar 28, 2010 [Epub ahead of print].
- Yüksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Bulent Karabulut, Canfeza Sezgin, Harika Atmaca, Ulus A. Sanlı, Selim Uzunoglu, Ruchan Uslu. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone-and drug-refractory prostate cancer cells Journal of International Medical Research, 2010.
- Eyigor S, Karapolat H, Korkmaz OK, Eyigor C, Durmaz B, Uslu R, Uyar M. The frequency of fibromyalgia syndrome and quality of life in hospitalized cancer patients. Eur J Cancer Care (Engl). 2009 Mar:18(2):195-201.
- Ercument Cengiz, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Mustafa K. Gul, Cigdem Erten, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Overcoming drug resistance in hormone-and drug refractory prostate cancer cell line, PC-3 by a synergistic combination of docetaxel and gossypol. Mol Biol Rep, 2009 Mar 14. [Epub ahead of print]
- Yasemin Yildirim, Ozen Onen Sertoz, Meltem Uyar, Cicek Fadiloglu, Ruchan Uslu. Hopelessness in Turkish cancer inpatients: The relation of hopelessness with psychological and disease-related outcomes. European Journal of Oncology Nursing 2009 Apr:13(2):81-6. Epub 2009 Feb 26.
- Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int. 2009 Feb:33(2):239-46. Epub 2008 Dec 11.
- Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Medical Oncology, 2009 Jun 13. [Epub ahead of print]
- Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca*, Selim Uzunoglu*, Bulent Karabulut, Ulus A. Sanli and Ruchan Uslu. Regulation of growth factors in hormone and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. BJU Int 2009 104 (1): 107-114.
- Demirci S, Yildirim YK, Ozsaran Z, Uslu R, Yalman D, Aras AB. Evaluation of burnout syndrome in oncology employees. Medical Oncology, Sep 26. [Epub ahead of print] 2009.
- Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line, MCF-7. J BUON. 2009 Jul-Sep:14(3):479-85.
- Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Purcu DU, Uzunoglu S, Karabulut B, Sanli UA, Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw. 2009 Sep:20(3):121-30.
- Sanli UA, Gorumlu G, Erten C, Gul MK, Cengiz E, Kucukzeybek Y, Karaca B, Atmaca H, Uzunoglu S, Karabulut B, Uslu R. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biol Int. 2009 Nov:33(11):1165-72. Epub 2009 Aug 28.
- U. Varol, B. Karaca, D. Tunali, M. Degirmenci, Y. Cirak, D.U. Purcu, S. Uzunoglu, C. Sezgin, B. Karabulut, U. A Sanli, R. Uslu. The effect of racemic gossypol and AT-101 on angiogenic profile of ovcar-3 cells: a preliminary molecular framework for gossypol enantiomers. Experimental Oncology, Dec: 31(4): 220-225, 2009.
- Yurekli B, Karaca B, Cetinkalp S, Saygili F, Uslu R. .Can gossypol be a hope for transsexual patients (male to female) before sex reassignment surgery? Just for adjusting the body to mind. Medical Hypotheses, Oct: 73(4): 625-6, Epub 2009 Aug 3, 2009.
- Yurekli BS, Karaca B, Cetinkalp S, Uslu R. Is it the time for metformin to take place in adjuvant treatment of Her-2 positive breast cancer? Teaching new tricks to old dogs. Medical Hypotheses, Oct: 73(4): 606-7. Epub 2009 Jun 27, 2009.
- S. Eyigor, H. Karapolat, O.K. Korkmaz, R. Uslu. The level of satisfaction in cancer patients with completed treatments: A 7-year screening. Journal of B.U.ON 14: 681-687, 2009.
- Yüksel KÜÇÜKZEYBEK, Gürbüz GÖRÜMLÜ, Şaziye BURÇAK KARACA, Ali Can KAZANDI, Bülent KARABULUT, Rüçhan USLU, Ulus Ali ŞANLI, Erdem GÖKER. Trastuzumab Induced Maculopapular Skin Reactions Localized on the Left Forearm and Arm: A Case Report. Turkiye Klinikleri J Med Sci,29(6):1743-6, 2009.
- Eyigor S, Eyigor C, Uslu R. Assessment of pain, fatigue, sleep and quality of life (QoL) in elderly hospitalized cancer patients. Archives of Gerontology and Geriatrics, , Nov-Dec:51(3):e57-61, 2010. Epub Dec 30, 2009.
- Saydam BK, Goksel G, Korkmaz E, Kapkac M, Ozdemir N, Sezgin C, Uslu R. Comparison of the clinical and pathological features between patients with recurrent metastatic breast carcinoma and patients with initially metastatic breast carcinoma. Saudi Med J. (C), 2008 Jan:29(1):81-6.
- Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R, Sanli UA, Goker E.Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer. J BUON. 2008 Apr-Jun:13(2):199-203.
- Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA and Uslu R. Enhancement of Docetaxel-Induced Cytotoxicity and Apoptosis by All-Trans Retinoic Acid (ATRA) Through Downregulation of Survivin (Birc5), Mcl-1 and Ltbeta-R in Hormone- and Drug Resistant Prostate Cancer Cell Line, DU145. J Exp & Clin Cancer Res 2008 Sep 12:27(1):37
- Saydam BK, Goksel G, Korkmaz E, Zekioglu O, Kapkac M, Sanli UA, Uslu R, Sezgin C. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey. Med Princ Pract (C) 2008:17(6):475-80. Epub 2008 Oct 3.
- Gorumlu G, Kucukzeybek Y, Kemal Gul M, Karaca B, Terek M. Cosan, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R. Pegylated liposomal doxorubucin in heavily pretreated epithelial ovarian cancer patients. J BUON 2008 13:349-352.
- Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, Atmaca H, Uzunoglu S, Sanli UA, Karabulut B, Uslu R. Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. Eur Cytokine Netw. 2008 Dec:19(4):176-84.
- Goksel G, Taneli F, Uslu R, Ulman C, Dinc G, Coskun T, Kandiloglu AR. Serum her-2/neu and survivin levels and their relationship to histological parameters in early-stage breast cancer. J Int Med Res. 2007 Mar-Apr:35(2):165-72.
- Terek, MC: Karabulut, B: Selvi, N: Akman, L: Karasulu, Y: Ozguney, I: Sanli, AU: Uslu, R: Ozsaran, A. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 16 (2): 532-537 Mar-Apr 2006.
- Sanli UA, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Med Princ Pract. 2006:15(4):288-92.
- N. Askar, T. Cırpan, E. Toprak, B. Karabulut, N. Selvı, M.C. Terek, R. Uslu, U.A. Sanlı & E. Goker. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. International Journal of Gynecological Cancer 2006 Jul-Aug:16(4):1552-6.
- Ruchan Uslu, Ulus A. Sanli, Yilmaz Dikmen, Bulent Karabulut, Aydin Ozsaran, Canfeza Sezgin, Gamze G. Muezzinoglu, Serdar B Omay SB, Erdem Goker. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. International Journal of Gynecologic Cancer 15:240-245, 2005.
- Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Osman Zekioglu, Necmettin Ozdemir, Erdem Goker. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. Journal of Chemotherapy Feb:17(1):96-103, 2005.
- Karabulut B, Sezgin C, Terek MC, Uslu R, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Goker E.Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy. 2005 Oct:51(6):347-51. Epub 2005 Oct 14.
- Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus A Sanli, Gamze Goksel, Yildiray Yuzer, Erdem Goker. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology 2005
- Uslu R, Uyar M. Cancer and palliative care. Agri Jul:17(3):5-10, 2005
- Gülperi Öktem, Bulent Karabulut, Nur Selvi, Canfeza Sezgin, Ulus Ali Sanli, Ruchan Uslu, Mine Ertem Yurtseven, Serdar Bedii Omay. Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research 14: 381-386, 2004.
- Erdem Goker, Ulus Ali Sanli, Yildiray Yüzer, Ruchan Uslu, Bulent Karabulut, Ahmet Memis, Ahmet Coker, Ali Mentes. Bioembolisation for Unresectable Hepatocellular Carcinoma: Preliminary Results of a Translational Research Study. Journal of Experimental& Clinical Cancer Research 23: 403-409, 2004.
- Sezgin VC, Sanli UA, Karabulut B, Uslu R, Muezzinoglu GG, Ozdemir N, Goker E. Capecitabine (X) monotherapy in patients (pts) with pretreated metastatic breast cancer (MBC): Is response correlated to cerbB-2 expression? JOURNAL OF CLINICAL ONCOLOGY 22 (14): 66S-66S 760 Suppl. S, JUL 15 2004.
- Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Nur Selvi, Hakan H. Aydin, Guray Saydam, Erdem Goker, Serdar B. Omay. Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncology Reports Nov-Dec:10(6):2083-8, 2003.
- Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, Omay SB. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res 2002 Apr:26(4):391-398.
- Zuhal Parildar, Ruchan Uslu, Tijen Tanyalcin, Eker Doganavsargil, Fatma Kutay. The urinary excretion of glycosaminoglycans and heparan sulphate in lupus nephritis. Clinical Rheumatology Aug: 21(4): 284-8, 2002.
- Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Guray Saydam, Serdar Bedii Omay, Erdem Goker. Which dosing scheme is suitable for the taxanes? An in vitro model. Archives of Pharmacal Research Aug:25(4):550-5, 2002.
- Cag Cal, Ruchan Uslu, Gurhan Gunaydin, Ceyhun Ozyurt, S. Bedii Omay. Doxazosin: A New Cytotoxic Agent for Prostate Cancer ? British Journal of Urology Int., 85 (6): 672-675, 2000.
- H. Hakan Aydin, Nur Selvi, Güray Saydam, Mahmut Tobu, Selim Uzunoglu, Ruchan Uslu, Filiz Buyukkececi, Serdar B. Omay. Upregulation of serine/threonine protein phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukemic HL-60 cells. Clinical and Labaratory Haematology Oct: 22 (5): 271-274, 2000.
- G. Saydam, S. Yüksel, M. Töbü, R. Uslu, E. Terzioğlu, F. Büyükkeçeci, S. B. Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Blood 96:11, 141b, 2000.
- Ruchan Uslu, Ulus A. Sanli, Canfeza Sezgin, Bulent Karabulut, Serdar B. Omay, Erdem Goker. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clinical Cancer Research 6: 4957-4964, 2000.
- Ulus Ali Sanli, Ruchan Uslu, Canfeza Sezgin, Bulent Karabulut, Erdem Goker. Docetaxel: A First Choice in the Management of Anthracycline-Resistant Metastatic Breast Cancer. Journal of B.U.O.N, 5: 399-403,2000.
- Selim Uzunoglu, Ruchan Uslu, Mahmut Tobu, Guray Saydam, Ender Terzioglu, Filiz Buyukkececi, Serdar Bedii Omay. Augmentation of methylprednisolone-induced differentiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. Leukemia Research,23(5): 507-512, 1999.
- Serdar B. Omay, Mahmut Tobu, Guray Saydam , Selim Uzunoglu , Nur Selvi, Hakan H. Aydin, Ruchan Uslu , Safak Yuksel , Filiz Buyukkececi. Methylprednisolone-induced differentiation of myeloid leukemia cells is enhanced by calcineurin inhibitors. BLOOD, 94: (10) 4064 , Part 2, Suppl. 1 NOV 15 1999.
- Ruchan Uslu, Canfeza Sezgin, Bulent Karabulut , Ulus A. Sanli, Mahmut Tobu, Guray Saydam, Filiz Buyukkececi, Serdar B. Omay, Erdem Goker . Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines. CLINICAL CANCER RESEARCH, 5: 271 , Suppl. S NOV 1999.
- Ruchan Uslu, Aydi Ozsaran, Ulus A. Sanli, Yilmaz Dikmen, Ege N. T. Goker, Erdem Goker. The effect of Taxol treatment on serum interleukin-8 (IL-8) levels in patients with ovarian carcinoma. CLINICAL CANCER RESEARCH, 5: 394 , Suppl. S NOV 1999.
- Ender Terzioglu, Cengiz Kirmaz, Ruchan Uslu, Aytül Sin, Ali Kokuludag, Hayriye Uzuner, Filiz Sebik and Tomris Kabakci. Superior vena cava syndrome together with multiple venous thrombosis in Behcet's Disease (A case report). Clinical Rheumatology , 17 (2): 176-177, 1998.
- Benjamin Bonavida, Jeff Safrit, Hideki Morimoto, Yoichi Mizutani, Ruchan Uslu, Nicolo Borsellino, Patrick Frost, Jonathan Berek, Arie Belldegrun, Jacob Zighelboim, Chuen Pei Ng and Shunsuke Mori. Cross-resistance of tumor cells to chemotherapy and immunotherapy: approaches to reverse resistance and implications in gene therapy (review). Oncology Reports, 4: 201-205, 1997.
- Ruchan Uslu, Nicolo Borsellino, Patrick Frost, Hermes Garban, Chuen-Pei Ng, Yoichi Mizutani, Arie Belldegrun and Benjamin Bonavida. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis. Clinical Cancer Research, 3: 963-972, 1997.
- Patrick Frost , Ruchan Uslu , Arie Belldegrun , Benjamin Bonavida . Chemosensitization of human prostate carcinoma cell lines to Fas-mediated cytotoxicity by TIL. Journal of Allergy and Clinical Immunology. 99: (1) 1816-1816, Part 2, Suppl. S JAN 1997.
- Patrick Frost , Ruchan Uslu, Arie Belldegrun , Benjamin Bonavida . CD4 T cell mediated apoptosis of melanoma cells does not involve Fas CD95 pathways. Journal of Allergy and Clinical Immunology. 99: (1) 1817-1817, Part 2, Suppl. S JAN 1997.
- Ruchan Uslu and Benjamin Bonavida. Involvement of the mitochondrion respiratory chain in the synergy achieved by treatment of human ovarian carcinoma cell lines with both Tumor Necrosis-a and Cis-Diamminedichloroplatinum. Cancer, 77: 725-732, 1996.
- Ruchan Uslu, Anaheid Jewett, and Benjamin Bonavida. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-Fas antibody-mediated cytotoxicity and apoptosis. Gynecologic Oncology, 62:282-291, 1996.
- Ruchan Uslu and Benjamin Bonavida. Free radicals dependent and independent pathways of CDDP-mediated cytotoxicity and apoptosis in ovarian tumor cell lines. International Journal of Oncology, 6: 1003-1009, 1995.

Publications in Non-Indexed Journals (38 entries)- Derya Hopancı Bıçaklı, Rüçhan Uslu. Kanser kaşeksisi ve nütrisyonel destek. Türk Onkoloji Dergisi, 2012 (yayın için kabul edildi).
- Derya Hopancı Bıçaklı, Rüçhan Uslu. Likopen ve Kanser. Türk Onkoloji Dergisi, 27 (2): 93-97, 2012.
- Pınar Gürsoy, Rüçhan Uslu. Palyatif Bakım Kavramı: Nerede, Nasıl, Ne Zaman, Kimlerle? (The Concept of Palliative Care: Where, How, When, with Who?) Turkiye Klinikleri J Anest Reanim-Special Topics 2012;5(2):69-74.
- Aslı Kısım, Burçak Karaca, Harika Atmaca, Duygu Ünüvar Purcu, Selim Uzunoğlu, Rüçhan Uslu. Türk meme kanseri hastalarında ve normal meme dokusu örneklerinde FGFR2 gen polimorfizminin belirlenmesi. Meme Sağlığı Dergisi, 7 (1): 34-39, 2011.
- Derya Hopancı Bıçaklı, Rüçhan Uslu. Çinko-selenyum ve kanser. Doktor 61: 84-88, 2011.
- Püsem PATIR, Can KARACA, Burçak KARACA, Taner AKALIN, Rüçhan Uslu. Clear cell sarcoma orginating from the sole of right foot which is in deep settling: presentation of a rare entity. Türk Onkoloji Dergisi, 25(1):33-36, Mart 2010.
- Yüksel Küçükzeybek, Bülent Karabulut, Halit Yetiş, Rüçhan Uslu, Ulus A. Sanli, Adam Uslu, Cengiz Demir, Erdem Göker. Fluorouracil and folinic acid bolus Schedule (nordic regimen) combined with irinotecan as first-line chemotherapy in metastatic colcorectal cancer. Eastern Journal of Medicine, 15(1):7-14, Jan-March 2010.
- Layka Abbasi Asbagh, Aslı Deniz, Selim Uzunoğlu, Rüçhan Uslu. Translational Perspective of Mathematical Models Used in The Assessment Of Cellular Synergy in Cytotoxicity Assays. C.B.Ü. Fen Bilimleri Dergisi. 2008 Cilt 4 (1). sh. 127 –134, 2008.
- Özden DEDELİ, Çiçek FADILOĞLU, Rüçhan USLU. Kanserli bireylerin fonksiyonel durumları ve algıladıkları sosyal desteğin incelenmesi. Türk Onkoloji Dergisi 2008:23(3):132-139.
- Sibel Eyigor, Hale Karapolat, Hilal Adanur, Yasemin Kuzeyli, Ruchan Uslu, Berrin Durmaz. Rehabilitasyon Açısından Meme Kanserli Hastalarda Yorgunluk, Depresyon, Cinsel Sorunlar ve Yaşam Kalitesi. Romatoloji ve Tıbbi Rehabilitasyon Dergisi 19 (2): 87-90, 2008.
- Eyigör, S, H. Karapolat, O.K. Korkmaz, R. Uslu ve B. Durmaz, “Hastanede Yatan Kanser Hastalarının Birincil Bakıcılarının Yaşam Kalitesi, Anksiyete ve Depresyon Durumu, İzmir Tepecik Hast. Dergisi 17, 163-168, 2007.
- Ercüment Cengiz, Rüçhan Uslu. Kolorektal Kanserlerde Gen mutasyonları ve Tümör Biyolojisi. Doktor 37: 58-62, 2007.
- Burçak Karaca, Rüçhan Uslu. Kolorektal Kanserlerde Metastazlara Yaklaşım. Doktor 37: 68-72, 2007.
- Yüksel Küçükzeybek, Rüçhan Uslu. Baş-Boyun Kanserlerinde Hedefe Yönelik Tedaviler. Doktor 41: 106-107, 2007.
- Burçak Karaca, Rüçhan Uslu. Kanser Ağrısı Nedenleri ve Onkolojik Bakış Açısı. Hipokrat 16: 3–6, 2007.
- Sibel Eyigör, Hale Karapolat, Onur Korkmaz, Can Eyigör, Rüçhan Uslu, Berrin Durmaz, Meltem Uyar. Frequency of fibromyalgia syndrome and effects of the pain distribution on the quality of life in hospiatlized cancer patients. Romatizma 22 (4): 126–131, 2007.
- Eyigör, S, H. Karapolat, O. K. Korkmaz, R. Uslu, M. Uyar ve B. Durmaz “Tedavisi Tamamlanmış Kanser Hastalarında Memnuniyet Düzeyi ve Rehabilitasyon Yaklaşımı: 5 Yıllık Tarama, Romatoloji ve Tıbbi Rehabilitasyon Dergisi 18, 139-143, 2007.
- Burçak Karaca, Rüçhan Uslu. Postmenapozal Meme Kanserinde Adjuvan Hormonoterapi Kullanımı. Doktor 33: 76-80, 2006.
- Yüksel Küçükzeybek, Ercüment Cengiz, Bülent Karabulut, Murat Sezak, Çağ Çal, Rüçhan Uslu. Urakus Adenokarsinomu: Bir Olgu Ve Literatürün Gözden Geçirilmesi. Türk Hematoloji Onkoloji Dergisi 16 (4): 205–210, 2006.
- Bülent Karabulut, Veliddin C. Sezgin, Gamze Göksel, Ulus A Şanlı, Rüçhan Uslu, Erdem Göker. Yüksek Riskli Malign Melanomun Adjuvan Tedavisinde Orta Yüksek Doz İnterferon Alfa-2B Tedavisinin Etkinliği ve Tolerabilitesi. Türk Hematoloji Onkoloji Dergisi 1 (15): 6-14, 2005
- Veliddin C. Sezgin, Bülent Karabulut, Rüçhan Uslu, Ulus A Şanlı, Erdem Göker. Daha önceden antrasiklin ve taksan tedavisi almış metastatik meme kanserli hastalarda gemsitabin tedavisi. Türk Hematoloji Onkoloji Dergisi 2 (15): 68-72, 2005.
- Bülent Alkan, Bülent Karabulut, Veliddin C. Sezgin, Rüçhan Uslu, Ulus A Şanlı Necmettin Özdemir, Erdem Göker. Adjuvant Kemoterapi Uygulanmış Meme Kanserli Hastalarda Prognostik Faktörler. Türk Hematoloji Onkoloji Dergisi 14 (3): 99-104, 2004.
- Bülent Karabulut, Fatih Kırçelli, Veliddin C. Sezgin, Gamze G. Müezzinoğlu, Ulus A Şanlı, Rüçhan Uslu, Erhan Gökmen, Erdem Göker. Kemoterapi Sonrasında Gelişen Nekrotizan Miyofasiitis: Olgu Sunumu. Türk Hematoloji Onkoloji Dergisi 14 (2): 99-104, 2004.
- Bülent Karabulut, V. Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker, Necmettin Özdemir, Selahattin Sanal. Meme kanserinde c-ErBb-2 ekspresyonu ve diğer prognostik faktörler ile ilişki var mı?. Ege Tıp Dergisi, 42 (3): 161-165, 2003.
- V. Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker, Selahattin Sanal, Necmettin Özdemir. Meme kanserinde Ki-67 ekspresyonu ve diğer prognostik faktörler ile ilişkisi. Ege Tıp Dergisi, 42 (3): 173-177, 2003.
- Canfeza Sezgin, Ulus Ali Şanlı, Bülent Karabulut, Rüçhan Uslu, Gamza G. Müezzinoğlu, Erdem Göker, Necmettin Özdemir. Metastatik Meme Kanserinin tedavisinde Capecitabine: Etkinlik ve Toksisite Türk Hematoloji Onkoloji Dergisi 4 (13): 200-206, 2003.
- Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker. Arsenic Trioxide has Additive Cytotoxic Effect on MCF-7 Breast Cancer Cell Line With Taxanes.Turkish Journal of Medical Sciences, Volume 32, Issue 6, 2002.
- Ulus Ali Şanlı, Bülent Karabulut, Fatih tekin, V. Canfeza Sezgin, Güray saydam, Gamze Göksel Müezzinoğlu, Fahri Şahin, Rüçhan Uslu, Erdem Göker. Mide karsinomu seyrinde eozinofili: Olgu sunumu. Türk Hematoloji-Onkoloji Dergisi, Cilt: 12, Sayı: 4, Sayfa: 206-209, 2002.
- Rüçhan Uslu, Cem Cengiz, Ulus Ali Şanlı, V. Canfeza Sezgin, Güray Saydam, Bülent Karabulut, Funda Yılmaz, Gül Yüce, Tankut İlter, Serdar Bedii Omay, Erdem Göker. Hepatosellüler kanser tanısı konmuş hastalarda P53 mutasyonu sıklığı ve klinikopatolojik korelasyon. Türk Hematoloji-Onkoloji Dergisi, Cilt: 11, Sayı: 2, Sayfa: 82-87, 2001.
- Bülent Karabulut, Güray Saydam, Mustafa Özmen, Ulus ali Şanlı, Canfeza Sezgin, Mine Hekimgil, Rüçhan Uslu, Erdem Göker, Filiz Büyükkeçeci. Meme kanseri ve kronik lenfositik löseminin birlikte görülmesi: Olgu sunumu. Türk Hematoloji-Onkoloji Dergisi, Cilt: 11, Sayı: 2, Sayfa: 91-94, 2001.
- Rüçhan Uslu, Taylan Kabalak. Endokrinolojide uyarı ve süpresyon testleri. Akademi 2-4: 86-100, 2000.
- Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker. Kolorektal Kanserlerde Kemoterapi. Hematoloji-Onkoloji Güncel Derleme Dergisi, 2(2): 127-132, 2000.
- Ulus A. Şanlı, Rüçhan Uslu, Erdem Göker. Nükleozid Analogları. Hematoloji-Onkoloji Güncel Derleme Dergisi, 2: 122-135, 1999.
- Rüçhan Uslu, Güray Saydam, Tomris Kabakçı. Tümör İmmünoterapisi. Klinik Bilimler & Doktor Dergisi. 3(2): 166-169, 1997
- Güray Saydam, Rüçhan Uslu, Ercan Ok, Gürhun Atabay. Kas yıkımına bağlı akut böbrek yetmezliği. Klinik Bilimler & Doktor Dergisi, 3(6): 823-826, 1997.
- Rüçhan Uslu, Aytül Sin, Tomris Kabakçı. İntravenöz İmmünglobülin Tedavisi ve Etki Mekanizmaları. İlaç ve Tedavi Dergisi 9(7):411-417, 1996.
- Rüçhan Uslu, Güray Saydam, Tomris Kabakçı. Tümör İmmünolojisi. Medikal Network, Klinik Bilimler 2(9): 196-201, 1996.
- Güray Saydam, Rüçhan Uslu, Gürhun Atabay. P Glikoprotein. Medikal Network, Klinik Bilimler 2(9):203-207, 1996

International Conference Proceedings (83 entries)- Suayib Yalcin, Ruchan Uslu, Faysal Dane, Ugur Yilmaz, Nurullah Zengin, Evin Buyukunal, Suleyman Buyukberber, Celalettin Camci, Orhan Sencan, Saadettin Kilickap, Fatih Ozdener and Duygu Cevik. Bevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study. Journal of Clinical Oncology, 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 30, No 15_suppl (May 20 Supplement), 2012: 3565.
- Hopanci Bicakli D., Cakar B., Yılmaz M., Karaca B., Durusoy R., Uyar M., Uslu R. Nutritional Behavior Can Prevent Metabolic Synrome In Breast Cancer Patients. ESPEN September 2012 Barcelona- Spain. Clinical Nutrition Supp. 2012:7(1):155.
- Burcak Karaca, Harika Atmaca, Aslı Kısım, Emir Bozkurt, Burcu Çakar, Zeki Surmeli, Pinar Gursoy, Bulent Karabulut, Selım Uzunoglu, Canfeza Sezgın, Ruchan Uslu. Comparison of a novel, label-free, and real-time cell based system (xCELLigence) with a conventional viability assay (XTT) to determine the anti-proliferative effect of AT-101 in human breast cancer cells. IMPAKT Breast Cancer Conference 2012, Brussels, Belgium, 3-5 May, 2012.
- Zeki Surmeli, Pınar Gursoy, Burcu Cakar, Aslı Kısım, Harika Atmaca, Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Burcak Karaca. Zoledronic Acid in Combination with Serine/Threonine Phosphatase Inhibitors Induces Cytotoxicity and Apoptosis in Human Breast Cancer Cells via Decreasing the Activities of PP1 and PP2A. IMPAKT Breast Cancer Conference 2012, Brussels, Belgium, 3-5 May, 2012.
- Hopanci Bicakli D., Cakar B., Yetiz D., Uyar M., Uslu R. Malignant Ascites May Cause Underestimation Of Malnutrition In Palliative Care Patients. ESPEN September 2012 Barcelona-Spain. Clinical Nutrition Supp.2012:7(1):77.
- Burcak Karaca, Ugur Muslu, Zeki Surmeli, Burcu Cakar, Harika Atmaca, Aslı Kısm, Canfeza Sezgin, Selim Uzunoglu, Bulent Karabulut, Ruchan Uslu. Octreotide in Combination with Docetaxel Triggers Apoptosis by Inducing SSTR2 and SSTR5 Levels in Human Breast Cancer Cells, MCF-7 and MDA-MB-231. IMPAKT Breast Cancer Conference 2012, Brussels, Belgium, 3-5 May, 2012.
- Sertoz, Ozen Onen; Avci, Aysel; Uslu, Ruchan. Building A Psyco-Oncology Unit At A Cancer Center. Is This Really One Of The Ways To Break The Stigma Related To Psychiatric Care Among Cancer Patients? COSA 39th Annual Scientific Meeting and IPOS 14th World Congress of Psycho-Oncology 13-15 Nov 2012, Brisbane, Australia. Asia-Pacific Journal Of Clinical Oncology 8 SI (3): 255-256, Meeting Abstract: 512, NOV 2012.
- O Abulkhair, R Uslu, C Sezgin, S Büyükberber, T Darwish, A Isikdogan, M Gumus, F Dane, A Sevinc, H Halawani, D Uncu, N Marrero, J Tobler, C Soares, S Landis, E Moraes, R Gidekel, S Santillana, P Nunez, S Cagnolati, and JG Rodriguez. Clinical outcomes among ErbB2+ MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study). Thirty-Fifth Annual CTRC-AACR San Antonio Breast Cancer Symposium-- Dec 4-8, 2012; San Antonio, TX. Cancer Res 2012;72 (24 Suppl):Abstract nr OT1-1-08.
- Yalcin S, Uslu R, Dane F, Yilmaz U, Zengin N, Buyukunal E, Buyukberber S, Camci C, Akbulut H, Kılıckap S. A randomized, multicentre phase III trial of bevacizumab + capecitabine as maintenance treatment after initial treatment with bevacizumab + XELOX in previously untreated metastatic colorectal cancer. 2011 Gastrointestinal Cancers Symposium, Proceedings, Abstract No: 474, San Fransico, CA/USA, Jan 20-22, 2011.
- F. Icli, K. Altundag, U. Coskun, S. Paydas, G. Basaran, P. Saip, G. G. Dogu, Y. Eralp, R. Uslu, A. Sevinc, H. Onur, N. M. Mandel, C. Sezgin, M. Altinbas, N. Guler, A. Isikdogan, E. Gokmen, K. Uygun, Z. Ustuner, A. Yaren. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group. ASCO 2011, June 3-7, 2011, Chicago, Illinois, J Clin Oncol 29: 2011 (suppl; abstr 629).
- S. Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Buyukunal, S. Buyukberber, C. Camci, O. Sencan, S. Kilickap. Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trial. ASCO 2011, June 3-7, 2011, Chicago, Illinois, J Clin Oncol 29: 2011 (suppl; abstr 3579).
- D. Hopanci Bicakli, B. Cakar, B. Güler, M. Uyar, R. Uslu. Nutritional evaluation in palliative care patients with malignancy: a single instituon experience from Turkey. 33rd ESPEN Congress, Clinical Nutrition (Supp) 6: Abst. No: PP138-SUN, Gothenburg, Sweden, 3-6 September, 2011.
- Harika Atmaca, Burcak Karaca, Asli Kisim, Selim Uzunoğlu, Ruchan Uslu. Expression profiling of apoptotic proteins in human breast cancer cells treated with AT-101 by protein array technology. European Biotechnology Congress, Current Opinion In Biotechnology 22 (Supp: 1), Pages: S123-S123, Istanbul, TURKEY, Sep 28-Oct 01, 2011.
- Bozkurt E, Atmaca H, Karaca B, Kısım A, Uzunoğlu S, Uslu R. Preliminary Study of the Thyme (Thymus serpyllum) Extract On Human Normal and Breast Cancer Cells. EACR-Anticancer Agents Research Congress, P: 3 Antalya, Turkey, 13-16 September, 2011.
- Kısım A, Atmaca H, Bozkurt E, Muslu U, Çakar B, Uzunoğlu S, Sezgin C, Karabulut B, Uslu R, Karaca B. Synergistic Cytotoxic/ Apoptotic Effects Of Octreotide In Combination With Docetaxel In Human Breast Cancer Cells. EACR-Anticancer Agents Research Congress, P: 35, Antalya, Turkey, 13-16 September, 2011.
- Atmaca H, Kısım A, Bozkurt E, Çakar B, Varol U, Karabulut B, Uzunoğlu S, Sezgin C, Uslu R, Karaca B. Dynamic Measurement Of Anti-proliferative Effects Of At-101 In Human Breast Cancer Cells By A Novel, Label-free, And Real-time Cell Based Xcelligence System. EACR-Anticancer Agents Research Congress, P: 36 Antalya, Turkey, 13-16 September, 2011.
- Umut Varol, Burcak Karaca, Burcu Cakar , Ugur Muslu , Yalcın Cırak , Canfeza Sezgin, Ruchan Uslu, Bulent Karabulut. Survival Analysis Of Metastatic Colorectal Cancer Patients Who Were Treated By Five Major Therapeutic Agents Over The Course of the Disease. 1st International Gastrointestinal Cancer Conference, Abstract Book, P: 134, Antalya, TURKEY, November 25-27, 2011.
- S.Yalcin, R. Uslu, F. Dane, U. Yilmaz, N. Zengin, E. Büyükünal, S. Büyükberber, C. Camci, O. Sencan, S. Kiliçkap. Bevacizumab Plus Capecitabine As Maintenance Treatment After Inıtial Treatment with Bevacizumab plus Xelox in Previously Untreated Metastatic Colorectal Cancer: Updated Findings From a Randomized, Multicenter Phase III Trial. 1st International Gastrointestinal Cancer Conference, Abstract Book, P: 143, Antalya, TURKEY, November 25-27, 2011.
- Umut Varol, Burcak Karaca, Burcu Cakar , Ugur Muslu , Yalcın Cırak , Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu. Comparing Time to Disease Progression of Irinotecan and Oxaliplatin Based Chemotherapies in Colorectal Cancer Patients With Liver Only Metastasis. 1st International Gastrointestinal Cancer Conference, Abstract Book, P: 147, Antalya, TURKEY, November 25-27, 2011.
- D. Hopanci Biçaklı, D. Tunalı, M. Değirmenci, B. Karaca, B. Karabulut, R. Uslu. TAC regimen induced metabolic syndrome-x in breast cancer patients. 32nd ESPEN Congress, Clinical Nutrition Supp. P-136, Nice/FRANCE, 5-8 September 2010.
- B.Karaca, H. Atmaca, A. Kısım, U. Muslu, B. Karabulut, C. Sezgin, S. Uzunoglu, R. Uslu. Synergistic cytotoxic and apoptotic effect by AT-101 and cisplatin combination through DNA methyltransferase and histone deacetylase enzymes in human ovarian cancer cells. 35th ESMO Congress, Annals of Oncology Supp 21 (8), p: viii55, Milan/Italy, 8-12 October 2010.
- R. Uslu, B.Karaca, H. Atmaca, A. Kısım, B. Cakar, B. Karabulut, C. Sezgin, S. Uzunoglu. Fibroblast growth factor receptor 2 (FGFR2) polymorphism status of Turkish breast cancer patients. 35th ESMO Congress, Annals of Oncology Supp 21 (8), p: viii118, Milan/Italy, 8-12 October 2010.
- Didem Tunali, Derya Hopancı Bicakli, Mustafa Degirmenci, Burcak Karaca, Bulent Karabulut, Ruchan Uslu. Adjuvant TAC chemotherapy induces metabolic syndrome-x in breast cancer patients. 3rd International Congress on Nutrition and Cancer, Abstract Book, P:8, Bodrum/Turkey, October 20-24, 2010.
- Derya Hopancı Bicakli, Ugur Muslu, Burcak Karaca, Didem Tunali, Ruchan Uslu. The nutritional risc screening (Nrs-2002) of cancer patients. 3rd International Congress on Nutrition and Cancer, Abstract Book, P:12, Bodrum/Turkey, October 20-24, 2010.
- Burçak Karaca, Aslı Kısım, Harika Atmaca, Bülent Karabulut, Canfeza Sezgin, Selim Uzunoğlu, Rüçhan Uslu. AT-101 sensitizes human breast cancer cells to APO-2 ligand/tumor necrosis factor related apoptosis inducing ligand (TRAIL) through synergistic cytotoxicity and apoptosis. 8th Mediterranean Conference on Oncology "INNOVATIONS IN BREAST CANCER MANAGMENT", Congress Book p: 52, Sözel No: 0003, Antalya/Turkey, 28-30 November 2010.
- Burçak Karaca, Fatma Düşünür, Burcu Çakar, Uğur Muslu, Bülent Karabulut, Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Erdem Göker. Molecular subtypes of breast cancer in very young women (35 years) with operable breast cancer. 8th Mediterranean Conference on Oncology "INNOVATIONS IN BREAST CANCER MANAGMENT", Congress Book p: 54, Sözel No: 0005, Antalya/Turkey, 28-30 November 2010.
- Burçak Karaca, Raika Durusoy, Bermeth Junushova, Rüçhan Uslu. Breast cancer patients’ satisfaction of doctors as compared to other types of tumor: experiences from a university hospital. 8th Mediterranean Conference on Oncology "INNOVATIONS IN BREAST CANCER MANAGMENT", Congress Book p: 72, Poster No: 0012, Antalya/Turkey, 28-30 November 2010.
- Burçak Karaca, Harika Atmaca, Ali Güher Eniseler, Duygu Ünüvar Purcu, Aslı Kısım, Bülent Karabulut, Selim Uzunoglu, Rüçhan Uslu. Synergistic effect of gossypol, a cotton-plant seed, with conventional chemotherapeutics in MCF–7 cells. Third International Congress of Molecular Medicine, IUBMB Life 61: 336, Istanbul/TURKEY, 5 –8 May 2009.
- Harika Atmaca, Selim Uzunoğlu, Gürbüz Görümlü, Burçak Karaca Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Anti-proliferative, Anti-apoptotic and Anti-angiogenic Effects of Gossypol in Combination with Zoledronic Acid in Human Ovarian Cancer Cell Line OVCAR–3. Third International Congress of Molecular Medicine, IUBMB Life 61: 348. Istanbul/TURKEY, 5 –8 May 2009.
- Harika Atmaca, Gurbuz Gorumlu, Burcak Karaca, Ercument Cengiz, Cigdem Erten, Yuksel Kucukzeybek, Mustafa K. Gul, Selim Uzunoglu, Bulent Karabulut, Ulus A Sanli, Ruchan Uslu. Effect of ATRA/Zoledronic Acid Combination on the Apoptotic Pathways of the Human Androgen and Drug Refractory Prostate Cancer Cell Line, DU-145. Joint 4th EORTC Pathobiology Group Annual Metin & 1st International Multidisciplinary Cancer Research Congress, Abstract Book P-44, Antalya/TURKEY, 21-24 May 2009.
- Aslı Kısım, Gurbuz Gorumlu, Cigdem Erten, Mustafa K. Gul, Ercument Cengiz, Yuksel Kucukzeybek, Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A Sanli, Ruchan Uslu. Differential Expression Profile of Apoptotic Proteins by Gossypol/Zol Acid Combination on the Human Androgen and Drug Refractory Prostate Cancer Cell Line, DU-145. Joint 4th EORTC Pathobiology Group Annual Metin & 1st International Multidisciplinary Cancer Research Congress, Abstract Book P-46, Antalya/TURKEY, 21-24 , 2009
- Burcak Karaca, Duygu Ünüvar Purcu, Murat Kapkaç, Necmettin Özdemir, Gürbüz Görümlü, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A Sanli, Ruchan Uslu. Comparison of Human Breast Cancer and Estrogen Receptor Signaling mRNA Expression Profiles of Normal and Pathologic Tissue Samples from Turkish Breast Cancer Patients. Joint 4th EORTC Pathobiology Group Annual Metin & 1st International Multidisciplinary Cancer Research Congress, Abstract Book P-46, Antalya/TURKEY, 21-24 May 2009.
- Harika Atmaca, Burçak Karaca Selim Uzunoğlu, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Synergistic Inhibition of Angiogenin by Combined Treatment with Gossypol and Cisplatin in a Human Ovarian Cancer Cell Line, OVCAR-3. Third International Congress Molecular Medicine, IUBMB Life 61: 349, Istanbul/TURKEY, 5 –8 May 2009.
- Y. Bolukbasi, D. Yalman, G. Cok, T. Goksel, R. Uslu, S. Ozkok. Concomitant cisplatin-docetaxel chemotherapy with 3-D conformal radiotherapy followed by adjuvant cisplatin-docetaxel chemotherapy in locally advanced non-small cell lung cancer: Toxicity and tolerability. 2008 ASCO Meeting, May 20 suppl: abstr 7600, J Clin Oncol 26: 2008.
- Yüksel Küçükzeybek, Gürbüz Görümlü, Burçak Karaca, Mustafa Değirmenci, Didem Tunalı, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu, Ulus Ali Şanlı, Erdem Göker. Irinotecan and Cetuximab in Patients with Heavily Pretreated Metastatic Colorectal Cancer. 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, suppl 1, Volume 15, p 085, Hepato-Gastroenterology Current Medical and Surgical Trends, October 8-11, İstanbul, 2008.
- Burçak Karaca, Selehattin Bıçak, Yüksel Küçükzeybek, Gürbüz Görümlü, , Mustafa Değirmenci, Didem Tunalı, Bülent Karabulut, Rüçhan Uslu, Ulus Ali Şanlı, Erdem Göker. Efficacy of Treatment with Somatostatin Analogs in Advanced Gastroenteropancreatic Neuroendocrine Tumors ( GEP-NET). 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, suppl 1, Volume 15, p 410, Hepato-Gastroenterology Current Medical and Surgical Trends, October 8-11, İstanbul, 2008.
- Burçak Karaca, Yüksel Küçükzeybek, Gürbüz Görümlü, , Mustafa Değirmenci, Didem Tunalı, Bülent Karabulut, Rüçhan Uslu, Ulus Ali Şanlı, Erdem Göker. Retrospective Analysis of Gastrointestinal Stromal Tumors (GIST) at Ege University School of Medicine. 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, suppl 1, Volume 15, p 512, Hepato-Gastroenterology Current Medical and Surgical Trends, October 8-11, İstanbul, 2008.
- Mustafa Değirmenci, Burçak Karaca, Yüksel Küçükzeybek, Gürbüz Görümlü, , Didem Tunalı, Fatma Yavaş, Ulus Ali Şanlı, Rüçhan Uslu, Bülent Karabulut, Canfeza Sezgin, Erdem Göker. Brain metastasis during the follow-up of gastrointestinal system cancers: a rare entity. 18th World Congress of the International Association of Surgeons, Gastroenterologists and Oncologists, suppl 1, Volume 15, p 524, Hepato-Gastroenterology Current Medical and Surgical Trends, October 8-11, İstanbul, 2008.
- Deniz A, Asbagh LA, Uzunoglu S, Uslu R. The evaluation of mathematical models of drug combination analysis and search for new ones. Physical and Chemical Foundations of Bioinformatics Methods International Workshop, Max Planc Institue, Dresden, Germany, June 18-22, 2007.
- Y.K. Yıldırım, Y. Tokem, N. Bozkurt, C. Fadıloğlu, M. Uyar, R. Uslu. Validation of the memorial symptom assessment scale in cancer patients. 20th International Anniversary Symposium Supportive Cancer Care in Cancer, Abstract Book P-226 (Supportive Care in Cancer, 15 (6) 2007) St Galen, Switzerland, June 27–30, 2007.
- M. Uyar, R. Uslu, A. Coker, H. Elbi, S. Eyigör, C. Eyigör, C. Fadıloğlu, O. O. Sertoz, F. Senuzun, Y. K. Yıldırım. Cancer and Palliative Care: Model of Turkey. 20th International Anniversary Symposium Supportive Cancer Care in Cancer, Abstract Book P–239 (Supportive Care in Cancer, 15 (6) 2007), St Galen, Switzerland, June 27–30, 2007.
- E. Cengiz, Y. Küçükzeybek, M.K. Gül, Ç. Erten, B. Karaca, G. Görümlü, L.A. Asbagh, H. Atmaca, S. Uzunoğlu, U.A. Şanlı, B. Karabulut, R. Uslu. Additive/synergistic antitumoral effect of combination of docetaxel and zoledronic acid on hormone and drug refractory prostate cancer cell lines. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P62, Antalya October 16–21, 2007.
- Y. Küçükzeybek, M.K. Gül, E. Cengiz, B. Karaca, Ç. Erten, G. Görümlü, L.A. Asbagh, H. Atmaca, S. Uzunoğlu, U.A. Şanlı, B. Karabulut, R. Uslu. Synergistic effect of docetaxel and ATRA on human hormone and drug resistant prostate cancer cell lines DU–145 and PC–3. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P63, Antalya October 16–21, 2007.
- B. Karaca, Ç. Erten, G. Görümlü, E. Cengiz, M.K. Gül, Y. Küçükzeybek, L.A. Asbagh, H. Atmaca, S. Uzunoğlu, U.A. Şanlı, B. Karabulut, R. Uslu. A new drug combination for hormone and drug refractory prostate cancer: All-Trans Retinoic Acid (ATRA) and zoledronic acid. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P64, Antalya October 16–21, 2007.
- Ç. Erten, G. Görümlü, Y. Küçükzeybek, M.K. Gül, E. Cengiz, B. Karaca, L.A. Asbagh, H. Atmaca, S. Uzunoğlu, U.A. Şanlı, B. Karabulut, R. Uslu. Synergistic cytotoxic effect of docetaxel and gossypol on human hormone and drug resistant prostate cancer cell lines. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P65, Antalya October 16–21, 2007.
- G. Görümlü, M.K. Gül, Ç. Erten, B. Karaca, E. Cengiz, Y. Küçükzeybek, L.A. Asbagh, H. Atmaca, S. Uzunoğlu, U.A. Şanlı, B. Karabulut, R. Uslu. Additive/synergistic effect of zoledronic acid and gossypol on human hormone and drug resistant prostate cancer cell lines DU–145 and PC–3. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P66, Antalya October 16–21, 2007.
- L.A. Asbagh, H. Atmaca, S. Uzunoğlu, G. Görümlü, B. Karaca, Y. Küçükzeybek, M.K. Gül, E. Cengiz, Ç. Erten, U.A. Şanlı, B. Karabulut, R. Uslu. Comparison of XTT and Alamar Blue (Resazurin) Assay in the assesmnet of cytotoxic effect of zoledronic acid and gossypol combination in human drug-resistant ovarian cancer cell line OVCAR–3. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P67, Antalya October 16–21, 2007
- B.Y. Karasulu, G. Kantarcı, B. Karaca, L.A. Asbagh, R. Uslu, E. Göker, T. Güneri. Preparation and in vitro cytotoxicity study of methotraxate loaded microemulsion. 3rd International Meeting on Medicinal and Pharmaceutical Chemistry, Abstracts Book P67, Antalya October 16–21, 2007.
- B. Gurcu, D. Bicakci, O. Makay, A. Uguz, B. Karaca, B. Karabulut, M. Uyar, R. Uslu, A. Coker. Nutritional assesment in adult cancer patients receiving chemotherapy. 28th Congress of ESPEN, Abstract Book pp:74 (Abs. No: PO109) İstanbul, Turkey, October 2006.
- Senem Dubova, Yasemin K. Yıldırım, Özlem Demir, Zeynep Özsaran, Deniz Yalman, Ayfer Haydaroğlu, Ruchan Uslu. Evaluation of burnout in oncology employees. 31st ESMO Congress, Abstract Book (Annals of Oncology) 974P, İstanbul, Turkey, September 2006.
- Eyigör, S., O.K. Korkmaz, H. Karapolat, B. Durmaz ve R. Uslu, "The Relationship of Pain, Fatigue and Quality of Life in Hospitalized Cancer Patients," 5th Congress of the European Federation of IASP Chapters (EFIC), İstanbul, European Journal of Pain Vol. 10, Suppl. S1, S134, Elsevier, 2006.
- A. Çoker, F. Yılmaz, D. Nart, R. Uslu, E. Göker, O. Tekesin, O. Ozutemiz, M. Zeytunlu, M. Akyıldız, N. Elmas. Periampullary NET tumors: A single center experience. ASCO 2006 Gastrointestinal Cancer Symposium Abstract No: 140, USA Jan 2006.
- Gorumlu G, Kucukzeybek Y, Karabulut B, et al. Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients. 31st ESMO Congress, Abstract Book, Annals of Oncology (17) Supp 9, pp:172 İstanbul, Turkey, September 2006.
- Kucukzeybek Y, Gorumlu G, Karabulut B, et al. Docetaxel plus platinum combination regimen in locally advanced or metastatic head and neck cancer. 31st ESMO Congress, Abstract Book, Annals of Oncology (17) Supp 9, pp:187 İstanbul, Turkey, September 2006.
- Bülent Karabulut, Serkan Ocakçı, Rüçhan Uslu, Ulus A. Şanlı, Erhan Gökmen, Erdem Göker. Cetuximab plus irinotecan in refractory metastatic colorectal cancer. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/23, Istanbul, Turkey (2005).
- Niyazi Aşkar, Erzat Toprak, Bülent Karabulut, Nur Selvi, Mustafa Terek, Rüçhan Uslu, Ulus A. Şanlı, Erdem Göker. Arsenic Trioxide (As2O3) exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/24, Istanbul, Turkey (2005).
- Ercüment Cengiz, Bülent Karabulut, Yüksel Küçükzeybek, Burçak Karaca, Rüçhan Uslu, Ulus A. Şanlı, Erhan Gökmen, Erdem Göker. The efficacy and tolerability of capecitabine in metastatic colorectal cancer. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/25, Istanbul, Turkey (2005).
- Bülent Karabulut, Halit Yetiş, Ulus A. Şanlı, Rüçhan Uslu, Adam Uslu, Erdem Göker. Flourouracil and folinic acid bolus Schedule (Nordic regimen) combined with irinotecan as a first-line chemotherapy in metastatic colorectal cancer. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/26, Istanbul, Turkey (2005).
- H. Yeşim Karasulu, Bülent Karabulut, Rüçhan Uslu, Ulus A. Şanlı, Erdem Göker, Taner Güneri. Controlled release of methotrexate from w/o microemulsion and its in vitro anti-tumor activity. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/27, Istanbul, Turkey (2005).
- Bülent Karabulut, Rüçhan Uslu, Ulus A. Şanlı, Ayşenur Memiş, Taner Akalın, Dündar Sabah, Güven Yücetürk, Erdem Göker. The efficacy and tolerability of cisplatin and doxorubicin combination regimen as a neo-adjuvant therapy of osteogenic sarcoma. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/28, Istanbul, Turkey (2005).
- Mustafa Terek, Bülent Karabulut, Nur Selvi, Levent Akman, Yeşim Karasulu, Ulus A. Şanlı, Rüçhan Uslu, Ulus A. Şanlı, Erdem Göker, Aydın Özsaran. Arsenic trioxide loaded microemulsion enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. 2nd ISC International Conference on Cancer Theurapeutics, Abstract book, POII/29, Istanbul, Turkey (2005).
- S. Ozkok, S. Dubova, Y. Yuzer, D. Yalman, R. Uslu, A. Coker, M. Zeytunlu, E. Goker. Postoperative adjuvant gemcitabine alone and concurrent with radiation after resection of locally advanced pancreatic carcinoma. EJC Supplements 3 (2): 207-208 Suppl. S, OCT 2005.
- V. C. Sezgin, U. A. Sanli, B. Karabulut, R. Uslu, G. G. Muezzinoglu, N. Ozdemir, E. Goker. Capecitabine monotherapy in patients with pretreated metastatic breast cancer: Is response correlated to cerbB-2 expression? ASCO Annual Meeting, Journal Of Clinical Oncology Vol:22, No: 14S July 15 Supp (Abstract No: 760), 2004.
- Sanli UA, Uslu R, Karabulut B, Sezgin VC, Saydam G, Omay SB, Buyukkececi F, Goker E. Which dosing scheme is suitable for the taxanes. 6th International Symposium on Predictive Oncology&Intervention Strategies Paris February 9-12, 2002. Cancer Detection and Prevention 2002 Symposium Volume, S-178, Abst No: 462, 2002.
- Omay SB, Sanli UA, Uslu R, Sezgin VC, Karabulut B, Selvi N, Aydin HH, Saydam G, Goker E, Buyukkececi F. Alterations in the activity of serine/threonine protein phosphatases during ATRA-induced apoptosis of human breast cancer cells. 6th International Symposium on Predictive Oncology&Intervention Strategies Paris February 9-12, 2002. Cancer Detection and Prevention 2002 Symposium Volume, S-97, Abst No: 170, 2002.
- G. Öktem, B. Karabulut, N. Selvi, C. Sezgin, U.A.Şanlı, R. Uslu, A. Uysal, M.E. Yurtseven, S.B. Omay. Differantial induction of İNOS by doxorubucin and docetaxel in MCF-7 cell line. The 7th World Congress on Advances in Oncology, 5th International Symposium on Molecular Medicine, October 10-12, 2002, Crete, Greece. International Journal of Molecular Medicine, Volume 10, suppl 1, S-24, Abst No: 179, 2002.
- Yuksel S, Saydam G, Tobu M, Uslu R, Terzioglu E, Tombuloglu M, Cagirgan S, Buyukkececi F, Omay SB. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. 5th Annual Meeting of the European Haematology Association. Birmingham, UK, 25-28 June 2000. The Hematology Journal, 1 (suppl 1): p:16, Abst# 063, 2000.
- G. Saydam, S. Yüksel, M. Töbü, R. Uslu, E. Terzioğlu, F. Büyükkeçeci, S. B. Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Blood 96:11, 141b, 2000.
- S.B. Omay, S. Uzunoglu, R. Uslu, M. Tobu, G. Saydam, E. Terzioglu, F. Buyukkececi. Augmentation of methylprednisolone-induced differantiation of myeloid leukemia cells by serine/threonine protein phosphatase inhibitors. FEBS'99, 26th meeting of the federation of European Biochemical Societies, 19-24 June 1999, Nice, France. Biochimie, 81 (suppl):s261, 1999.
- Uslu R, Sezgin C, Karabulut B, Sanli UA, Tobu M, Saydam G, Buyukkececi F, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity in prostate and ovarian carcinoma lines. Molecular Targets and Cancer Therapeutics , Discovery, Development, and Clinic Validation. November 16-19, 1999, Washington DC, USA. Proceedings of the AACR-NCI-EORTC International Conference: p: 55, Abstract No: 271, 1999.
- Uslu R, Ozsaran A, Sanli UA, Dikmen Y, Goker ENT, Goker E. The effect of Taxol treatment on serum IL-8 levels in patients with ovarian carcinoma. Molecular Targets and Cancer Therapeutics , Discovery, Development, and Clinical Validation. November 16-19, 1999, Washington DC, USA. Proceedings of the AACR-NCI-EORTC International Conference: p: 80, Abstract No: 394, 1999.
- S. B. Omay, M. Tobu, G. Saydam, S. Uzunoglu, N. Selvi, H. H. Aydin, R. Uslu, S, Yuksel, F. Buyukkececi. Methylprednisolone-induced differentiation of myeloid leukemia cells enhanced by calcineurin inhibitors. American Society of Hematology Forty-First Annual Meeting, New Orleans, LA, USA, December 3-7, 1999. Blood 94 (10) Suppl. 1 (Part 2 of 2), p: 195b, Abs# 4064, November 15, 1999.
- Aydin H. H, Selvi N, Saydam G, Tobu M, Uzunoglu S, Uslu R, Buyukkececi F and Omay S. B. PP2A regulatory subunit upregulation during methylprednisolone-induced leukemic differantiation. 3rd joint meeting Signal Transduction Society, Study Groups ‘Signal Transduction’ of the German Societies for Immunology and Cell Biology. Signal Transduction: Receptors, Mediators and Genes, Berlin, Germany, 02-04.12.1999. Program and Abstracts Book, P: 88, Abst# P31, 1999.
- Zuhal Parıldar, Ruchan Uslu, Tijen Tanyalçın, Eker Doğanavşargil, Fatma Kutay. Urinary glycosaminoglycan and heparan sulfate excretion in SLE. 11th Balkan Biochemical Biophysical Days, May 15-17 1997, Thessaloniki, Greece. Book of Abstract, Page 114, Abstract no:341, 1997.
- R.Uslu, E.Terzioğlu, C.Kırmaz, G.Ergezer, A.Sin, A.Kokuludağ, F.Sebik, Y.Batur, T.Kabakçı. Serum IgE and IL-4 values in cirrhosis and chronic active hepatitis patients. EAACI'97, June 1-5 1997, Rhodes, Greece. Allergy Supp (Abstract book) 37 (52):37, 1997
- Frost P, Uslu R, Belldegrun A, Bonavida B. Chemosensitization of human prostate carcinoma cell lines to Fas-mediated cytotoxicity by TIL. Journal of Allergy and Clinical Immunology. 99: (1) 1816-1816, Part 2, Suppl. S JAN 1997.
- Frost P, Uslu R, Belldegrun A, Bonavida B. CD4 T cell mediated apoptosis of melanoma cells does not involve Fas CD95 pathways. Journal of Allergy and Clinical Immunology. 99: (1) 1817-1817, Part 2, Suppl. S JAN 1997.
- E. Terzioğlu, R. Uslu, Ş. Kose, A. Sin, C. Kırmaz, F. Sebik, T. Kabakçı. Delayed hypersensitivity testing in normal and atopic individuals. EAACI' 96, 2-5 June 1996, Budapest, Hungary. Allergy, Supp.(Abstract book) 31 (51): 134, 1996
- B. Bonavida, R.Uslu , and J. Berek. Chemosensitization of resistant ovarian tumor cells to anti-fas mediated cytotoxicity and apoptosis. Society for Gynecologic Investigation, 43rd annual meeting, March 20-23, 1996- Philadelphia, PA, USA. Journal of the Society for Gynecologic Investigation (supplement), 3(2) :194A (Abstract no:271), 1996.
- R.Uslu, N. Borsellino, Y. Mizutani, A. Belldegrun, B. Bonavida. Chemosensitization of DU145 and PC-3 human prostate carcinoma cell lines by cisplatin, adriamycin and etoposide to anti-Fas antibody-mediated cytotoxicity and apoptosis. 87th Annual Meeting of the American Association for Cancer Research, April 20-24, 1996, Washington DC, USA. Proceedings American Association for Cancer Research 37:480 (Abstract no:3279), 1996.
- Ruchan Uslu and Benjamin Bonavida. Regulation at different stages in mitochondrial electron transport for cytotoxicity, apoptosis and synergy by TNF-a and CDDP against human ovarian cancer lines 86th Annual Meeting of the American Association for Cancer Research, March 18-22, 1995, Toronto, Ontorio, Canada. Proceedings American Association for Cancer R esearch 36: 630 (Abstract no: 3751), 1995.
- Ruchan Uslu, Nicolo Borsellino, and Benjamin Bonavida. Sensitization of human prostate carcinoma cell lines to anti-Fas antibody-mediated cytotoxicity and apoptosis by cisplatin, adriamycin and etoposide. 1st World Congress on Advances in Oncology, October 22-26, 1995, Athens / Greece (Oral prezentasyon).Int J Oncol: 7(Suppl): 984, 1995
- Ruchan Uslu, Hideki Morimoto, and Benjamin Bonavida. Intracellular pathways in cytotoxicity mediated by the synergistic activity of TNF-a and drugs / toxins. 5th International TNF Congress, May 30- June 3, 1994, Monterey, California, USA. European Cytokine Network 5 (2): 131 (Abstract no:87), 1994.

National Conference Proceedings (100 entries)- Harika Atmaca, Emir Bozkurt, Selim Uzunoğlu, Rüçhan Uslu, Burçak Karaca. MCF-7 ve MDA-MB-453 Meme Kanseri Hücre Kültürlerinde Farklı Yolaklar Üzerinden Çalışan Trabectedin (E-743) Aracılı Apoptozis. 4.Multidisipliner Kanser Araştırma Kongresi, Bursa, 13-16 Aralık 2012 (Sözlü bildiri).
- Burcu Çakar, Emir Bozkurt, Zeki Sürmeli, Pınar Gürsoy, Aslı Kısım, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Burçak Karaca. Glioblastoma Multiforme Hücre Kültürlerinde (U-87 MG ve T98G) VEGF Sentezinin (-/-) Gossypol (AT-101) İle İnhibisyonu. 4.Multidisipliner Kanser Araştırma Kongresi, Bursa, 13-16 Aralık 2012 (Sözlü bildiri).
- Emir Bozkurt, Harika Atmaca, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Ulus Ali Şanlı, Rüçhan Uslu, Burçak Karaca. Glioblastoma Multiforme Hücre Kültürlerinde (U-87MG ve T98G) Trabectedin’in (E-743) Sitotoksik ve Apoptotik Etkilerinin Araştırılması. 4.Multidisipliner Kanser Araştırma Kongresi, Bursa, 13-16 Aralık 2012.
- Emir Bozkurt, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Rüçhan Uslu, Burçak Karaca. İnsan Prostat Kanseri Hücre Kültürlerinde (PC-3 ve DU-145) Adaçayı (Salvia) Ekstraktının Sitotoksik ve Apoptotik Etkilerinin Araştırılması. 21. Ulusal Biyoloji Kongresi (Uluslar arası katılımlı), İzmir, 3-7 Eylül 2012.
- Emir Bozkurt, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Rüçhan Uslu, Burçak Karaca. Kekik (Thymus) ekstraktının normal meme epiteli (MCF-10A) ve meme kanseri (MDA-MB-231) hücre kültürlerinde sitotoksik, apoptotik ve epigenetik etkilerinin araştırılması. 21. Ulusal Biyoloji Kongresi (Uluslararası katılımlı), İzmir, 3-7 Eylül 2012.
- Harika Atmaca, Emir Bozkurt, Aslı Kısım, Selim Uzunoğlu, Rüçhan Uslu, Burçak Karaca. Dosetaksele duyarlı (PC-3 - DU-145) ve dirençli (PC-3/R - DU-145/R) prostat kanseri hücre hatlarında anjiyojenik sitokinlerin belirlenmesi ve ekspresyon düzeylerinin karşılaştırılması. 21. Ulusal Biyoloji Kongresi (Uluslararası katılımlı), İzmir, 3-7 Eylül 2012.
- Aslı Kısım, Harika Atmaca, Emir Bozkurt, Selim Uzunoğlu, Rüçhan Uslu, Burçak Karaca. Resveratrol Ajanının Bazı İnsan Kanseri Hücre Kültürlerindeki Zamana Bağlı Antiproliferatif Etkilerinin Karşılaştırmalı Analizi. 21. Ulusal Biyoloji Kongresi (Uluslararası katılımlı), İzmir, 3-7 Eylül 2012.
- Burçak Karaca, Burcu Çakar, Zeki Sürmeli, Pınar Gürsoy, Uğur Muslu, Emir Bozkurt, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Zoledronik Asit’in Serin/Treonin Protein Fosfataz İnhibitörleriyle Kombinasyonunun İnsan Meme Kanseri Hücrelerinde Akt Protein Düzeyine Etkisinin Araştırılması. 4. Tıbbi Onkoloji Kongresi, Antalya, 21-25 Mart 2012.
- Hakan Çamyar, Burcu Çakar, Uğur Muslu, Emir Bozkurt, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu, Burçak Karaca. Docetaksel/Octreotid Sinerjistik Kombinasyonu İnsan Meme Kanseri Hücre Hatlarında Somatostatin Reseptörleri 2 ve 5’i İndükleyerek Apotozise Neden Olmaktadır. 4. Tıbbi Onkoloji Kongresi, Antalya, 21-25 Mart 2012.
- Umut Varol, Zeki Sürmeli, Pınar Gürsoy, Burcu Çakar, Uğur Muslu, Aslı Kısım, Emir Bozkurt, Harika Atmaca, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu, Burçak Karaca. Dosetaksel’e Dirençli Prostat Kanseri Hücre Hatlarında Dosetaksel’in Sitotoksik ve Apoptotik Etkisinin Zoledronik Asit Ön Muamelesiyle Arttırılması. 4. Tıbbi Onkoloji Kongresi, Antalya, 21-25 Mart 2012.
- Burçak Karaca, Uğur Muslu, Burcu Çakar, Aslı Kısım, Emir Bozkurt, Harika Atmaca, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Meme Kanseri Hücre Kültürlerinde AT-101’in Sitotoksik Etkilerinin Xcelligence Sistemi ile Dinamik Takipi ve Bulguların XTT Yöntemiyle Karşılaştırılması. 8. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, Bildiri: 28, sayfa: 38, 14-18 Eylül 2011, Muğla.
- Burçak Karaca, Hakan Çamyar, Burcu Çakar, Didem Tunalı, Umut Varol, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. İnsan Meme Kanseri Hücre Hatlarında Docetaxel-Octreotid Kombinasyonunun Olası Sinerjistik Sitotoksik/Apoptotik Etkilerinin Araştırılması. 8. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, Bildiri: 29, sayfa: 39, 14-18 Eylül 2011, Muğla.
- Burcu Çakar, Derya Hopancı Bıçaklı, Burcu Güneş, Püsem Patır, Uğur Muslu, Umut Varol, Mehmet Uyar, Rüçhan Uslu. Kanser Hastalarında Palyatif Yaklaşımda Beslenme Desteği: Tek Merkez Deneyimi. 8. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, Bildiri: 30, sayfa: 40, 14-18 Eylül 2011, Muğla.
- Burcu Çakar, Uğur Muslu, Melih Özışık, Hatice Özışık, Ceyda Tunakan Dalgıç, Raika Durusoy, Burçak Karaca, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Triple Negatif Meme Kanser Hastalarında Vücut Kitle İndeksinin Prognostik Öneminin Değerlendirilmesi. 8. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, Bildiri: 31, sayfa: 41, 14-18 Eylül 2011, Muğla.
- Umut Varol, Berna Gürsel, Püsem Patır, Burcu Güler, Burcu Çakar, Uğur Muslu, Burçak Karaca, Bülent Karabulut, Rüçhan Uslu. Ege Üniversitesi Palyatif Bakım Merkezine Yatırılan Onkoloji Hastalarının Demografik Verileri. 8. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, Bildiri: 119, sayfa: 156, 14-18 Eylül 2011, Muğla.
- Umut Varol, Yelda Varol, Burçak Karaca, Uğur Muslu, Yalçın Çırak, Recep Savas, Rüçhan Uslu. Kolorektal kanserli hastalarda saptanan milimetrik pulmoner nodüllerin prognostik önemi. 3. Gastrointestinal Onkoloji Kongresi, Kongre Bildiri Kitabı, B:43, sayfa: 54, 07-10 Nisan 2011, Antalya.
- Umut Varol, Yalçın Çırak, Uğur Muslu, Burçak Karaca, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu. Sadece karaciğer metastazı olan kolorektal kanserli hastalarda irinotekan ile oxaliplatin bazlı kemoterapilerin progresyonsuz sağkalım açısından karşılaştırılması. 3. Gastrointestinal Onkoloji Kongresi, Kongre Bildiri Kitabı, B:45, sayfa: 57, 07-10 Nisan 2011, Antalya.
- Şuayib Yalçın, Rüçhan Uslu, Faysal Dane, Uğur Yılmaz, Nurullah Zengin, Evin Büyükünal, Süleyman Büyükberber, Celalettin Camcı, Orhan Şencan, Saadetin Kılıçkap. Metastatik Kolorektal Adenokarsinomalı Hastalarda Kapesitabin, Okzaliplatin ve Bevasizumab İle Kombine Başlangıç Tedavisi Sonrasında, İdame Tedavisi Olarak Bevasizumab ve Kapesitabin’in Etkililik Ve Güvenliliğinin Değerlendirildiği Randomize Açık Prospektif Faz III (Stop And Go) Ulusal Çalışma. 19. Ulusal Kanser Kongresi, Bildiri Özetleri Kitabı, S:27, sayfa: 39, 20-24 Nisan 2011, Antalya (Sözel Bildiri).
- Burcu Çakar, Burçak Karaca, Uğur Muslu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Nüks Glioblastome Multiforme (GBM) Vakalarında Uygulanan Bevacizumab-İrinotekan Kombinasyon Tedavisi’ndeki Deneyimlerimiz. 19. Ulusal Kanser Kongresi, Bildiri Özetleri Kitabı, P:310, sayfa:430, 20-24 Nisan 2011, Antalya.
- Cenk Gökalp, Burçak Karaca, Burcu Çakar, Yalçın Çırak, Aslı Kısım, Harika Atmaca, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Prostat Kanseri Hücre Hatlarında Zoledronik Asit Uygulamasının Sitotoksik ve Anti-Anjiogenik Etkilerinin Araştırılması. 19. Ulusal Kanser Kongresi, Bildiri Özetleri Kitabı, P:334, sayfa:457, 20-24 Nisan 2011, Antalya.
- Burçak Karaca, Mustafa Değirmenci, Umut Varol, Uğur Muslu, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu. AT-101/Octreotid Sinerjistik Kombinasyonu Hormon Dirençli İnsan Prostat Kanseri Hücre Hatlarında Somatostatin Reseptörleri 2 ve 5’İ İndükleyerek Apotozise Neden Olmaktadır. 19. Ulusal Kanser Kongresi, Bildiri Özetleri Kitabı, P:355, sayfa:480, 20-24 Nisan 2011, Antalya.
- Burçak Karaca, Yalçın Çırak, Didem Tunalı, Burcu Çakar, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Zoledronik Asit’in Protein Fosfataz İnhibitörleri İle Kombinasyonunun İnsan Hormon- Refrakter Prostat Kanseri Hücrelerinde Farnesilpyrofosfat Sentaz Üzerine Etkilerinin Araştırılması. 19. Ulusal Kanser Kongresi, Bildiri Özetleri Kitabı, P:356, sayfa: 481, 20-24 Nisan 2011, Antalya.
- Banu Pınar Şarer Yürekli, Aslı Kısım, Harika Atmaca, Burçak Karaca, Rüçhan Uslu, Şevki Çetinkalp, Gökhan Özgen, Candeğer Yılmaz, Füsun Saygılı. (-)- Gossypol’ün (AT-101) AtT-20/D16v-F2 Pitüiter Kortikotrop Adenom Hücreleri Üzerindeki Sitotoksik, Apoptotik ve Hormon Salgısı Üzerine Etkilerinin Araştırılması. 33. Türkiye Endokrinoloji ve Metabolizma Hastalıkları Kongresi, 12-16 Ekim 2011, Antalya.
- Mustafa Değirmenci, Burçak Karaca, Yalçın Çırak, Uğur Muslu, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Pankreas nöroendokrin karsinomunda derin hipokalsemi: Olgu sunumu. 2. Ulusal Gastrointestinal Onkoloji Kongresi, Bildiriler kitabı, Olgu Sunumu 2, Sayfa: 58 Antalya, 07-11 Nisan 2010.
- Mustafa Değirmenci, Umut Varol, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu, Oktay Tekeşin, Funda Yılmaz, Ahmet Çoker. Pankreasın osteoklast tipi dev hücreli tümörü: Olgu sunumu. 2. Ulusal Gastrointestinal Onkoloji Kongresi, Bildiriler kitabı, Olgu Sunumu 13, Sayfa: 58 Antalya, 07-11 Nisan 2010.
- Burçak Karaca, Didem Tunalı, Mustafa Değirmenci, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu. AT-101/Cisplatin sinerjistik kombinasyonunun over kanseri hücre hatlarında DNA metiltransferaz ve histon deasetilaz enzim aktivitesi üzerine etkileri. 7. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, PN:05, sayfa: 34, 22-26 Eylül, Antalya, 2010.
- . Burcu Çakar, Aslı Kısım, Burçak Karaca, Yalçın Çırak, Harika Atmaca, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu. İnsan meme kanseri hücre hatlarında AT-101/TRAİL kombinasyonunun sitotoksik ve apoptotik etkilerinin araştırılması. 7. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, PN:06, sayfa:35, 22-26 Eylül, Antalya, 2010.
- Gürbüz Görümlü, Yüksel Küçükzeybek, Bülent Karabulut, Rüçhan Uslu, Erdem Göker. Metastatik kolorektal kanserde EGFR ekspresyonu, KRAS ve BRAF mutasyon durumu ile setuksimab yanıtı arasındaki ilişki. 7. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, PN:43, sayfa: 85, 22-26 Eylül, Antalya, 2010.
- Yüksel Küçükzeybek, Gürbüz Görümlü, Ercüment Cengiz, Çiğdem Erten, Burçak Karaca, Mustafa Kemal Gül, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Metastatik kolorektal kanserde EGFR ekspresyonu, KRAS ve BRAF mutasyon durumu ile setuksimab yanıtı arasındaki ilişki. 7. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, PN:47, sayfa: 92, 22-26 Eylül, Antalya, 2010.
- Uğur Muslu, Duygu Ünüvar Purcu, Burçak Karaca, Umut Varol, Harika Atmaca, Selim Uzunoğlu, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu. Türk meme kanseri hastalarında kanserli ve normal meme dokusu örneklerinde FGFR2 gen polimorfizminin belirlenmesi. 7. Ulusal Tıbbi Onkoloji Kongresi, Kongre Bildiri Kitabı, PN:51, sayfa: 96, 22-26 Eylül, Antalya, 2010.
- Burçak Karaca, Gürbüz Görümlü, Mustafa Değirmenci, Didem Tunalı, Umut Varol, Yalçın Çırak, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. AT101/Cisplatin kombinasyonunun insan over kanseri hücre hatları üzerindeki olası sinerjistik sitotoksik ve apoptotik etkilerinin araştırılması. 6. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, BN:43, sayfa:55, 24-28 Eylül, Antalya, 2009.
- Umut Varol, Burçak Karaca, Gürbüz Görümlü, Mustafa Değirmenci, Didem Tunalı, Yalçın Çırak, Harika Atmaca, Aslı Kısım, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Dosetaksel-octreotid kombinasyonunun prostat kanseri hücre hatlarında apoptotik proteinler üzerindeki etkilerinin araştırılması. 6. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, BN:63, sayfa:75, 24-28 Eylül, Antalya, 2009.
- Mustafa Değirmenci, Derya Bıçaklı Hopancı, Didem Tunalı, Raika Durusoy, Burçak Karaca, Umut Varol, Gürbüz Görümlü, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Erken evre meme kanseri hastalarında adjuvan TAC kemoterapisi lipid profilini bozuyor mu? 6. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, BN:76, sayfa:88, 24-28 Eylül, Antalya, 2009.
- Burçak Karaca, Duygu Ünüvar Purcu, Murat Kapkaç, Necmettin Özdemir, Gürbüz Görümlü, Harika Atmaca, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Meme kanserli hastaların doku örneklerinde meme kanseri ve östrojen reseptör sinyalizasyonu mRNA ekspresyon profillerinin PCR array ile saptanması. 6. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, BN:78, sayfa:90, 24-28 Eylül, Antalya, 2009.
- Burçak Karaca, Duygu Ünüvar Purcu, Murat Kapkaç, Necmettin Özdemir, Gürbüz Görümlü, Harika Atmaca, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Meme kanserli hastaların doku örneklerinde meme kanseri ve östrojen reseptör sinyalizasyonu mRNA ekspresyon profillerinin PCR array ile saptanması. X. Ulusal Meme Hastalıkları Kongresi, Özet Kitabı, PN:100, sayfa:47, 30-4 Ekim, Çeşme/İzmir, 2009.
- Harika Atmaca, Gürbüz Görümlü, Duygu Ünüvar Purcu, Burçak Karaca, Mustafa Değirmenci, Yalçın Çırak, Didem Tunalı, Aslı Kısım, Selim Uzunoğlu, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. ATRA/Zoledronik asit kombinasyonunun insan yumurtalık kanseri OVCAR-3 ve MDAH 2774 hücre hatlarındaki sinerjistik etkilerinin araştırılması. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Özet Kitabı, P30, sayfa: 69, 28-31 Ekim, Bodrum, 2009.
- Aslı Kısım, Kani Masaroğulları, Burçak Karaca, Gürbüz Görümlü, Mustafa Değirmenci, Didem Tunalı, Yalçın Çırak, Duygu Ünüvar Purcu, Selim Uzunoğlu, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. Meme kanseri MCF-7 hücre hattında AT101/paklitaksel’in tekli ve kombine dozlarının sitotoksik ve apoptotik etkilerinin araştırılması. XI Ulusal Tıbbi Biyoloji ve Genetik Kongresi, Özet Kitabı, P32, sayfa: 70, 28-31 Ekim, Bodrum, 2009.
- L.A. Asbagh, S. Uzunoglu, B. Karaca, Y. Küçükzeybek, G. Görümlü, U.A. Şanlı, B. Karabulut, R. Uslu. Gossypol reduces secretion of monocyte chemoattractant protein 1 (mcp-1/ccl2) and gro-α: in hormone-refractrory prostate cancer cell line PC-3. II. Multidisipliner Kanser Araştırma Sempozyumu, 24-27 Şubat 2008, Bursa.
- B. Junushova, B. Karaca, G. Kandiloğlu, B. Karabulut, R. Uslu. Servix alveoler rabdomyosarkomu-Nadir bir olgu. 4. Uludağ İç Hastalıkları Kış Kongresi, 23 no’lu sözel bildiri, Bursa, 21-24 Şubat 2008.
- M.M. İlhan, C. Sezgin, Z. Ak, B. Arynova, B. Karabulut, U. A. Şanlı, O. Zekioğlu, R. Uslu, E. Göker. Rekürren metastatik meme kanserli hastalarda sağkaımı etkileyen faktörler. 2. Tıbbi Onkoloji Kongresi, P02, 26-30 Mart 2008, Antalya.
- M.M. İlhan, C. Sezgin, E. Zengin, N. Özdemir, B. Karabulut, U. A. Şanlı, R. Uslu, E. Göker. Triple negatif meme kanserinde sağkalımı etkileyen parametreler. 2. Tıbbi Onkoloji Kongresi, P09, 26-30 Mart 2008, Antalya.
- Ç. Fadıloğlu, R. Uslu, Ö. Tekir, S. Samancıoğlu Kanser hastalığında ölüme ve ölüm kaygısına ilişkin hasta, hasta yakınları ve hemşirelerin bakış açılarının değerlendirilmesi. 2. Tıbbi Onkoloji Kongresi, P48, 26-30 Mart 2008, Antalya.
- Yüksel Küçükzeybek, Gürbüz Görümlü, Burçak Karaca, Harika Atmaca, Selim Uzunoğlu, Canfeza Sezgin, Bülent Karabulut, Ulus Ali Şanlı, Rüçhan Uslu. İbandronik asit’in meme ve prostat kanseri hücre hatlarında farklı sitotoksik, apoptotik ve anti-anjiogenetik etkisi. 5. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, B26, sayfa:40, 25-29 Haziran Antalya, 2008.
- Burçak Karaca, Yüksel Küçükzeybek, Gürbüz Görümlü, Çiğdem Erten, M. Kemal Gül, Ercüment Cengiz, Harika Atmaca, Selim Uzunoğlu, Ulus Ali Şanlı, Canfeza Sezgin, Bülent Karabulut, Rüçhan Uslu. Prostat kanseri tedavisinde yeni bir antianjiojenik ajan: Gossypol. 5. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, B36, sayfa:50, 25-29 Haziran Antalya, 2008.
- Burçak Karaca, Yüksel Küçükzeybek, Gürbüz Görümlü, Çiğdem Erten, M. Kemal Gül, Ercüment Cengiz, Harika Atmaca, Selim Uzunoğlu, Bülent Karabulut, Ulus Ali Şanlı, Canfeza Sezgin, Rüçhan Uslu. Zoledronik asit-ATRA kombinasyonu hormon refrakter prostat kanseri hücre hatlarında BIRC5’i (sürvivin) inhibe ediyor. 5. Ulusal Tıbbi Onkoloji Kongresi, Özet Kitabı, B37, sayfa:51, 25-29 Haziran Antalya, 2008.
- Can Eyigör, Alihan Pirim, Burçak Karaca, Yasemin K. Yıldırım, Rüçhan Uslu, Meltem Uyar. Pankreas kanserli hastalarda, tümör lokalizasyonu ağrı tedavisinin planlanmasına yol gösterir mi?. 9. Ulusal Ağrı Kongresi, 16-19 Mayıs 2007, İstanbul. Özet Kitabı
- Yasemin K. Yıldırım, Yasemin Tokem, Nilüfer Bozkurt, Çiçek Fadıloğlu, Meltem Uyar, Rüçhan Uslu. Kanserli hastalarda memorial semptom tanılama skalasının Türkçe versiyonunun geçerlilik çalışması. 9. Ulusal Ağrı Kongresi, 16-19 Mayıs 2007, İstanbul. Özet Kitabı, sayfa 136.
- Eyigör, S., H. Karapolat, O.K. Korkmaz, R. Uslu ve B. Durmaz, "Hospitalize Kanser Hastalarında Yaşam Kalitesi, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PB-254, Antalya, 2007.
- Eyigör, S., H. Karapolat, H. Adanur, Y. Kuzeyli, R. Uslu ve B. Durmaz, "Meme Kanserli Hastalarda Vücut İmajı, Seksüel Problemler ve Yaşam Kalitesi, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PB-255, Antalya, 2007.
- Eyigör, S., H. Karapolat, O.K. Korkmaz ve R. Uslu, "Hospitalize Edilmiş ve Tedavisi Tamamlanmış Kanser Hastalarını Memnun Edebilmiş miyiz?, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PB-256, Antalya, 2007.
- Eyigör, S., H. Karapolat, H. Adanur, R. Uslu ve B. Durmaz, "Meme Kanserli Hastalarda Pilates Egzersizlerinin Yaşam kalitesi, Yorgunluk, Depresyon ve Fiziksel Performans Üzerine Etkisi: Ön Çalışma, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PB-257, Antalya, 2007.
- Eyigör, S., H. Karapolat, O.K. Korkmaz, R. Uslu ve B. Durmaz, "İleri Evre Kanser Hastalarının Primer Bakıcılarının Yaşam Kalitesi ve Psikolojik Durumu, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PB-258, Antalya, 2007.
- Eyigör, S., H. Karapolat, O.K. Korkmaz, Y. Kirazlı ve R. Uslu, "Meme Kanserli Hastalarda Osteoporoz ve 1 Yıllık Takip Sonuçlarımız, 21. Ulusal Fiziksel Tıp ve Rehabilitasyon Kongresi, PC-347, Antalya, 2007.
- Çiçek Fadıloğlu, Yurdanur Çetinkaya, Fisun Şenuzun, Rüçhan Uslu. Kanser hastasına bakım verenlerde stres semptomları ölçeğinin Türkçe geçerlilik ve güvenirlik incelemesi. I. Tıbbi Onkoloji Kongresi, 29 Mart-2 Nisan 2006, Belek/Antalya. Program ve Özet Kitabı, SB39, sayfa 32, (sözel bildiri).
- Bülent Karabulut, Rüçhan Uslu, Ulus A. Şanlı, Erhan Gökmen, Necmettin Özdemir, Erdem Göker. Metastatik meme kanserinde dosetaksel: Prognostik parametrelerin sağ kalım ve yanıt oranları üzerine etkisi. VIII. Ulusal Meme Hastalıkları Kongresi, Bildiri Özet Kitabı, sayfa 304, p169, İstanbul, (2005).
- Bülent Karabulut, Serkan Ocakçı, Ulus A. Şanlı, Murat Kapkaç, Zeynep Özsaran, Necmettin Özdemir, Erdem Göker, Rüçhan Uslu. Meme kanserinin adjuvan tedavisinde ardışık doksorubisin (A) ve siklofosfamid – 5 florourasil – metotreksat (CMF) kombinasyon tedavisi: Prognostik parametrelerin sağ kalım üzerine etkisi. VIII. Ulusal Meme Hastalıkları Kongresi, Bildiri Özet Kitabı, sayfa 303, p168, İstanbul, (2005).
- Fatih Kırçelli, Bülent Karabulut, V. Canfeza Sezgin, Gamze Göksel Müezzinoğlu, Ulus Ali Şanlı, Rüçhan Uslu, Erhan Gökmen. Kemoterapi sonrasında gelişen nekrotizan miyofasitis: olgu sunumu. XV. Ulusal Kanser Kongresi, 23-27 Nisan 2003, Kemer, Antalya. Program ve Bildiri Özet Kitabı, P286, sayfa 111.
- V. Canfeza Sezgin, Ulus Ali Şanlı, Bülent Karabulut, Rüçhan Uslu,, Gamze Göksel Müezzinoğlu, Erdem Göker. Metastatik meme kanserinin tedavisinde capecitabine: etkinlik ve toksisite. XV. Ulusal Kanser Kongresi, 23-27 Nisan 2003, Kemer, Antalya. Program ve Bildiri Özet Kitabı, P355, sayfa 132 (poster bildirisi).
- Ulus Ali Şanlı, Rüçhan Uslu, Bülent Karabulut, V. Canfeza Sezgin, Gamze Göksel Müezzinoğlu, Erdem Göker. Antrasiklin-docetaxel dirençli ileri evre meme kanseri tedavisinde haftalık, alterne paclitaxel-vinorelbine rejimi. XV. Ulusal Kanser Kongresi, 23-27 Nisan 2003, Kemer, Antalya. Program ve Bildiri Özet Kitabı, P345, sayfa 129 (poster bildirisi).
- Bülent Karabulut, Nur Selvi, Ulus Ali Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Gamze Göksel Müezzinoğlu, Erdem Göker. DU-145 prostat kanseri hücre hattı üzerinde okreotidin dual etkisi. XV. Ulusal Kanser Kongresi, 23-27 Nisan 2003, Kemer, Antalya. Program ve Bildiri Özet Kitabı, P533, sayfa 188 (poster bildirisi).
- Canfeza Sezgin, Ulus A. Şanlı, Bülent Karabulut, Murat Öztürk, Rüçhan Uslu, Yıldıray Yüzer, Ali Ş. Menteş, Banu Ç. Bilkay, Erdem Göker. İnoperabl/metastatik pankreas kanserli 49 hastada tek ajan Gemcitabine tedavi sonuçları. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, SB-02, sayfa 49, 2001.
- Canfeza Sezgin, Ulus A. Şanlı, Bülent Karabulut, Murat Öztürk, Rüçhan Uslu, Mustafa Korkut, Banu Ç. Bilkay, Erdem Göker. Nüks/metastatik kolorektal kanserli hastalarda ikinci hat olarak irinotecan (CPT-11) tedavisi: etkinlik ve toksisite. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, SB-07, sayfa 65, 2001.
- Bülent Karabulut, Canfeza Sezgin, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Adem Güler, Erdem Göker. Lokal ileri veya metastatik mide kanserinde paclitaxel ve cisplatin kombine tedavisinin etkinliği ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, SB-16, sayfa 90, 2001.
- Bülent Karabulut, Canfeza Sezgin, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Adem Güler, Erdem Göker. Yüksek riskli, opere, nonmetastatik mide kanserinde adjuvant paclitaxel/cisplatin kombine tedavisinin etkinliği ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, SB-16, sayfa 90, 2001.
- Murat Öztürk, Ulus A. Şanlı, Bülent Karabulut, Canfeza Sezgin, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. Antrasikline dirençli metastatik meme kanser olgularında docetaxel etkinliği. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, SB-16, sayfa 90, 2001.
- Canfeza Sezgin, Ulus A. Şanlı, Bülent Karabulut, Murat Öztürk, Rüçhan Uslu, Mustafa Korkut, Banu Ç. Bilkay, Erdem Göker. Nüks/metastatik 54 kolorektal kanserli hastada birinci hat olarak irinotecan (CPT-11) tedavisi: etkinlik ve toksisite. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-1KO, sayfa 120, 2001.
- Canfeza Sezgin, Bülent Karabulut, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. İnoperabl/metastatik mide kanserli hastalarda irinotecan/5-fluorourasil kombinasyon tedavisinin 23 hastada etkinlik ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-1Mİ, sayfa 123, 2001.
- Canfeza Sezgin, Bülent Karabulut, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Adem Güler, Banu Ç. Bilkay, Erdem Göker. Opere mide kanserinin adjuvant tedavisinde irinotecan/5-fluorourasil kombinasyonu. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-1Mİ, sayfa 124, 2001.
- Canfeza Sezgin, Ulus A. Şanlı, Bülent Karabulut, Murat Öztürk, Rüçhan Uslu, Yıldıray Yüzer, Ali Ş. Menteş, Banu Ç. Bilkay, Erdem Göker. Opere pankreas kanserinde adjuvant tek ajan Gemcitabine sağaltımı. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-1PA, sayfa 127, 2001.
- Murat Öztürk, Bülent Karabulut, Canfeza Sezgin, Ulus A. Şanlı, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. Primer veya metastatik beyin tümörlerinin tedavisinde fotemustine etkinlik ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-4, sayfa 158, 2001.
- Bülent Karabulut, Canfeza Sezgin, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. Sarkomlarda megadoz ifosfamid: faz I çalışmalarında belirlenen maksimum tolere edilebilir doz (MTD) günümüz destek tedavileri ile yeniden değerlendirilmeli mi? XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-2, sayfa 170, 2001.
- Bülent Karabulut, Canfeza Sezgin, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. Lokal ileri veya metastaz yapmış baş-boyun kanserli hastalarda destek tedavi amaçlı kemoterapi: paclitaxel-ifosfamid-cisplatin (TIP) kombine rejiminin etkinlik ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-3, sayfa 224, 2001.
- Yılmaz Dikmen, Bülent Karabulut, Canfeza Sezgin, Murat Öztürk, Ulus A. Şanlı, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. Cisplatine refrakter over kanserli hastalarda topetecan etkinliği ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-3, sayfa 224, 2001.
- Canfeza Sezgin, Bülent Karabulut, Ulus A. Şanlı, Murat Öztürk, Rüçhan Uslu, Banu Ç. Bilkay, Erdem Göker. İnoperabl lokal nüks/metastatik baş-boyun kanserlerinin palyatif tedavisinde paclitaxel+cisplatin/carboplatin kombinasyonunun etkinliği ve toksisitesi. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-3, sayfa 226, 2001.
- Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, Canfeza Sezgin, Aydın Özsaran, Yılmaz Dikmen, Ender Terzioğlu, Erdem Göker. Over kanseri tedavisinde yeni kemoterapötik etki-yeni tümör belirleyici: Paclitaxel ve IL-8. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-3, sayfa 228, 2001.
- Rüçhan Uslu, Ulus A. Şanlı, Canfeza Sezgin, Bülent Karabulut, Ender Terzioğlu, Serdar Bedii Omay, Erdem Göker. Over ve prostat kanseri hücre hatlarında arsenik trioksit aracılıklı sitotoksisite ve apoptozis. XIV. Ulusal Kanser Kongresi, 30 Nisan- 04 Mayıs 2001, İstanbul. Bildiri Özetleri Kitabı, PO-3, sayfa 228, 2001.
- Rüçhan Uslu, H. İbrahim Durak, S. Ayhan Çalışkan, Mahmut Töbü, Hayriye Koçanoğulları, Nihal Erdem, Fulya Günşar, Mehmet Özkahya, Gökhan Özgen, Fehmi Akçiçek. Anabilim dalı soru bankası; 2000-2001 yılında İç Hastalıkları AD. da çoktan seçmeli yazılı sınavların hazırlanma ve uygulanmasına yönelik çalışmalar. II. Ulusal Tıp Eğitimi Kongresi, 24-28 Nisan 2002, İzmir. Bildiri Özeti Kitabı, F2, sayfa 125, 2001. (0,33 puan)
- Fehmi Akçiçek, Rüçhan Uslu, H. İbrahim Durak, S. Ayhan Çalışkan, Asiye Topal, Vedat İnal, Seçkin Çağırgan, Erdem Göker, Ali Kokuludağ, Gürhun Atabay. Eğitimde liderliğin önemi; 2000-2001 eğitim-öğretim yılı Ege Üniversitesi Tıp Fakültesi İç Hastalıkları AD. Yazılı sınav ve soru bankası yönergesi. II. Ulusal Tıp Eğitimi Kongresi, 24-28 Nisan 2002, İzmir. Bildiri Özeti Kitabı, F12, sayfa 135, 2001. (0,33 puan)
- Şafak Yüksel, Güray Saydam, Mahmut Töbü, Rüçhan Uslu, Ender Terzioğlu, Filiz Büyükkeçeci, Serdar Bedii Omay. Lösemik diferansiasyonda arsenik trioksid ve metilprednisolon farklı sinyal ileti yolaklarını kullanmaktadır. XXVIII: Ulusal Hematoloji Kongresi ve V. Mezuniyet Sonrası Eğitim Kursu. 1-4 Kasım 2000, İzmir, Bildiri Özetleri Kitabı, SP-216, sayfa 240, 2000.
- Çağ Çal, Rüçhan Uslu, U. Ali Şanlı, Ceyhun Özyurt, Gürhan Günaydın, S. Bedii Omay, Erdem Göker. İlaca rezistan prostat kanseri hücre hatlarında doksazosin ve kemoterapötik ajanların sinerjistik sitotoksisiteleri. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S9, sayfa 3 (sözel bildiri).
- Aydın Özsaran, U. Ali Şanlı, Yımaz Dikmen, Rüçhan Uslu, Coşan Terek, Erdem Göker. Paclitaxel/Cisplatin kombine kemoterapi rejimine refrakter veya bu tedavi sonrasında nüks olan over kanserli hastalarda "salvage" kemoterapisi yararlı mı?. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S41, sayfa 11 (sözel bildiri).
- Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Bülent Karabulut, Erdem Göker. Osteosarkomda neoadjuvant/adjuvant yüksek doz methotraxate içeren çok ajanlı kemoterapinin etkinliği. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S61, sayfa 16 (sözel bildiri).
- Bülent Karabulut, Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Yıldıray Yüzer, A. Şükrü Menteş, Erdem Göker. Bioembolizasyon: Labaratuvardan kliniğe hepatosellüler karsinom (HCC) için yeni bir sağaltım modeli. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S81, sayfa 21 (sözel bildiri).
- V. Canfeza Sezgin, Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, Erdem Göker. Nüks/metastatik kolorektal kanserli hastalarda ikinci hat tedavi: İrinotecan (CPT 11). XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, S85, sayfa 22 (sözel bildiri).
- Ulus A. Şanlı, Rüçhan Uslu, Bülent Karabulut, V. Canfeza Sezgin, Erdem Göker. Metastatik meme kanseri olgularında ilk hat olarak kullanılan docetaxel/adriamycin kombinasyonu. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P73, sayfa 45.
- Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Bülent Karabulut, Erdem Göker. Antrasikline dirençli metastatik meme kanseri olan hastalarda tek ajan olarak docetaxel'in etkinliği. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P74, sayfa 45.
- Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, V. Canfeza Sezgin, Erdem Göker. Önceki Faz I çalışmalarda belirlenen maksimum tolere edilebilir doz (MTD) günümüz destek tedavileri ile yeniden değerlendirilmeli mi ?: ifosfamide deneyimi. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P242, sayfa 86.
- V. Canfeza Sezgin, Rüçhan Uslu, Ulus A. Şanlı, Bülent Karabulut, Erdem Göker. Pankreas kanserinde tek ajan Gemcitabine (GEM) sağlatımı. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P259, sayfa 91.
- Rüçhan Uslu, Cem Cengiz, U. Ali Şanlı, Funda Yılmaz, Gül Yüce, S. Bedii Omay, Erdem Göker. Türkiye'de hepatosellüler karsinom (HCC) olgularında p53 tümör baskılayıcı gen mutasyonu karsinogenezde ne kadar etkili? Doğuda mıyız, batıda mı?. XIII. Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P267, sayfa 93.
- Bülent Karabulut, Ulus A. Şanlı, Rüçhan Uslu, V. Canfeza Sezgin, Erdem Göker. Evre III Malign Melanomada postoperatif adjuvant interferon a2b (IFN): Hangi doz en iyisi ? Ulusal Kanser Kongresi, 27-Nisan-1 Mayıs 1999, Antalya. Bildiri Özetleri Kitabı, P309, sayfa 103.
- Erdem Göker, Rüçhan Uslu, Aydın Özsaran, Ulus A. Şanlı, Yılmaz Dikmen, Ender Terzioğlu, Nuran Alan, Ege N. Tavnergen Göker. Over kanserli hastalarda Taxol tedavisinin serum interlökin-8 (IL-8) düzeyleri üzerine etkisi. Jinekoloji ve Obstetrik Kongresi, 19-23 Mayıs 1999, Antalya. Bilimsel Program Kitapçığı, s: 14.
- N.Selvi, H. H. Aydın, G. Saydam, M. Töbü, R. Uslu, F. Büyükkeçeci, S. B. Omay. Metil prednisolonla indüklenen lösemik hücre diferansiasyonu ve apoptozunda protein fosfataz 2a katalitik ve regülatuvar subünitlerin rolü. XXVII. Ulusal Hematoloji Kongresi ve IV. Mezuniyet Sonrası Eğitim Kursu, 11-13 Kasım 1999, İstanbul, Sözel/Poster Bildiri Özetleri Kitabı, SP232, Sayfa 293, 1999.
- R. Uslu, U. Şanlı, G. Aşçı, C. Sezgin, M. Aytimur, S. Sanal, E. Göker. Sarkomlarda mega doz ifosfamid: Toksisite çalışması. 2. Türk ortopedik onkoloji kongresi, 22-24 Nisan 1998, Ankara. Özet Bildiri Kitapçığı sayfa 91.
- U. A. Şanlı, R. Uslu, B. Ç. Bilkay, S. Sanlı, E. Göker. Osteosarkomlu olgularda kemoterapi sonuçlarımız. 2. Türk ortopedik onkoloji kongresi, 22-24 Nisan 1998, Ankara. Özet Bildiri Kitapçığı, sayfa 92.
- S. Uzunoğlu, R. Uslu, G. Saydam, S. Çağırgan, M. Tombuloğlu, F. Büyükkeçeci, S. B. Omay. Fosfataz inhibitörlerinin metilprednisolonla indüklenen lösemik diferansiasyona ve apoptozise etkisi. 26. Ulusal Hematoloji Kongresi ve 3. Mezuniyet Sonrası Hematoloji Kursu, 31 Ekim-3 Kasım 1998, Ankara. Poster bildiri özetleri kitapçığı, P26, sayfa 94.
- E.Terzioğlu, C.Kırmaz, A.sin, N.Erdem, R.Uslu, A. Kokuludağ, Ö.Topalak, F.Sebik, Y.Batur, T.Kabakçı. Kronik aktif hepatitli ve sirozlu hastalarda serum IgE ve IL-4 düzeyleri. 14. Ulusal İmmünoloji Kongresi, 5-7 Mayıs 1997, İstanbul. Abstract Kitabı, P32, sayfa 130.
- A.sin, E.Terzioğlu, A. Kokuludağ, C.Kırmaz, R.Uslu, N.Erdem, M.Yalçın, F.Sebik, T.Kabakçı. Selektif IgA eksikliği ve Ankilozan Spondilitis (AS). 14. Ulusal İmmünoloji Kongresi, 5-7 Mayıs 1997, İstanbul. Abstract Kitabı, P39, sayfa 137
- N.Erdem, E.Terzioğlu, A. Kokuludağ, C.Kırmaz, R.Uslu, N. Kılınçsoy, A.Sayıner, Ö.Günel, F.Sebik, T.Kabakçı. Churg-Strauss Sendromu. 14. Ulusal İmmünoloji Kongresi, 5-7 Mayıs 1997, İstanbul. Abstract Kitabı, P43, sayfa 141.
- Zuhal Parıldar, Rüçhan Uslu, Tijen Tanyalçın, Eker Doğanavşargil, Fatma Kutay. SLE'de üriner glikozaminoglikan ve heparan sülfat atılımı. XIV. Ulusal biyokimya kongresi ve klinik labaratuvarlarda otomasyon sempozyumu, 28-31 Ekim 1997, İzmir. Özet Kitabı, C529
- E.Terzioğlu, C.Kırmaz, A.sin, A. Kokuludağ, N.Erdem, R.Uslu, F.Sebik, Y.Batur, T.Kabakçı. Sirozlu ve kronik aktif hepatitli hastalarda serum IgG subgrupları. 14. Ulusal İmmünoloji Kongresi, 5-7 Mayıs 1997, İstanbul. Abstract Kitabı, P31, sayfa 129.

Number of References26 times self referenced.
528 times referenced by other.
Referrer Publications (630 entries)- 2014, Thi, BMH; Campolmi, N; He, ZG; Pipparelli, A; Manissolle, C; Thuret, JY; Piselli, S; Forest, F; Peoc'h, M; Garraud, O; Gain, P; Thuret, G. Microarray Analysis of Cell Cycle Gene Expression in Adult Human Corneal Endothelial Cells. PLOS ONE, 9 (4):10.1371/journal.pone.0094349 APR 18 2014.
- 2014, Jo, JH; Chung, MJ; Park, JY; Bang, S; Park, SW; Chung, JB; Song, SY. Clinical Characteristics of Long-Term Survivors of Inoperable Pancreatic Cancer An 8-Year Cohort Analysis in Korea. PANCREAS, 43 (7):1022-1031; OCT 2014.
- 2014, Minami, K; Kamijo, Y; Nishizawa, Y; Tabata, S; Horikuchi, F; Yamamoto, M; Kawahara, K; Shinsato, Y; Tachiwada, T; Chen, ZS; Tsujikawa, K; Nakagawa, M; Seki, N; Akiyama, SI; Arima, K; Takeda, Y; Furukawa, T. Expression of ABCB6 Is Related to Resistance to 5-FU, SN-38 and Vincristine. ANTICANCER RESEARCH, 34 (9):4767-4773; SEP 2014.
- 2014, Hu, XM; Yuan, B; Tanaka, S; Zhou, QB; Onda, K; Toyoda, H; Hirano, T. Involvement of oxidative stress associated with glutathione depletion and p38 mitogen-activated protein kinase activation in arsenic disulfide-induced differentiation in HL-60 cells. LEUKEMIA & LYMPHOMA, 55 (2):392-404; 10.3109/10428194.2013.802779 FEB 2014.
- 2014, Morris, G; Maes, M. Mitochondrial dysfunctions in Myalgic Encephalomyelitis/chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. METABOLIC BRAIN DISEASE, 29 (1):19-36; 10.1007/s11011-013-9435-x MAR 2014.
- 2014, Kontos, CK; Christodoulou, MI; Scorilas, A. Apoptosis-related BCL2-family Members: Key Players in Chemotherapy. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 14 (3):353-374; MAR 2014.
- 2014, Hu, XJ; Xie, MY; Kluxen, FM; Diel, P. Genistein modulates the anti-tumor activity of cisplatin in MCF-7 breast and HT-29 colon cancer cells. ARCHIVES OF TOXICOLOGY, 88 (3):625-635; 10.1007/s00204-013-1184-4 MAR 2014.
- 2014, Zhao, M; Ding, JX; Zeng, K; Zhao, J; Shen, F; Yin, YX; Chen, Q. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer? TUMOR BIOLOGY, 35 (2):1051-1056; 10.1007/s13277-013-1139-7 FEB 2014.
- 2014, Dunn, SL; Olamijulo, GB; Fuglseth, HL; Holden, TP; Swieringa, LL; Sit, MJ; Rieth, NP; Tintle, NL. The State-Trait Hopelessness Scale: Development and Testing. WESTERN JOURNAL OF NURSING RESEARCH, 36 (4):552-570; 10.1177/0193945913507634 APR 2014.
- 2014, Sommerfeld, SD; Zhang, Z; Costache, MC; Vega, SL; Kohn, J. Enzymatic Surface Erosion of High Tensile Strength Polycarbonates Based on Natural Phenols. BIOMACROMOLECULES, 15 (3):830-836; 10.1021/bm4016539 MAR 2014.
- 2014, Jafary, H; Ahmadian, S; Soleimani, M. The enhanced apoptosis and antiproliferative response to combined treatment with valproate and nicotinamide in MCF-7 breast cancer cells. TUMOR BIOLOGY, 35 (3):2701-2710; 10.1007/s13277-013-1356-0 MAR 2014.
- 2014, Choi, KE; Jung, YS; Kim, DH; Song, JK; Kim, JY; Jung, YY; Eum, SY; Kim, JH; Yoon, NY; Yoo, HS; Han, SB; Hong, JT. Myriocin induces apoptotic lung cancer cell death via activation of DR4 pathway. ARCHIVES OF PHARMACAL RESEARCH, 37 (4):501-511; 10.1007/s12272-013-0315-z APR 2014.
- 2014, Pina, F; Botelho, F; Lopes, T; Lopes, I; Figueiredo, G; Portugal, R; Ferro, A; Cruz, F; Barros, H; Lunet, N. Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening? EUROPEAN JOURNAL OF CANCER PREVENTION, 23 (3):166-172; 10.1097/CEJ.0b013e3283647453 MAY 2014.
- 2014, Tanriverdi, O. Is a new perspective for definition and diagnostic criteria of fibromyalgia in early stage cancer patients necessary? MEDICAL HYPOTHESES, 82 (4):433-436; 10.1016/j.mehy.2014.01.018 APR 2014.
- 2014, Ratovitski, EA. Phospho-Delta Np63 alpha/microRNA network modulates epigenetic regulatory enzymes in squamous cell carcinomas. CELL CYCLE, 13 (5):749-761; 10.4161/cc.27676 MAR 1 2014.
- 2014, Hamada, T; Nakai, Y; Yasunaga, H; Isayama, H; Matsui, H; Takahara, N; Sasaki, T; Takagi, K; Watanabe, T; Yagioka, H; Kogure, H; Arizumi, T; Yamamoto, N; Ito, Y; Hirano, K; Tsujino, T; Tada, M; Koike, K. Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy. BRITISH JOURNAL OF CANCER, 110 (8):1943-1949; 10.1038/bjc.2014.131 APR 15 2014.
- 2014, Rennert, G; Rennert, HS; Pinchev, M; Lavie, O. The effect of bisphosphonates on the risk of endometrial and ovarian malignancies. GYNECOLOGIC ONCOLOGY, 133 (2):309-313; 10.1016/j.yuno.2014.02.014 MAY 2014.
- 2014, Gadelha, ICN; Fonseca, NBS; Oloris, SCS; Melo, MM; Soto-Blanco, B. Gossypol Toxicity from Cottonseed Products. SCIENTIFIC WORLD JOURNAL, 10.1155/2014/231635 2014.
- 2014, Oh, YI; Kim, JH; Kang, CW. Protective effect of short-term treatment with parathyroid hormone 1-34 on oxidative stress is involved in insulin-like growth factor-I and nuclear factor erythroid 2-related factor 2 in rat bone marrow derived mesenchymal stem cells. REGULATORY PEPTIDES, 189 1-10; 10.1016/j.regpep.2013.12.008 FEB 10 2014.
- 2014, Zhang, BY; Zhang, KJ; Liu, ZM; Hao, FY; Wang, M; Li, XC; Yin, ZS; Liang, H. Secreted Clusterin Gene Silencing Enhances Chemosensitivity of A549 Cells to Cisplatin Through AKT and ERK1/2 Pathways in Vitro. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 33 (4):1162-1175; 10.1159/000358685 2014.
- 2014, Ulukaya, E; Sarimahmut, M; Cevatemre, B; Ari, F; Yerlikaya, A; Dimas, K. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro. BIOMEDICINE & PHARMACOTHERAPY, 68 (4):477-482; 10.1016/j.biopha.2014.03.013 MAY 2014.
- 2014, Sak, K; Jurisoo, K; Raal, A. Estonian folk traditional experiences on natural anticancer remedies: From past to the future. PHARMACEUTICAL BIOLOGY, 52 (7):855-866; 10.3109/13880209.2013.871641 JUL 2014.
- 2014, Kumar, S; Yedjou, CG; Tchounwou, PB. Arsenic trioxide induces oxidative stress, DNA damage, and mitochondrial pathway of apoptosis in human leukemia (HL-60) cells. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 33 10.1186/1756-9966-33-42 MAY 16 2014.
- 2014, Khan, KH; Blanco-Codesido, M; Molife, LR. Cancer therapeutics: Targeting the apoptotic pathway. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 90 (3):200-219; 10.1016/j.critrevonc.2013.12.012 JUN 2014.
- 2014, Khan, KH; Blanco-Codesido, M; Molife, LR. Cancer therapeutics: Targeting the apoptotic pathway. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 90 (3):200-219; 10.1016/j.critrevonc.2013.12.012 JUN 2014.
- 2014, Khan, KH; Blanco-Codesido, M; Molife, LR. Cancer therapeutics: Targeting the apoptotic pathway. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 90 (3):200-219; 10.1016/j.critrevonc.2013.12.012 JUN 2014.
- 2014, Kim, JY; Yi, BR; Go, RE; Hwang, KA; Nam, KH; Choi, KC. Methoxychlor and triclosan stimulates ovarian cancer growth by regulating cell cycle- and apoptosis-related genes via an estrogen receptor-dependent pathway. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 37 (3):1264-1274; 10.1016/j.etap.2014.04.013 MAY 2014.
- 2014, Xiao, X; Miao, Q; Chang, C; Gershwin, ME; Ma, X. Common variable immunodeficiency and autoimmunity - an inconvenient truth. AUTOIMMUNITY REVIEWS, 13 (8):858-864; 10.1016/j.autrev.2014.04.006 AUG 2014.
- 2014, Yang, MH; Kim, HT; Lee, KT; Yang, S; Lee, JK; Lee, KH; Rhee, JC. KML001 Inhibits Cell Proliferation and Invasion in Pancreatic Cancer Cells through Suppression of NF-kappa B and VEGF-C. ANTICANCER RESEARCH, 34 (7):3469-3474; JUL 2014.
- 2014, He, T; Haapa-Paananen, S; Kaminskyy, VO; Kohonen, P; Fey, V; Zhivotovsky, B; Kallioniemi, O; Perala, M. Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. ONCOGENE, 33 (27):3538-3549; 10.1038/onc.2013.313 JUL 3 2014.
- 2014, Leze, E; Maciel-Osorio, CFE; Mandarim-de-Lacerda, CA. Advantages of Evaluating Mean Nuclear Volume as an Adjunct Parameter in Prostate Cancer. PLOS ONE, 9 (7):10.1371/journal.pone.0102156 JUL 9 2014.
- 2014, Berger, JL; Smith, A; Zorn, KK; Sukumvanich, P; Olawaiye, AB; Kelley, J; Krivak, TC. Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era. ONCOTARGETS AND THERAPY, 7 1409-1413; 10.2147/OTT.S62881 2014.
- 2014, D'Haese, JG; Hartel, M; Demir, IE; Hinz, U; Bergmann, F; Buchler, MW; Friess, H; Ceyhan, GO. Pain sensation in pancreatic diseases is not uniform: The different facets of pancreatic pain. WORLD JOURNAL OF GASTROENTEROLOGY, 20 (27):9154-9161; 10.3748/wjg.v20.i27.9154 JUL 21 2014.
- 2014, Magadoux, L; Isambert, N; Plenchette, S; Jeannin, JF; Laurens, V. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (Review). INTERNATIONAL JOURNAL OF ONCOLOGY, 45 (3):919-928; 10.3892/ijo.2014.2517 SEP 2014.
- 2014, Wang, Y; Masuyama, H; Nobumoto, E; Zhang, GM; Hiramatsu, Y. The inhibition of constitutive androstane receptor-mediated pathway enhances the effects of anticancer agents in ovarian cancer cells. BIOCHEMICAL PHARMACOLOGY, 90 (4):356-366; 10.1016/j.bcp.2014.06.003 AUG 15 2014.
- 2014, Bilici, A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. WORLD JOURNAL OF GASTROENTEROLOGY, 20 (31):10802-10812; 10.3748/wjg.v20.i31.10802 AUG 21 2014.
- 2014, Wu, H; Liu, L; Sun, W; Zhao, X; Wang, JN; Wang, L. Factors related to burnout among Chinese female hospital nurses: cross-sectional survey in Liaoning Province of China. JOURNAL OF NURSING MANAGEMENT, 22 (5):621-629; SI 10.1111/jonm.12015 JUL 2014.
- 2014, Li, D; Li, YB; Xing, HB; Guo, JL; Ping, Y; Tang, GP. Synergistic Enhancement of Lung Cancer Therapy Through Nanocarrier-Mediated Sequential Delivery of Superantigen and Tyrosin Kinase Inhibitor. ADVANCED FUNCTIONAL MATERIALS, 24 (35):5482-5492; 10.1002/adfm.201400456 SEP 17 2014.
- 2014, Bai, XL; Zhang, Q; Ye, LY; Hu, QD; Fu, QH; Zhi, X; Su, W; Su, RG; Ma, T; Chen, W; Xie, SZ; Chen, CL; Liang, TB. Inhibition of Protein Phosphatase 2A Enhances Cytotoxicity and Accessibility of Chemotherapeutic Drugs to Hepatocellular Carcinomas. MOLECULAR CANCER THERAPEUTICS, 13 (8):2062-2072; 10.1158/1535-7163.MCT-13-0800 AUG 2014.
- 2014, Zhao, ZH; Zhang, H; Chi, XQ; Li, H; Yin, ZY; Huang, DT; Wang, XM; Gao, JH. Silica nanovehicles endow arsenic trioxide with an ability to effectively treat cancer cells and solid tumors. JOURNAL OF MATERIALS CHEMISTRY B, 2 (37):6313-6323; 10.1039/c4tb00874j 2014.
- 2014, Atmaca, H; Uzunoglu, S. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells. EUROPEAN CYTOKINE NETWORK, 25 (1):1-7; 10.1684/ecn.2014.0347 MAR 2014
- 2014, Yeh, YS; Huang, ML; Chang, SF; Chen, CF; Hu, HM; Wang, JY. FOLFIRI Combined with Bevacizumab as First-Line Treatment for Metastatic Colorectal Cancer Patients with Hyperbilirubinemia after UGT1A1 Genotyping. MEDICAL PRINCIPLES AND PRACTICE, 23 (5):478-481; 10.1159/000358799 2014.
- 2013, He, Ningning; Kim, Nayoung; Yoon, Sukjoon. Somatic mutation patterns and compound response in cancers. BMB REPORTS, 46 (2):97-102; 10.5483/BMBRep.2013.46.2.226 FEB 28 2013.
- 2013, Krok, Jessica L.; Baker, Tamara A.; McMillan, Susan C. Age Differences in the Presence of Pain and Psychological Distress in Younger and Older Cancer Patients. JOURNAL OF HOSPICE & PALLIATIVE NURSING, 15 (2):107-113; 10.1097/NJH.0b013e31826bfb63 APR 2013.
- 2013, Sokalska, A; Anderson, M; Villanueva, J; Ortega, I; Bruner-Tran, KL; Osteen, KG; Duleba, AJ. Effects of Simvastatin on Retinoic Acid System in Primary Human Endometrial Stromal Cells and in a Chimeric Model of Human Endometriosis. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 98 (3):E463-E471; 10.1210/jc.2012-3402 MAR 2013.
- 2013, Han, YH; Yuan, J; Luo, ZG; Zhao, J; Wu, JB; Liu, RY; Lopez, V. Determinants of hopelessness and depression among Chinese hospitalized esophageal cancer patients and their family caregivers. PSYCHO-ONCOLOGY, 22 (11):2529-2536; 10.1002/pon.3315 NOV 2013.
- 2013, Stan, DL; Collins, NM; Olsen, MM; Croghan, I; Pruthi, S. The Evolution of Mindfulness-Based Physical Interventions in Breast Cancer Survivors. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 10.1155/2012/758641 2012.
- 2013, Akdogan, E; Cengiz, S; Yilmaz, M; Sonmez, M; Durmus, A; Oval, E; Omay, SB. Evaluation of protein tyrosine phosphatase activity in patients with acute leukemia. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 17 (1):83-87; 10.5114/wo.2013.33780 FEB 2013.
- 2013, Byrne, S; Petry, NM. Reliability and validity of the Functional Assessment of Human Immunodeficiency Virus Infection (FAHI) in patients with drug and alcohol use disorders. AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV, 25 (1):118-125; 10.1080/09540121.2012.687811 2013.
- 2013, Di Bella, G; Mascia, F; Colori, B. The Di Bella Method (DBM) in the treatment of prostate cancer: a preliminary retrospective study of 16 patients and a review of the literatüre. NEUROENDOCRINOLOGY LETTERS, 34 (6):523-528; 2013.
- 2013, Chen, WB; Wang, ZX; Jiang, CP; Ding, YT. PP2A-Mediated Anticancer Therapy. GASTROENTEROLOGY RESEARCH AND PRACTICE, 10.1155/2013/675429 2013.
- 2013, Barriere, G; Tartary, M; Rigaud, M. Metformin: A Rising Star to Fight the Epithelial Mesenchymal Transition in Oncology. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 13 (2):333-340; FEB 2013.
- 2013, Lattanzio, L; Tonissi, F; Monteverde, M; Milano, G; Merlano, MC; Lo Nigro, C. Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells. ANTI-CANCER DRUGS, 24 (2):120-130; 10.1097/CAD.0b013e328358d1dc FEB 2013.
- 2013, Guidi, F; Modesti, A; Landini, I; Nobili, S; Mini, E; Bini, L; Puglia, M; Casini, A; Dyson, PJ; Gabbiani, C; Messori, L. The molecular mechanisms of antimetastatic ruthenium compounds explored through DIGE proteomics. JOURNAL OF INORGANIC BIOCHEMISTRY, 118 94-99; 10.1016/j.jinorgbio.2012.10.003 JAN 2013.
- 2013, Thaler, R; Spitzer, S; Karlic, H; Berger, C; Klaushofer, K; Varga, F. Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells. BIOCHEMICAL PHARMACOLOGY, 85 (2):173-185; 10.1016/j.bcp.2012.10.016 JAN 15 2013.
- 2013, Rajpar, S; Fizazi, K. Bone Targeted Therapies in Metastatic Castration-Resistant Prostate Cancer. CANCER JOURNAL, 19 (1):66-70; 10.1097/PPO.0b013e31827f123e JAN-FEB 2013.
- 2013, Aprile, G; Avellini, C; Reni, M; Mazzer, M; Foltran, L; Rossi, D; Cereda, S; Iaiza, E; Fasola, G; Piga, A. Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma. TUMOR BIOLOGY, 34 (1):131-137; 10.1007/s13277-012-0520-2 FEB 2013.
- 2013, Bonifazi, A; Piergentili, A; Del Bello, F; Farande, Y; Giannella, M; Pigini, M; Amantini, C; Nabissi, M; Farfariello, V; Santoni, G; Poggesi, E; Leonardi, A; Menegon, S; Quaglia, W. Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 11.(1) Reversed Enantioselectivity of 1,4-Dioxane Derivatives in alpha(1)-Adrenergic and 5-HT1A Receptor Binding Sites Recognition. JOURNAL OF MEDICINAL CHEMISTRY, 56 (2):584-588; 10.1021/jm301525w JAN 24 2013.
- 2013, Moon, CH; Lee, SJ; Lee, HY; Lee, JC; Cha, H; Cho, WJ; Park, JW; Park, HJ; Seo, J; Lee, YH; Song, HT; Min, YJ. KML001 Displays Vascular Disrupting Properties and Irinotecan Combined Antitumor Activities in a Murine Tumor. PLOS ONE, 8 (1):10.1371/journal.pone.0053900 JAN 11 2013.
- 2013, Hall, C; Troutman, SM; Price, DK; Figg, WD; Kang, MH. Bcl-2 Family of Proteins as Therapeutic Targets in Genitourinary Neoplasms. CLINICAL GENITOURINARY CANCER, 11 (1):10-19; 10.1016/j.clgc.2012.09.002 MAR 2013.
- 2013, Sirilla, J; Overcash, J. Quality of life (QOL), supportive care, and spirituality in hematopoietic stem cell transplant (HSCT) patients. SUPPORTIVE CARE IN CANCER, 21 (4):1137-1144; 10.1007/s00520-012-1637-y APR 2013.
- 2013, Dhamne, S; Brown, RE; Covinsky, M; Dhamne, C; Eldin, K; Tatevian, N. Clear Cell Sarcoma of Kidney: Morphoproteomic Analysis Reveals Genomic Correlates and Therapeutic Options. PEDIATRIC AND DEVELOPMENTAL PATHOLOGY, 16 (1):20-27; 10.2350/11-01-0968-OA.1 JAN-FEB 2013.
- 2013, Taguchi, T; Yamamoto, D; Masuda, N; Oba, K; Nakayama, T; Nagata, T; Nomura, M; Yoshidome, K; Yoshino, H; Matsunami, N; Miyashita, M; Furuya, Y; Ishida, T; Wakita, K; Sakamoto, J; Noguchi, S. Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 71 (3):741-747; 10.1007/s00280-012-2068-7 MAR 2013.
- 2013, Hamilton, TK; Hu, NP; Kolomitro, K; Bell, EN; Maurice, DH; Graham, CH; Siemens, DR. Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer. WORLD JOURNAL OF UROLOGY, 31 (2):325-330; 10.1007/s00345-012-0848-7 APR 2013.
- 2013, Akkaya, N; Atalay, NS; Selcuk, ST; Alkan, H; Catalbas, N; Sahin, F. Frequency of fibromyalgia syndrome in breast cancer patients. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 18 (2):285-292; 10.1007/s10147-012-0377-9 APR 2013.
- 2013, Castilla, C; Chinchon, D; Medina, R; Torrubia, FJ; Japon, MA; Saez, C. PTPL1 and PKC delta contribute to proapoptotic signalling in prostate cancer cells. CELL DEATH & DISEASE, 4 10.1038/cddis.2013.90 APR 2013.
- 2013, Feldhaeusser, Br; Turek, M; Lawrence, J; Cornell, K; Gogal, Rm. Influence Of Dıfferent Cell Storage/Culture Condıtıons On Spontaneous Prolıferatıon And Level Of Tyrosıne Kınase Receptor Inhıbıtıon In Two Felıne Injectıon-Sıte Sarcoma Cell Lınes. Journal Of Immunoassay & Immunochemıstry, 34 (3):266-282; 10.1080/15321819.2012.722577 Jul 3 2013.
- 2013, Vicinanza, R; Zhang, YJ; Henning, SM; Heber, D. Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and Apoptosis. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 10.1155/2013/247504 2013.
- 2013, Perrotti, D; Neviani, P. Protein phosphatase 2A: a target for anticancer therapy. LANCET ONCOLOGY, 14 (6):E229-E238; MAY 2013.
- 2013, O'Toole, SA; Beith, JM; Millar, EKA; West, R; McLean, A; Cazet, A; Swarbrick, A; Oakes, SR. Therapeutic targets in triple negative breast cancer. JOURNAL OF CLINICAL PATHOLOGY, 66 (6):530-542; 10.1136/jclinpath-2012-201361 JUN 2013.
- 2013, Siedentopf, F; Utz-Billing, I; Gairing, S; Schoenegg, W; Kentenich, H; Kollak, I. Yoga for Patients with Early Breast Cancer and its Impact on Quality of Life - a Randomized Controlled Trial. GEBURTSHILFE UND FRAUENHEILKUNDE, 73 (4):311-317; 10.1055/s-0032-1328438 APR 2013.
- 2013, Ren, ST; Liao, YR; Kang, XN; Li, YP; Zhang, H; Ai, H; Sun, Q; Jing, J; Zhao, XH; Tan, LF; Shen, XL; Wang, B. The Antitumor Effect of a New Docetaxel-Loaded Microbubble Combined with Low-Frequency Ultrasound In Vitro: Preparation and Parameter Analysis. PHARMACEUTICAL RESEARCH, 30 (6):1574-1585; 10.1007/s11095-013-0996-5 JUN 2013.
- 2013, Kim, JY; Chung, JY; Lee, SG; Kim, YJ; Park, JE; Yun, J; Park, YC; Kim, BG; Yoo, YH; Kim, JM. p53 interferes with microtubule-stabilizing agent-induced apoptosis in prostate and colorectal cancer cells. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 31 (6):1388-1394; 10.3892/ijmm.2013.1333 JUN 2013.
- 2013, Liu, LQ; Fiorentino, L; Rissling, M; Natarajan, L; Parker, BA; Dimsdale, JE; Mills, PJ; Sadler, GR; Ancoli-Israel, S. Decreased Health-Related Quality of Life in Women With Breast Cancer Is Associated With Poor Sleep. BEHAVIORAL SLEEP MEDICINE, 11 (3):189-206; 10.1080/15402002.2012.660589 JUL 1 2013.
- 2013, Pavlidis, ET; Pavlidis, TE. Role of bevacizumab in colorectal cancer growth and its adverse effects: A review. WORLD JOURNAL OF GASTROENTEROLOGY, 19 (31):5051-5060; 10.3748/wjg.v19.i31.5051 AUG 21 2013.
- 2013, Yu, L; Su, YS; Zhao, J; Wang, H; Li, W. Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells. FEBS LETTERS, 587 (16):2542-2551; 10.1016/j.febslet.2013.06.029 AUG 19 2013.
- 2013, Kaneko, M; Ryu, S; Nishida, H; Tamasato, K; Shimodaira, Y; Nishimura, K; Kume, M. Nurses' recognition of the mental state of cancer patients and their own stress management - a study of Japanese cancer-care nurses. PSYCHO-ONCOLOGY, 22 (7):1624-1629; 10.1002/pon.3191 JUL 2013.
- 2013, Eyigor, S. Fifth-Year Medical Students' Knowledge of Palliative Care and Their Views on the Subject. JOURNAL OF PALLIATIVE MEDICINE, 16 (8):941-946; 10.1089/jpm.2012.0627 AUG 2013.
- 2013, Ciammella, P; De Bari, B; Fiorentino, A; Franco, P; Cavuto, S; Alongi, F; Livi, L; Filippi, AR. The "BUONGIORNO" Project: Burnout Syndrome Among Young Italian Radiation Oncologists. CANCER INVESTIGATION, 31 (8):522-528; 10.3109/07357907.2013.830735 OCT 2013.
- 2013, Ni, ZH; Dai, XF; Wang, B; Ding, W; Cheng, PK; Xu, L; Lian, JQ; He, FT. Natural Bcl-2 inhibitor (-)-gossypol induces protective autophagy via reactive oxygen species-high mobility group box 1 pathway in Burkitt lymphoma. LEUKEMIA & LYMPHOMA, 54 (10):2263-2268; 10.3109/10428194.2013.775437 OCT 2013.
- 2013, Ling, Q; Xu, X; Zheng, SS; Kalthoff, H. The diversity between pancreatic head and body/tail cancers: clinical parameters and in vitro models. HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 12 (5):480-487; 10.1016/S1499-3872(13)60076-4 OCT 15 2013.
- 2013, Choi, ES; Chung, T; Kim, JS; Lee, H; Kwon, KH; Cho, NP; Cho, SD. Mithramycin A induces apoptosis by regulating the mTOR/McI-1/tBid pathway in androgen-independent prostate cancer cells. JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION, 53 (2):89-93; 10.3164/jcbn.13-28 SEP 1 2013.
- 2013, El-Kenawi, AE; El-Remessy, AB. Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. BRITISH JOURNAL OF PHARMACOLOGY, 170 (4):712-729; 10.1111/bph.12344 OCT 2013.
- 2013, Combs, S; Kluger, BM; Kutner, JS. Research Priorities in Geriatric Palliative Care: Nonpain Symptoms. JOURNAL OF PALLIATIVE MEDICINE, 16 (9):1001-1007; 10.1089/jpm.2013.9484 SEP 1 2013.
- 2013, Nordholm-Carstensen, A; Wille-Jorgensen, PA; Jorgensen, LN; Harling, H. Indeterminate Pulmonary Nodules at Colorectal Cancer Staging: A Systematic Review of Predictive Parameters for Malignancy. ANNALS OF SURGICAL ONCOLOGY, 20 (12):4022-4030; 10.1245/s10434-013-3062-y NOV 2013.
- 2013, Zhu, WJ; Fu, WJ; Hu, LK. NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3. JOURNAL OF INTELLIGENT MATERIAL SYSTEMS AND STRUCTURES, 24 (16):665-673; 10.1089/cbr.2012.1443 NOV 2013.
- 2013, Zhu, Wenjie. NVP-BEZ235, Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor, Prominently Enhances Radiosensitivity of Prostate Cancer Cell Line PC-3. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, NOV 1 2013.
- 2013, Roberts, DL; Cannon, KJ; Wellik, KE; Wu, Q; Budavari, AI. Burnout in Inpatient-Based Versus Outpatient-Based Physicians: A Systematic Review and Meta-analysis. JOURNAL OF HOSPITAL MEDICINE, 8 (11):653-664; 10.1002/jhm.2093 NOV 2013.
- 2013, Garnier, N; Petruccelli, LA; Molina, MF; Kourelis, M; Kwan, S; Diaz, Z; Schipper, HM; Gupta, A; del Rincon, SV; Mann, KK; Miller, WH. The novel arsenical Darinaparsin circumvents BRG1-dependent, HO-1-mediated cytoprotection in leukemic cells. LEUKEMIA, 27 (11):2220-2228; 10.1038/leu.2013.54 NOV 2013.
- 2013, Wang, Xin; Zhang, Xu; Xu, Zhiliang; et al. Reversal Effect of Arsenic Sensitivity in Human Leukemia Cell Line K562 and K562/ADM Using Realgar Transforming SolutionBIOLOGICAL & PHARMACEUTICAL BULLETIN, 36 (4): 641-648, APR 2013.
- 2013, Vallance, J; Lavallee, C; Culos-Reed, N; Trudeau, M. Rural and Small Town Breast Cancer Survivors' Preferences for Physical Activity. INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 20 (4):522-528; 10.1007/s12529-012-9264-z DEC 2013.
- 2013, Kratz, AL; Schepens, SL; Murphy, SL. Effects of Cognitive Task Demands on Subsequent Symptoms and Activity in Adults With Symptomatic Osteoarthritis. AMERICAN JOURNAL OF OCCUPATIONAL THERAPY, 67 (6):683-691; 10.5014/ajot.2013.008540 NOV-DEC 2013.
- 2013, Xu, YY; Gu, X; Gong, MC; Guo, GY; Han, KY; An, RH. Galectin-3 inhibition sensitizes human renal cell carcinoma cells to arsenic trioxide treatment. CANCER BIOLOGY & THERAPY, 14 (10):897-906; 10.4161/cbt.25937 OCT 1 2013.
- 2013, Kapoor, S. Attenuating Effect of Gossypol on Tumor Growth in Systemic Malignancies. CELL BIOCHEMISTRY AND BIOPHYSICS, 67 (3):1551-1552; 10.1007/s12013-013-9673-x DEC 2013.
- 2013, Zheng, CY; Lam, SK; Li, YY; Fong, BMW; Mak, JCW; Ho, JCM. Combination of arsenic trioxide and chemotherapy in small cell lung cancer. LUNG CANCER, 82 (2):222-230; 10.1016/j.lungcan.2013.08.022 NOV 2013.
- 2013, Stubblefield, MD; Schmitz, KH; Ness, KK. Physical Functioning and Rehabilitation for the Cancer Survivor. SEMINARS IN ONCOLOGY, 40 (6):784-795; 10.1053/j.seminoncol.2013.09.008 DEC 2013.
- 2013, Zhang, YL; Kenny, HA; Swindell, EP; Mitra, AK; Hankins, PL; Ahn, RW; Gwin, K; Mazar, AP; O'Halloran, TV; Lengyel, E. Urokinase Plasminogen Activator System-Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy. MOLECULAR CANCER THERAPEUTICS, 12 (12):2628-2639; 10.1158/1535-7163.MCT-13-0204 DEC 2013.
- 2013, Aoyagi, T; Morii, T; Ohtsuka, K; Ohnishi, H; Tajima, T; Yoshiyama, A; Mochizuki, K; Satomi, K; Ichimura, S. Lung Cancer Cell Line Sensitivity to Zoledronic Acid Is BAX-dependent. ANTICANCER RESEARCH, 33 (12):5357-5363; DEC 2013.
- 2013, Rehman, K; Naranmandura, H. Double-Edged Effects of Arsenic Compounds: Anticancer and Carcinogenic Effects. CURRENT DRUG METABOLISM, 14 (10):1029-1041; DEC 2013.
- 2013, Cruz, DJM; Bonotto, RM; Gomes, RGB; da Silva, CT; Taniguchi, JB; No, JH; Lombardot, B; Schwartz, O; Hansen, MAE; Freitas, LH. Identification of Novel Compounds Inhibiting Chikungunya Virus-Induced Cell Death by High Throughput Screening of a Kinase Inhibitor Library. PLOS NEGLECTED TROPICAL DISEASES, 7 (10):10.1371/journal.pntd.0002471 OCT 2013.
- 2013, Sahin, ZA; Tan, M; Polat, H. Hopelessness, Depression and Social Support with End of Life Turkish Cancer Patients. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 14 (5):2823-2828; 10.7314/APJCP.2013.14.5.2823 2013.
- 2013, Srancikova, A; Horvathova, E; Kozics, K. Biological effects of four frequently used medicinal plants of Lamiaceae Minireview. NEOPLASMA, 60 (6): 585-597; 2013.
- 2012, Chmielewska, D; Kwasna, K; Piecha, M; Halski, T; Taradaj, J; Kubacki, J; Skrzypulec-Plinta, V. Selected methods of conservative treatment of stress urinary incontinence: current views. Part 1. PRZEGLAD MENOPAUZALNY, 11 (4):264-268; 10.5114/pm.2012.30227 AUG 2012.
- 2012, Kaya, Derya Ozer; Duzgun, Irem; Baltaci, Gul; et al. Effects of Calisthenics and Pilates Exercises on Coordination and Proprioception in Adult Women: A Randomized Controlled Trial JOURNAL OF SPORT REHABILITATION , 21 (3): 235-243, AUG 2012.
- 2012, Mishra, Shiraz I.; Scherer, Roberta W.; Snyder, Claire; et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 8, Article: CD008465, DOI:10.1002/14651858.CD008465.pub2, 2012.
- 2012, Stan, Daniela L.; Collins, Nerissa M.; Olsen, Molly M.; et al. The Evolution of Mindfulness-Based Physical Interventions in Breast Cancer Survivors. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE Article: 758641 DOI:10.1155/2012/758641, 2012.
- 2012, Mani, J; Vallo, S; Barth, K; Makarevic, J; Juengel, E; Bartsch, G; Wiesner, C; Haferkamp, A; Blaheta, RA. Zoledronic acid influences growth, migration and invasive activity of prostate cancer cells in vitro. PROSTATE CANCER AND PROSTATIC DISEASES, 15 (3):250-255; 10.1038/pcan.2012.9 SEP 2012.
- 2012, Li Yan; Li Jie; Zhang Xiaodong; Zhang Xiaotian; Lu Ming; Shen Lin. Safety of Bevacizumab with Chemotherapy in Treating Gastrointestinal Cancer. Chinese Journal of Clinical Oncology, 39 (12):844-848; 2012.
- 2012, Kawaii, S; Endo, K; Tokiwano, T; Yoshizawa, Y. Relationship between Structure and Antiproliferative Activity of 1-Azaflavanones. ANTICANCER RESEARCH, 32 (7):2819-2825; SI JUL 2012.
- 2012, Koppaka, V; Thompson, DC; Chen, Y; Ellermann, M; Nicolaou, KC; Juvonen, RO; Petersen, D; Deitrich, RA; Hurley, TD; Vasiliou, V. Aldehyde Dehydrogenase Inhibitors: a Comprehensive Review of the Pharmacology, Mechanism of Action, Substrate Specificity, and Clinical Application. PHARMACOLOGICAL REVIEWS, 64 (3):520-539; 10.1124/pr.111.005538 JUL 2012.
- 2012, You, BR; Park, WH. Arsenic trioxide induces human pulmonary fibroblast cell death via increasing ROS levels and GSH depletion. ONCOLOGY REPORTS, 28 (2):749-757; 10.3892/or.2012.1852 AUG 2012.
- 2012, Wells, C; Kolt, GS; Bialocerkowski, A. Defining Pilates exercise: A systematic review. COMPLEMENTARY THERAPIES IN MEDICINE, 20 (4):253-262; 10.1016/j.ctim.2012.02.005 AUG 2012.
- 2012, Akyol, Y; Tander, B; Goktepe, AS; Safaz, I; Kuru, O; Tan, AK. The Relationship of Fibromyalgia Syndrome with Neuropathic Pain, Quality of Life and Emotional Status in Male Traumatic Lower Limb Amputees. JOURNAL OF MUSCULOSKELETAL PAIN, 20 (2):87-94; 10.3109/10582452.2012.673548 JUN 2012.
- 2012, Kotowski, U; Heiduschka, G; Brunner, M; Erovic, BM; Martinek, H; Thurnher, D. Arsenic trioxide enhances the cytotoxic effect of cisplatin in head and neck squamous cell carcinoma cell lines. ONCOLOGY LETTERS, 3 (6):1326-1330; 10.3892/ol.2012.643 JUN 2012.
- 2012, Mathew, JE; Joseph, A; Srinivasan, K; Dinakaran, SV; Mantri, A; Movaliya, V. Effect of ethanol extract of Sphaeranthus indicus on cisplatin-induced nephrotoxicity in rats. NATURAL PRODUCT RESEARCH, 26 (10):933-938; 10.1080/14786419.2010.534999 2012.
- 2012, Wong, FY; Liem, N; Xie, C; Yan, FL; Wong, WC; Wang, LZ; Yong, WP. Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression. PLOS ONE, 7 (12):10.1371/journal.pone.0050786 DEC 4 2012.
- 2012, Bajwa, N; Liao, CZ; Nikolovska-Coleska, Z. Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review. EXPERT OPINION ON THERAPEUTIC PATENTS, 22 (1):37-55; 10.1517/13543776.2012.644274 JAN 2012.
- 2012, Wang, GX; Zhan, YA; Hu, HL; Wang, Y; Fu, B. Mesenchymal Stem Cells Modified to Express Interferon-beta Inhibit the Growth of Prostate Cancer in a Mouse Model. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 40 (1):317-327; JAN-FEB 2012.
- 2012, Yang, L; Yang, M; Zhang, H; et al. S100A8-targeting siRNA enhances arsenic trioxide-induced myeloid leukemia cell death by down-regulating autophagySource: INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 29 (1): 65-72, JAN 2012, DOI: 10.3892/ijmm.2011.806.
- 2012, Jones, ML; Ewing, CM; Isaacsa, WB; Getzenberg, RH. Prostate cancer-derived angiogenin stimulates the invasion of prostate fibroblasts. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 16 (1):193-201; 10.1111/j.1582-4934.2011.01283.x JAN 2012.
- 2012, Keogh, JWL; MacLeod, RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 43 (1):96-110; 10.1016/j.jpainsymman.2011.03.006 JAN 2012.
- 2012, Zhu, HY; Liu, P; Li, JY. BAG3: a new therapeutic target of human cancers? HISTOLOGY AND HISTOPATHOLOGY, 27 (3):257-261; MAR 2012.
- 2012, Ong, PS; Chan, SY; Ho, PC. Microarray analysis revealed dysregulation of multiple genes associated with chemoresistance to As2O3 and increased tumor aggressiveness in a newly established arsenic-resistant ovarian cancer cell line, OVCAR-3/AsR. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 45 (3):367-378; 10.1016/j.ejps.2011.12.003 FEB 14 2012.
- 2012, Xia, J; Li, YJ; Yang, QL; Mei, CZ; Chen, ZW; Bao, B; Ahmad, A; Miele, L; Sarkar, FH; Wang, ZW. Arsenic Trioxide Inhibits Cell Growth and Induces Apoptosis through Inactivation of Notch Signaling Pathway in Breast Cancer. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 13 (8):9627-9641; 10.3390/ijms13089627 AUG 2012.
- 2012, Arslan, S; Aydemir, O; Guler, M; Dagli, AF. Modulation of Postoperative Scarring with Tacrolimus and Octreotide in Experimental Glaucoma Filtration Surgery. CURRENT EYE RESEARCH, 37 (3):228-233; 10.3109/02713683.2011.635404 MAR 2012.
- 2012, Jiang, W; Chen, XW; Liao, MZ; Li, W; Lian, BF; Wang, LH; Meng, FL; Liu, XY; Chen, XJ; Jin, Y; Li, X. Identification of links between small molecules and miRNAs in human cancers based on transcriptional responses. SCIENTIFIC REPORTS, 2 10.1038/srep00282 FEB 21 2012.
- 2012, Caruso, A; Vigna, C; Bigazzi, V; Sperduti, I; Bongiorno, L; Allocca, A. Burnout among physicians and nurses working in Oncology. MEDICINA DEL LAVORO, 103 (2):96-105; MAR-APR 2012.
- 2012, Park, Woo Hyun; Kim, Suhn Hee. Arsenic trioxide induces human pulmonary fibroblast cell death via the regulation of Bcl-2 family and caspase-8. MOLECULAR BIOLOGY REPORTS, 39 (4):4311-4318; 10.1007/s11033-011-1218-z APR 2012.
- 2012, Pehlivan, S; Ovayolu, O; Ovayolu, N; Sevinc, A; Camci, C. Relationship between hopelessness, loneliness, and perceived social support from family in Turkish patients with cancer. SUPPORTIVE CARE IN CANCER, 20 (4):733-739; 10.1007/s00520-011-1137-5 APR 2012.
- 2012, Stan, DL; Rausch, SM; Sundt, K; Cheville, AL; Youdas, JW; Krause, DA; Boughey, JC; Walsh, MF; Cha, SS; Pruthi, S. Pilates for Breast Cancer Survivors: Impact on Physical Parameters and Quality of Life After Mastectomy. CLINICAL JOURNAL OF ONCOLOGY NURSING, 16 (2):131-141; 10.1188/12.CJON.131-141 APR 2012.
- 2012, Xu, Y; Jiang, YF; Wu, B. New Agonist- and Antagonist-based Treatment Approaches for Advanced Prostate Cancer. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 40 (4):1217-1226; JUL-AUG 2012.
- 2012, Brown, Justin C.; Huedo-Medina, Tania B.; Pescatello, Linda S.; Ryan, Stacey M.; Pescatello, Shannon M.; Moker, Emily; LaCroix, Jessica M.; Ferrer, Rebecca A.; Johnson, Blair T. The Efficacy of Exercise in Reducing Depressive Symptoms among Cancer Survivors: A Meta-Analysis. PLOS ONE, 7 (1):10.1371/journal.pone.0030955 JAN 27 2012.
- 2012, Dal Col, J; Mastorci, K; Fae, DA; Muraro, E; Martorelli, D; Inghirami, G; Dolcetti, R. Retinoic Acid/Alpha-Interferon Combination Inhibits Growth and Promotes Apoptosis in Mantle Cell Lymphoma through Akt-Dependent Modulation of Critical Targets. CANCER RESEARCH, 72 (7):1825-1835; 10.1158/0008-5472.CAN-11-2505 APR 1 2012.
- 2012, Inal, A; Kos, FT; Algin, E; Yildiz, R; Berk, V; Unek, IT; Colak, D; Kucukoner, M; Elkiran, ET; Helvaci, K; Geredeli, C; Dane, F; Balakan, O; Kaplan, MA; Durnali, AG; Harputoglu, H; Goksel, G; Ozdemir, N; Buyukberber, S; Gumus, M; Ozkan, M; Benekli, M; Isikdogan, A. Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine alone or gemcitabine plus cisplatin: retrospective analysis of a multicenter study. JOURNAL OF BUON, 17 (1):102-105; JAN-MAR 2012.
- 2012, Henry, JY; Lu, L; Adams, M; Meyer, B; Bartlett, JB; Dalgleish, AG; Galustian, C. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. PROSTATE, 72 (8):856-867; 10.1002/pros.21488 JUN 2012.
- 2012, Pectasides, D; Papaxoinis, G; Kalogeras, et al. XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis. BMC CANCER, 12 10.1186/1471-2407-12-271 JUN 29 2012.
- 2012, Huang Wanlan; Li Xuyuan; Wang Hoagbiao; Lin Wen; Lin Wenzhao; Lin Suiling; Lin Yingcheng. Study of sequence-dependent in vitro effects of zoledronic acid and paclitaxel upon human nasopharyngeal carcinoma cell line HNE1. National Medical Journal of China, 92 (16):1133-1137; 2012.
- 2012, Loriot, Y; Massard, C; Fizazi, K. Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. ANNALS OF ONCOLOGY, 23 (5):1085-1094; 10.1093/annonc/mdr573 MAY 2012.
- 2012, Yu, M; Shi, AB; Jin, B; Jiang, XG; Liang, HM; Ouyang, CX. Superior vena cava occlusion caused by Behcet disease. JOURNAL OF VASCULAR SURGERY, 55 (5):1488-1491; 10.1016/j.jvs.2011.10.035 MAY 2012.
- 2012, Lai, TY; Lin, JJ; Huang, WW; Kuo, SC; Wen, YF; Lai, IC; Lin, CC; Yang, JS; Chung, JG. Arsenic trioxide (As2O3) inhibits murine WEHI-3 leukemia in BALB/c mice in vivo. ENVIRONMENTAL TOXICOLOGY, 27 (6):364-371; 10.1002/tox.20650 MAY-JUN 2012.
- 2012, Lansakara, DSP; Rodriguez, BL; Cui, ZR. Synthesis and in vitro evaluation of novel lipophilic monophosphorylated gemcitabine derivatives and their nanoparticles. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 429 (1-2):123-134; 10.1016/j.ijpharm.2012.03.014 JUN 15 2012.
- 2012, Chaudhari, KR; Kumar, A; Khandelwal, VKM; Ukawala, M; Manjappa, AS; Mishra, AK; Monkkonen, J; Murthy, RSR. Bone metastasis targeting: A novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel. JOURNAL OF CONTROLLED RELEASE, 158 (3):470-478; 10.1016/j.jconrel.2011.11.020 MAR 28 2012.
- 2012, Thaler, R; Spitzer, S; Karlic, H; Klaushofer, K; Varga, F. DMSO is a strong inducer of DNA hydroxymethylation in pre-osteoblastic MC3T3-E1 cells. EPIGENETICS, 7 (6):635-651; 10.4161/epi.20163 JUN 2012.
- 2012, Muenyi CS, Pinhas AR, Fan TW, Brock GN, Helm CW, States JC. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Toxicol Sci. 2012 May;127(1):139-49. Epub 2012 Feb 13.
- 2012, Fidan, E; Yildiz, B; Kavgaci, H; Ozdemir, F; Aydin, F. Effects of zoledronic acid and ibandronic acid on renal functions and calcium, phosphorus and alkaline phosphatase levels in breast cancer patients with bone metastases: a retrospective analysis. WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 16 (2):176-178; 10.5114/wo.2012.28799 APR 2012.
- 2012, Kaymaz, BT; Selvi, N; Saydam, G; Sahin, F; Kosova, B. Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells. HEMATOLOGY, 17 (2):93-99; 10.1179/102453312X13221316477859 MAR 2012.
- 2012, Wang, Y; Xu, RC; Zhang, XL; Niu, XL; Qu, Y; Li, LZ; Meng, XY. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion. CYTOKINE, 59 (1):145-155; 10.1016/j.cyto.2012.04.013 JUL 2012.
- 2012, Zu, ZB; Jiang, XG; Liang, ZQ; Gu, ZL. Arsenic trioxide inhibits the growth of human glioma stem cells through activating the JNK pathway. MOLECULAR & CELLULAR TOXICOLOGY, 8 (2):187-193; 10.1007/s13273-012-0023-7 JUN 30 2012.
- 2012, Qin, X; Deng, Y; Liao, XC; Mo, CJ; Li, X; Wu, HL; He, YN; Huang, XM; Peng, T; Chen, ZP; Li, S. The IL-8 Gene Polymorphisms and the Risk of the Hepatitis B Virus/Infected Patients. DNA AND CELL BIOLOGY, 31 (6):1125-1130; 10.1089/dna.2011.1438 JUN 2012.
- 2012, Liu, ZW; Ren, GL; Shangguan, CY; Guo, LJ; Dong, ZX; Li, YY; Zhang, WN; Zhao, L; Hou, PF; Zhang, Y; Wang, XL; Lu, J; Huang, BQ. ATRA Inhibits the Proliferation of DU145 Prostate Cancer Cells through Reducing the Methylation Level of HOXB13 Gene. PLOS ONE, 7 (7):10.1371/journal.pone.0040943 JUL 13 2012.
- 2012, Vyas, A; Patitungkho, S; Jamadar, A; Adsule, S; Padhye, S; Ahmad, A; Sarkar, FH. ATRA-hydrazonate derivatives and their copper complexes against hormone-dependent (MCF-7), hormone-independent (MDA-MB-231 and BT-20) breast cancer and androgen-independent (PC3) prostate cancer cell lines. INORGANIC CHEMISTRY COMMUNICATIONS, 23 17-20; 10.1016/j.inoche.2012.05.027 SEP 2012.
- 2012, Rodel, F; Sprenger, T; Kaina, B; Liersch, T; Rodel, C; Fulda, S; Hehlgans, S. Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy. CURRENT MEDICINAL CHEMISTRY, 19 (22):3679-3688; AUG 2012.
- 2012, Puetz, TW; Herring, MP. Differential Effects of Exercise on Cancer-Related Fatigue During and Following Treatment A Meta-Analysis. AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 43 (2):E1-E24; 10.1016/j.amepre.2012.04.027 AUG 2012.
- 2012, Hsiao, WT; Tsai, MD; Jow, GM; Tien, LT; Lee, YJ. Involvement of Smac, p53, and caspase pathways in induction of apoptosis by gossypol in human retinoblastoma cells. MOLECULAR VISION, 18 (211-14):2033-2042; JUL 20 2012.
- 2012, Shpaisman, N; Sheihet, L; Bushman, J; Winters, J; Kohn, J. One-Step Synthesis of Biodegradable Curcumin-Derived Hydrogels as Potential Soft Tissue Fillers after Breast Cancer Surgery. BIOMACROMOLECULES, 13 (8):2279-2286; 10.1021/bm300518e AUG 2012.
- 2012, Jang, M; Kim, Y; Won, H; Lim, S; Jyothi, KR; Dashdorj, A; Min, YH; Kim, SY; Shokat, KM; Ha, J; Kim, SS. Carbonyl Reductase 1 Offers a Novel Therapeutic Target to Enhance Leukemia Treatment by Arsenic Trioxide. CANCER RESEARCH, 72 (16):4214-4224; 10.1158/0008-5472.CAN-12-1110 AUG 15 2012.
- 2012, Insalaco, L; Di Gaudio, F; Terrasi, M; Amodeo, V; Caruso, S; Corsini, LR; Fanale, D; Margarese, N; Santini, D; Bazan, V; Russo, A. Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 16 (9):2186-2195; 10.1111/j.1582-4934.2012.01527.x SEP 2012.
- 2012, Li, Xu-yuan; Lin, Ying-cheng; Huang, Wan-lan; et al. Zoledronic acid inhibits proliferation and impairs migration and invasion through downregulating VEGF and MMPs expression in human nasopharyngeal carcinoma cells. MEDICAL ONCOLOGY, 29 (2): 714-720 DOI: 10.1007/s12032-011-9904-1 JUN 2012.
- 2012, Kriseman, ML; Wang, WL; Sullinger, J; Schmeler, KM; Ramirez, PT; Herzog, CE; Frumovitz, M. Rhabdomyosarcoma of the cervix in adult women and younger patients. GYNECOLOGIC ONCOLOGY, 126 (3):351-356; 10.1016/j.ygyno.2012.05.008 SEP 2012.
- 2012, Lu, HR; Vlaminckx, E; Cools, F; Gallacher, DJ. Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: Importance of the choice of species, type of cardiac tissue and perfusion time. JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 66 (2):135-144; 10.1016/j.vascn.2012.03.002 SEP-OCT 2012.
- 2012, Liu Junyan; Wang Zhehai. Research Progress on Antitumor Effects of Zoledronic Acid. Chinese Journal of Clinical Oncology, 39 (12):874-876; 2012.
- 2012, Ding, Y; Huang, XB; Liu, TP; Fu, Y; Tan, ZP; Zheng, H; Zhou, TL; Dai, JG; Xu, WY. The Plasmodium Circumsporozoite Protein, a Novel NF-kappa B Inhibitor, Suppresses the Growth of SW480. PATHOLOGY & ONCOLOGY RESEARCH, 18 (4):895-902; 10.1007/s12253-012-9519-7 OCT 2012.
- 2012, Ulrich-Merzenich, G; Kelber, O; Koptina, A; Freischmidt, A; Hellmann, J; Muller, J; Zeitler, H; Seidel, MF; Ludwig, M; Heinrich, EU; Winterhoff, H. Novel neurological and immunological targets for salicylate-based phytopharmaceuticals and for the anti-depressant imipramine. PHYTOMEDICINE, 19 (10):930-939; 10.1016/j.phymed.2012.05.004 JUL 15 2012.
- 2012, Pinar, G; Pinar, T; Ayhan, A. The Strain and Hopelessness in Family Caregivers of Patients with Gynecologic Cancer Receiving Chemotherapy. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 22 (3):170-180; 10.4999/uhod.10104 2012.
- 2012, Rosati, A; Basile, A; Falco, A; d'Avenia, M; Festa, M; Graziano, V; De Laurenzi, V; Arra, C; Pascale, M; Turco, MC. Role of BAG3 protein in leukemia cell survival and response to therapy. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 1826 (2):365-369; 10.1016/j.bbcan.2012.06.001 DEC 2012.
- 2012, Thomas-Schoemann, A; Batteux, F; Mongaret, C; Nicco, C; Chereau, C; Annereau, M; Dauphin, A; Goldwasser, F; Weill, B; Lemare, F; Alexandre, J. Arsenic Trioxide Exerts Antitumor Activity through Regulatory T Cell Depletion Mediated by Oxidative Stress in a Murine Model of Colon Cancer. JOURNAL OF IMMUNOLOGY, 189 (11):5171-5177; 10.4049/jimmunol.1103094 DEC 1 2012.
- 2012, Li, XY; Lin, YC; Huang, WL; Lin, W; Wang, HB; Lin, WZ; Lin, SL. Zoledronic acid inhibits human nasopharyngeal carcinoma cell proliferation by activating mitochondrial apoptotic pathway. MEDICAL ONCOLOGY, 29 (5):3374-3380; 10.1007/s12032-012-0281-1 DEC 2012.
- 2012, Farooqi, AA; Fayyaz, S; Tahir, M; Iqbal, MJ; Bhatti, S. Breast Cancer Proteome Takes More Than Two to Tango on TRAIL: Beat Them at Their Own Game. JOURNAL OF MEMBRANE BIOLOGY, 245 (12):763-777; 10.1007/s00232-012-9490-y DEC 2012.
- 2012, Zhang Ying; Chen Cheng; Duan Jiahuai; Guo Lixin; Xiao Shuiyuan. Life Events,Anxiety Level and Job Satisfaction for Medical Staffs in Military. Chinese Journal of Clinical Psychology, 20 (4):567-570; 2012.
- 2012, Meulenbeld, H. J.; van Werkhoven, E. D.; Coenen, J. L. L. M.; et al. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro). EUROPEAN JOURNAL OF CANCER, 48 (16): 2993-3000, DOI: 10.1016/j.ejca.2012.05.014, 2012.
- 2012, Seneff, Stephanie; Lauritzen, Ann; Davidson, Robert; Lentz-Marino, Laurie. Is Endothelial Nitric Oxide Synthase a Moonlighting Protein Whose Day Job is Cholesterol Sulfate Synthesis? Implications for Cholesterol Transport, Diabetes and Cardiovascular Disease. ENTROPY, 14 (12):2492-2530; 10.3390/e14122492 DEC 2012.
- 2012, de Graaff, FM; Mistiaen, P; Deville, WLJM; Francke, AL. Perspectives on care and communication involving incurably ill Turkish and Moroccan patients, relatives and professionals: a systematic literature review. BMC PALLIATIVE CARE, 11 10.1186/1472-684X-11-17 SEP 18 2012.
- 2012, Brahmi, D; Ayed, Y; Hfaiedh, M; Bouaziz, C; Ben Mansour, H; Zourgui, L; Bacha, H. Protective effect of cactus cladode extract against cisplatin induced oxidative stress, genotoxicity and apoptosis in balb/c mice: combination with phytochemical composition. BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 12 10.1186/1472-6882-12-111 JUL 31 2012.
- 2012, Kaymaz, BT; Selvi, N; Saydam, G; Sahin, F; Kosova, B. Methylprednisolone induces apoptosis by interacting with the JAK/STAT pathway in HL-60 and K-562 leukemic cells. HEMATOLOGY 17 ( 2): 93-99, MAR 2012.
- 2011, Cantarero-Villanueva, I.; Fernandez-Lao, C.; Fernandez-De-Las-Penas, C.; Diaz-Rodriguez, L.; Sanchez-Cantalejo, E.; Arroyo-Morales, M. Associations among musculoskeletal impairments, depression, body image and fatigue in breast cancer survivors within the first year after treatment. EUROPEAN JOURNAL OF CANCER CARE 20 (5): 632-639 10.1111/j.1365-2354.2011.01245.x SEP 2011.
- 2011, Hasskarl, J; Kaufmann, M; Schmid, HA. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors. FUTURE ONCOLOGY 7 (7): 895-913 10.2217/FON.11.66 JUL 2011.
- 2011, Zhang, WJ; Wang, LX; Fan, QX; Wu, XN; Wang, F; Wang, R; Ma, ZJ; Yang, JH; Lu, SH. Arsenic trioxide re-sensitizes ER alpha-negative breast cancer cells to endocrine therapy by restoring ER alpha expression in vitro and in vivo. ONCOLOGY REPORTS 26 (3): 621-628 10.3892/or.2011.1352 SEP 2011.
- 2011, Epplen R, Stockle M, Engelmann U, et al. Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines. ACTA ONCOLOGICA 50 (1): 127-133, JAN 2011.
- 2011, Chitapanarux, I: Lorvidhaya, V: Tharavichitkul, E: Mayurasakorn, S: Sittitrai, P: Pattarasakulchai, T: Tananuwat, R: Srivanitchapoom, C. A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer. AURIS NASUS LARYNX 38 (1): 108-113 FEB 2011.
- 2011, Wang, K: Cheng, LF: Liang, YH: Liu, DH: Li, K: Wang, P. Adenovirus-mediated delivery of shRNA against bFGF mRNA suppresses growth of cultured human primary prostatic stromal cells. MOLECULAR BIOLOGY REPORTS 38 (2): 971-976 FEB 2011.
- 2011, Bracarda S, Logothetis C, Sternberg CN, et al. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer. BJU INTERNATIONAL 107: 13-20, Suppl. 2, APR 2011.
- 2011, Ning, Y: Manegold, PC: Hong, YK: Zhang, W: Pohl, A: Lurje, G: Winder, T: Yang, DY: LaBonte, MJ: Wilson, PM: Ladner, RD: Lenz, HJ. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. INTERNATIONAL JOURNAL OF CANCER 128 (9): 2038-2049 MAY 1 2011.
- 2011, Chauhan, HPS: Bhatiya, S: Bakshi, A: Makwana, KS. SYNTHESIS, SPECTROSCOPIC, Structural Characterization, And Antimicrobial Studies Of 1,3-Dithia-2-Arsacyclopentane Derivatives With Oxygen And Sulfur Donor Ligands. PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS 186 (3): 511-519 2011.
- 2011, Leyland-Jones, B: Smith, BR. Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. LANCET ONCOLOGY 12 (3): 286-295 MAR 2011.
- 2011, Tamura, T: Shomori, K: Nakabayashi, M: Fujii, N: Ryoke, K: Ito, H. Zoledronic acid, a third-generation bisphosphonate, inhibits cellular growth and induces apoptosis in oral carcinoma cell lines. ONCOLOGY REPORTS 25 (4): 1139-1143 APR 2011.
- 2011, Woolgar, JA: Ferlito, A: Devaney, KO: Rinaldo, A: Barnes, L. How trustworthy is a diagnosis in head and neck surgical pathology? A consideration of diagnostic discrepancies (errors). EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY 268 (5): 643-651 MAY 2011.
- 2011, Wang, Y: Zhang, Y: Yang, L: Cai, BZ: Li, JP: Zhou, Y: Yin, L: Yang, LL: Yang, BF: Lu, YJ. Arsenic trioxide induces the apoptosis of human breast cancer MCF-7 cells through activation of caspase-3 and inhibition of HERG channels. EXPERIMENTAL AND THERAPEUTIC MEDICINE 2 (3): 481-486 MAY-JUN 2011
- 2011, Haviland M. G.; Banta J. E.; Przekop P. Fibromyalgia: prevalence, course, and co-morbidities in hospitalised patients in the United States, 1999-2007 CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 29 (6) Supp: 69: S79-S87, NOV-DEC 2011.
- 2011, Kim, SW; Kim, SY; Kim, JM; Park, MH; Yoon, JH; Shin, MG; Na, HS; Bae, KY; Shin, IS; Yoon, JS. Relationship between a hopeful attitude and cellular immunity in patients with breast cancer. GENERAL HOSPITAL PSYCHIATRY 33 (4): 371-376 10.1016/j.genhosppsych.2011.04.002 JUL-AUG 2011
- 2011, Muenyi, Clarisse S.; States, Vanessa A.; Masters, Joshua H.; Fan, Teresa W.; Helm, C. William; States, Christopher. Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). JOURNAL OF OVARIAN RESEARCH 4 10.1186/1757-2215-4-9 JUN 22 2011.
- 2011, Lee, SM; Lee, OS; O'Halloran, TV; Schatz, GC; Nguyen, ST. Triggered Release of Pharmacophores from [Ni(HAsO3)]-Loaded Polymer-Caged Nanobin Enhances Pro-apoptotic Activity: A Combined Experimental and Theoretical Study. ACS NANO 5 (5): 3961-3969 MAY 2011.
- 2011, Pang, XF; Wu, YY; Wu, YG; Lu, BB; Chen, J; Wang, JQ; Yi, ZF; Qu, WJ; Liu, MY. (-)-Gossypol Suppresses the Growth of Human Prostate Cancer Xenografts via Modulating VEGF Signaling-Mediated Angiogenesis. MOLECULAR CANCER THERAPEUTICS 10 (5): 795-805 MAY 2011.
- 2011, Yuan, Z; Wang, F; Zhao, ZW; Zhao, XY; Qiu, J; Nie, CL; Wei, YQ. BIM-Mediated AKT Phosphorylation Is a Key Modulator of Arsenic Trioxide-Induced Apoptosis in Cisplatin-Sensitive and -Resistant Ovarian Cancer Cells. PLOS ONE 6 (5): Art. No. e20586 MAY 31 2011.
- 2011, Kim, YJ; Chung, JY; Lee, SG; Kim, JY; Park, JE; Kim, WR; Joo, BS; Han, SH; Yoo, KS; Yoo, YH; Kim, JM. Arsenic trioxide-induced apoptosis in TM4 Sertoli cells: The potential involvement of p21 expression and p53 phosphorylation. TOXICOLOGY 285 (3): 142-151 10.1016/j.tox.2011.04.013 JUL 29 2011.
- 2011, Mandili, G; Marini, C; Carta, F; Zanini, C; Prato, M; Khadjavi, A; Turrini, F; Giribaldi, G. Identification of Phosphoproteins as Possible Differentiation Markers in All-Trans-Retinoic Acid-Treated Neuroblastoma Cells. PLOS ONE 6 (5): Art. No. e18254 MAY 5 2011.
- 2011, Sun Hui; Zhang Shaojun. Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 410 (3): 692-697 DOI: 10.1016/j.bbrc.2011.06.060f JUL 8 2011.
- 2011, Montero-Marin Jesus; Garcia-Campayo Javier; Fajo-Pascual Marta; et al. Sociodemographic and occupational risk factors associated with the development of different burnout types: the cross-sectional University of Zaragoza study. BMC PSYCHIATRY 11 (49) DOI: 10.1186/1471-244X-11-49 MAR 29 2011.
- 2011, Machiels, JP; Schmitz, S. Management and palliative chemotherapy for metastatic or recurrent squamous cell carcinoma of the head and neck. EXPERT REVIEW OF ANTICANCER THERAPY 11 (3): 359-371 MAR 2011.
- 2011, Qi, RL; Shen, MW; Cao, XY; Guo, R; Tian, XJ; Yu, JY; Shi, XY. Exploring the dark side of MTT viability assay of cells cultured onto electrospun PLGA-based composite nanofibrous scaffolding materials. ANALYST 136 (14): 2897-2903 2011.
- 2011, Asmane, I; Ceraline, J; Duclos, B; Rob, L; Litique, V; Barthelemy, P; Bergerat, JP; Dufour, P; Kurtz, JE. New Strategies for Medical Management of Castration-Resistant Prostate Cancer. ONCOLOGY 80 (1-2): 1-11 2011
- 2011, Zeybek, ND; Inan, S; Ekerbicer, N; Vatansever, HS; Karakaya, J; Muftuoglu, SF. The effects of Gemcitabine and Vinorelbine on inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) distribution of MCF-7 breast cancer cells. ACTA HISTOCHEMICA 113 (1): 62-67 2011
- 2011, No Jae Hong ; Jeon Yong-Tark ; Kim Yong-Beom ; et al. Quantitative Detection of Serum Survivin and Its Relationship with Prognostic Factors in Ovarian Cancer. GYNECOLOGIC AND OBSTETRIC INVESTIGATION 71 (2): 136-140, DOI: 10.1159/000316049, 2011.
- 2011, Shen, P; Jiang, TW; Lu, HQ; Han, HX; Luo, RC. Combination of Poly I:C and arsenic trioxide triggers apoptosis synergistically via activation of TLR3 and mitochondrial pathways in hepatocellular carcinoma cells. CELL BIOLOGY INTERNATIONAL 35 (8): 803-810 10.1042/CBI20100739 AUG 2011.
- 2011, Wakatsuki, T; Irisawa, A; Terashima, M; Shibukawa, G; Takagi, T; Imamura, H; Takahashi, Y; Sato, A; Sato, M; Ikeda, T; Suzuki, R; Hikichi, T; Obara, K; Ohira, H. ATP assay-guided chemosensitivity testing for gemcitabine with biopsy specimens obtained from unresectable pancreatic cancer using endoscopic ultrasonography-guided fine-needle aspiration. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY 16 (4): 387-394.
- 2011, Asmane, I; Kurtz, JE; Bajard, A; Guastalla, JP; Meeus, P; Tredan, O; Galy, IL; Moullet, I; Ardisson, P; Vincent, L; Coeffic, D; Dufresne, A; Bergerat, JP; Ray-Coquard, I. Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. BULLETIN DU CANCER 98 (9): E80-E89 10.1684/bdc.2011.1436 OCT 2011
- 2011, Ai, ZL; Pan, HT; Suo, T; Lv, CT; Wang, YQ; Tong, SX; Liu, HB. Arsenic oxide targets stem cell marker CD133/prominin-1 in gallbladder carcinoma. CANCER LETTERS 310 (2): 181-187 10.1016/j.canlet.2011.06.035 NOV 28 2011.
- 2011, Ouyang, DY; Ji, YH; Saltis, M; Xu, LH; Zhang, YT; Zha, QB; Cai, JY; He, XH. Valproic acid synergistically enhances the cytotoxicity of gossypol in DU145 prostate cancer cells: An iTRTAQ-based quantitative proteomic analysis. JOURNAL OF PROTEOMICS 74 (10): 2180-2193 10.1016/j.jprot.2011.06.016 SEP 6 2011.
- 2011, Luong, HTT; Chaplin, J; McRae, AF; Medland, SE; Willemsen, G; Nyholt, DR; Henders, AK; Hoekstra, C; Duffy, DL; Martin, NG; Boomsma, DI; Montgomery, GW; Painter, JN. Variation in BMPR1B, TGFRB1 and BMPR2 and Control of Dizygotic Twinning. TWIN RESEARCH AND HUMAN GENETICS 14 (5): 408-416 10.1375/twin.14.5.408 OCT 2011.
- 2011, Li, Y; Hao, Y; Gao, M; Dong, W; Hu, MR; Yuan, ST; Song, L. IKK beta downregulation is critical for triggering JNKs-dependent cell apoptotic response in the human hepatoma cells under arsenite exposure. MOLECULAR AND CELLULAR BIOCHEMISTRY 358 (1-2): 61-66.
- 2011, Ali, AM; Ueno, T; Tanaka, S; Takada, M; Ishiguro, H; Abdellah, AZ; Toi, M. Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. EUROPEAN JOURNAL OF CANCER 47 (15): 2265-2272 10.1016/j.ejca.2011.06.015 OCT 201.1
- 2011, Wang, Y; Qu, Y; Niu, XL; Sun, WJ; Zhang, XL; Li, LZ. Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. CYTOKINE 56 (2): 365-375 10.1016/j.cyto.2011.06.005 NOV 2011.
- 2011, Huang, J; Hu, W; Sood, AK. Prognostic biomarkers in ovarian cancer. CANCER BIOMARKERS 8 (4-5): 231-251 10.3233/CBM-2011-0212 2011.
- 2011, Ayala, GX. Effects of a Promotor-Based Intervention to Promote Physical Activity: Familias Sanas y Activas. AMERICAN JOURNAL OF PUBLIC HEALTH 101 (12): 2261-2268 10.2105/AJPH.2011.300273 DEC 2011.
- 2011, Metcalf, S; Pandha, HS; Morgan, R. Antiangiogenic effects of zoledronate on cancer neovasculature.FUTURE ONCOLOGY 7 (11): 1325-1333 10.2217/FON.11.113 NOV 2011.
- 2011, Adams, SF; Marsh, EB; Elmasri, W; Halberstadt, S; VanDecker, S; Sammel, MD; Bradbury, AR; Daly, M; Karlan, B; Rubin, SC. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. GYNECOLOGIC ONCOLOGY, 123 (3):486-491; 10.1016/j.ygyno.2011.08.032 DEC 2011.
- 2011, Dai, YH; Wang, J; Xia, J; Hong, Y; Chen, N; Cheng, B. Genome-Wide Transcriptional Profiling Analysis of All Trans Retinoic Acid-Treated Tongue Carcinoma SCC-9 Cells. JOURNAL OF SURGICAL ONCOLOGY, 104 (7):830-835; 10.1002/jso.21998 DEC 2011.
- 2011, Chien, MH; Yeh, CB; Li, YC; Wei, LH; Chang, JH; Peng, YT; Yang, SF; Kuo, WH. Relationship of Interleukin-8 Gene Polymorphisms With Hepatocellular Carcinoma Susceptibility and Pathological Development. JOURNAL OF SURGICAL ONCOLOGY, 104 (7):798-803; 10.1002/jso.22037 DEC 2011.
- 2011, Liang, SY; Li, CC; Wu, SF; Wang, TJ; Tsay, SL. The Prevalence and Impact of Pain Among Taiwanese Oncology Outpatients. PAIN MANAGEMENT NURSING, 12 (4):197-205; 10.1016/j.pmn.2010.10.034 DEC 2011.
- 2011, Siddiqui, RA; Harvey, KA; Xu, ZD; Bammerlin, EM; Walker, C; Altenburg, JD. Docosahexaenoic acid: A natural powerful adjuvant that improves efficacy for anticancer treatment with no adverse effects. BIOFACTORS, 37 (6):399-412; 10.1002/biof.181 NOV-DEC 2011.
- 2011, Rho, JH; Zhang, W; Murali, M; Roehrl, MNA; Wang, JY. Human Proteins with Affinity for Dermatan Sulfate Have the Propensity to Become Autoantigens. AMERICAN JOURNAL OF PATHOLOGY, 178 (5):2177-2190; 10.1016/j.ajpath.2011.01.031 MAY 2011.
- 2011, Crawford, B. K.; Piault, E. C.; Lai, C.; Bennett, R. M. Assessing fibromyalgia-related fatigue: content validity and psychometric performance of the Fatigue Visual Analogue Scale in adult patients with fibromyalgia. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 29 (6):S34-S43; 69 NOV-DEC 2011.
- 2011, Montero-Marin, J; Monticelli, F; Casas, M; Roman, A; Tomas, I; Gili, M; Garcia-Campayo, J. Burnout syndrome among dental students: a short version of the "Burnout Clinical Subtype Questionnaire" adapted for students (BCSQ-12-SS). BMC MEDICAL EDUCATION, 11 10.1186/1472-6920-11-103 DEC 12 2011.
- 2010, Gheita, TA: Ezzat, Y: Sayed, S: El-Mardenly, G: Hammam, W. Musculoskeletal manifestations in patients with malignant disease. CLINICAL RHEUMATOLOGY 29 (2): 181-188 FEB 2010.
- 2010, Caraglia, M: Marra, M: Naviglio, S: Botti, G: Addeo, R: Abbruzzese, A. Zoledronic acid: an unending tale for an antiresorptive agent. EXPERT OPINION ON PHARMACOTHERAPY 11 (1): 141-154 JAN 2010
- 2010, Kamarajan, P: Bunek, J: Lin, Y: Nunez, G: Kapila, YL. Receptor-interacting Protein Shuttles between Cell Death and Survival Signaling Pathways. MOLECULAR BIOLOGY OF THE CELL 21 (3): 481-488 FEB 1 2010.
- 2010, Salazar, AM: Miller, HL: McNeely, SC: Sordo, M: Ostrosky-Wegman, P: States, JC. Suppression of p53 and p21(CIP1/WAF1) Reduces Arsenite-Induced Aneuploidy. CHEMICAL RESEARCH IN TOXICOLOGY 23 (2): 357-364 FEB 2010.
- 2010, Ruscica, M: Arvigo, M: Gatto, F: Dozio, E: Feltrin, D: Culler, MD: Minuto, F: Motta, M: Ferone, D: Magni, P. Regulation of prostate cancer cell proliferation by somatostatin receptor activation. MOLECULAR AND CELLULAR ENDOCRINOLOGY 315 (1-2): 254-262 FEB 5 2010.
- 2010, Shehata, HH: Abou Ghalia, AH: Elsayed, EK: Ziko, OO: Mohamed, SS. Detection of survivin protein in aqueous humor and serum of retinoblastoma patients and its clinical significance. CLINICAL BIOCHEMISTRY 43 (4-5): 362-366 MAR 2010.
- 2010, Sharma, B: Singh, S: Varney, ML: Singh, RK. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. EXPERT OPINION ON THERAPEUTIC TARGETS 14 (4): 435-442 APR 2010.
- 2010, Hicsonmez, G. A novel approach to treatment in childhood acute myeloblastic leukemia and myelodysplastic syndrome with high-dose methylprednisolone as a differentiation- and apoptosis-inducing agent of myeloid leukemic cells. TURKISH JOURNAL OF HEMATOLOGY 27 (1): 1-7 MAR 2010.
- 2010, Li, Xun: Wu, Ji-Feng. Recent Developments in Patent Anti-Cancer Agents Targeting the Matrix Metalloproteinases (MMPs). RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY 5 (2): 109-141 JUN 2010.
- 2010, Neville-Webbe, H.L., Coleman, R.E. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. EUROPEAN JOURNAL OF CANCER 46 (7): 1211–1222, 2010.
- 2010, Zhang, XQ: Huang, XF: Mu, SJ: An, QX: Xia, AJ: Chen, R: Wu, DC. Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. ASIAN JOURNAL OF ANDROLOGY 12 (3): 390-399 MAY 2010
- 2010, Gao M, Dong W, Hu MR, et al. GADD45 alpha Mediates Arsenite-Induced Cell Apoptotic Effect in Human Hepatoma Cells Via JNKs/AP-1-Dependent Pathway. JOURNAL OF CELLULAR BIOCHEMISTRY 109 (6): 1264-1273 APR 15 2010.
- 2010, Bayet-Robert M, Morvan D, Chollet P, et al. Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. BREAST CANCER RESEARCH AND TREATMENT 120 (3): 613-626, APR 2010
- 2010, Oh, YI: Kim, JH: Kang, CW. Oxidative stress in MCF-7 cells is involved in the effects of retinoic acid-induced activation of protein kinase C-delta on insulin-like growth factor-I secretion and synthesis. GROWTH HORMONE & IGF RESEARCH 20 (2): 101-109 APR 2010.
- 2010, Volate, SR: Kawasaki, BT: Hurt, EM: Milner, JA: Kim, YS: White, J: Farrar, WL. Gossypol Induces Apoptosis by Activating p53 in Prostate Cancer Cells and Prostate Tumor-Initiating Cells. MOLECULAR CANCER THERAPEUTICS 9 (2): 461-470 FEB 2010
- 2010, Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, et al. Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? MOLECULAR CANCER THERAPEUTICS 9 (5): 1092-1099, MAY 2010.
- 2010, Li, YL: Xing, D: Chen, Q: Chen, WR. Enhancement of chemotherapeutic agent-induced apoptosis by inhibition of NF-kappa B using ursolic acid. INTERNATIONAL JOURNAL OF CANCER 127 (2): 462-473 JUL 15 2010.
- 2010, Zhou, Liping: Luan, Hong: Dong, Xihua: Li, Yan. Activation of the PI3K/Akt and MAPK signaling pathways antagonizes adriamycin-induced HL-60 leukemia cell apoptosis. MOLECULAR MEDICINE REPORTS 3 (4): 641-644 JUL-AUG 2010.
- 2010, Ferrandina, G. Serious Ethical Dilemma of Single-Agent Pegylated Liposomal Doxorubicin Employed As a Control Arm in Ovarian Cancer Chemotherapy Trials Reply. JOURNAL OF CLINICAL ONCOLOGY 28 (19): E321-E322 JUL 1 2010
- 2010, Arrieta O, Gonzalez-De la Rosa CH, Arechaga-Ocampo E, et al. Randomized Phase II Trial of All-Trans-Retinoic Acid With Chemotherapy Based on Paclitaxel and Cisplatin As First-Line Treatment in Patients With Advanced Non-Small-Cell Lung CancerJOURNAL OF CLINICAL ONCOLOGY 28 21 3463-3471 JUL 20 2010.
- 2010, Gravina, GL: Marampon, F: Di Staso, M: Bonfili, P: Vitturini, A: Jannini, EA: Pestell, RG: Tombolini, V: Festuccia, C. 5-Azacitidine Restores and Amplifies the Bicalutamide Response on Preclinical Models of Androgen Receptor Expressing or Deficient Prostate Tumors. PROSTATE 70 (11): 1166-1178 AUG 1 2010.
- 2010, Richards, NG: Rittenhouse, DW: Freydin, B: Cozzitorto, JA: Grenda, D: Rui, H: Gonye, G: Kennedy, EP: Yeo, CJ: Brody, JR: Witkiewicz, AK. HuR Status is a Powerful Marker for Prognosis and Response to Gemcitabine-Based Chemotherapy for Resected Pancreatic Ductal Adenocarcinoma Patients. ANNALS OF SURGERY 252 (3): 499-506 SEP 2010.
- 2010, Han YH, Moon HJ, You BR, et al. Effects of arsenic trioxide on cell death, reactive oxygen species and glutathione levels in different cell types. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 25 (1): 121-128, 2010.
- 2010, Ren TT, Guo W, Peng CL, et al. Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway. CANCER BIOLOGY & THERAPY 10 (3): 12349, AUG 1 2010.
- 2010, Izdebska, M: Grzanka, A: Ostrowski, M: Zuryn, A: Grzanka, D. Effect of arsenic trioxide (Trisenox) on actin organization in K-562 erythroleukemia cells. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA 47 (3): 453-459 2009.
- 2010, Naumnik, W: Nilklinska, W: Ossolinska, M: Chyczewska, E. Serum levels of HMGB1, survivin, and VEGF in patients with advanced Non-small Cell Lung Cancer during chemotherapy. FOLIA HISTOCHEMICA ET CYTOBIOLOGICA 47 (4): 703-709 2009.
- 2010, Yan, F: Cao, XX: Jiang, HX: Zhao, XL: Wang, JY: Lin, YH: Liu, QL: Zhang, C: Jiang, BA: Guo, F. A Novel Water-Soluble Gossypol Derivative Increases Chemotherapeutic Sensitivity and Promotes Growth Inhibition in Colon Cancer. JOURNAL OF MEDICINAL CHEMISTRY 53 (15): 5502-5510 AUG 12 2010.
- 2010, Anbar, RD: Murthy, VV. Reestablishment of Hope as an Intervention for a Patient with Cystic Fibrosis Awaiting Lung Transplantation. JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE 16 (9): 1007-1010 SEP 2010.
- 2010, Zhong, F: Zhang, SN: Shao, CK: Yang, J: Wu, XY. Arsenic Trioxide Inhibits Cholangiocarcinoma Cell Growth and induces Apoptosis. PATHOLOGY & ONCOLOGY RESEARCH 16 (3): 413-420 SEP 2010.
- 2010, Eyigor, S. Physical Activity and Rehabilitation Programs Should Be Recommended on Palliative Care for Patients with Cancer. JOURNAL OF PALLIATIVE MEDICINE 13 (10): 1183-1184 OCT 2010.
- 2010, Green, J: Lipton, A. Anticancer Properties of Zoledronic Acid. CANCER INVESTIGATION 28 (9): 944-957 NOV 2010.
- 2010, Ourique, AF: Azoubel, S: Ferreira, CV: Silva, CB: Marchiori, MCL: Pohlmann, AR: Guterres, SS: Beck, RCR. Lipid-Core Nanocapsules as a Nanomedicine for Parenteral Administration of Tretinoin: Development and In Vitro Antitumor Activity on Human Myeloid Leukaemia Cells. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 6 (3): 214-223 JUN 2010.
- 2010, Chen, MJ: Yang, PY: Ye, YZ: Hu, DN: Chen, MF. Arsenic Trioxide Induces Apoptosis in Uveal Melanoma Cells Through the Mitochondrial Pathway. AMERICAN JOURNAL OF CHINESE MEDICINE 38 (6): 1131-1142 2010.
- 2010, Smith, DM: Patel, S: Raffoul, F: Haller, E: Mills, GB: Nanjundan, M. Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. CELL DEATH AND DIFFERENTIATION 17 (12): 1867-1881 DEC 2010.
- 2010, Zabaras, D: Konczak, I. Potential Physiological Activities Of Lipophilic And Hydrophilic Fractions From Australian-Grown Fruits. Recent Advances In Food And Flavor Chemistry: Food Flavors And Encapsulation, Health Benefits, Analytical Methods, And Molecular Biology Of Functional Foods : 361-368 2010.
- 2010, Demirci, U: Benekli, M: Buyukberber, S: Coskun, U. Late Side Effects of Cancer Therapy. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI 20 (4): 250-261 2010.
- 2010, El-Attar, HA: Kandil, MH: El-Kerm, YM: El-Ghandour, MK. Comparison of Serum Survivin and Alpha Fetoprotein in Egyptian Patients with Hepatocellular Carcinoma Associated with Hepatitis C Viral Infection. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION 11 (4): 897-903 2010.
- 2010, Volarevic, V: Milovanovic, M: Djekovic, A: Petrovic, B: Arsenijevic, N: Bugarcic, ZD. The cytotoxic effects of some selected gold(III) complexes on 4T1 cells and their role in the prevention of breast tumor growth in BALB/c mice. JOURNAL OF BUON 15 (4): 768-773 OCT-DEC 2010.
- 2010, Mandegary, A: Mehrabani, M. Effects of arsenic trioxide, all-trans-retinoic acid and dexamethasone on NB4 cell line. DARU-JOURNAL OF PHARMACEUTICAL SCIENCES 18 (4): 303-309 FAL 2010
- 2010, Montero-Marin J, Garcia-Campayo J, Fajo-Pascual M, et al. Sociodemographic and occupational risk factors associated with the development of different burnout types: the cross-sectional University of Zaragoza study. MEDICAL ONCOLOGY 27 (3): 968-974, SEP 2010.
- 2009, Dizdar, O: Aksoy, S: Altundag, K. Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma? ANNALS OF ONCOLOGY 20 (1): 189-189 JAN 2009.
- 2009, Chamorey E, Barriere J, Ferrero JM, et al. Reply to Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma? ANNALS OF ONCOLOGY 20 1 189-190 JAN 2009.
- 2009, Karasulu, HY: Kantarci, G: Karaca, B: Armagan, V: Guneri, T: Goker, E. Determining the Cytotoxicity of Methotrexate-Loaded Microemulsion on Human Breast, Ovarian, and Prostate Carcinoma Cell Lines: A New Modality for an Old Drug. DRUG DEVELOPMENT RESEARCH 70 (1): 49-56 FEB 2009.
- 2009, Wang, Y: An, RH: Dong, XS: Pan, SH: Duan, GW: Sun, XY. Protein Kinase C Is Involved in Arsenic Trioxide-Induced Apoptosis and Inhibition of Proliferation in Human Bladder Cancer Cells. UROLOGIA INTERNATIONALIS 82 (2): 214-221 2009
- 2009, Gunes, DA: Florea, AM: Splettstoesser, F: Busselberg, D. Co-application of arsenic trioxide (As2O3) and cisplatin (CDDP) on human SY-5Y neuroblastoma cells has differential effects on the intracellular calcium concentration ([Ca2+](i)) and cytotoxicity. NEUROTOXICOLOGY 30 (2): 194-202 MAR 2009
- 2009, Schilder, RJ: Pathak, HB: Lokshin, AE: Holloway, RW: Alvarez, RD: Aghajanian, C: Min, H: Devarajan, K: Ross, E: Drescher, CW: Godwin, AK. Phase II trial of single agent cetuximab in patients with persistent or recurrent epithelial ovarian or primary peritoneal carcinoma with the potential for dose escalation to rash. GYNECOLOGIC ONCOLOGY 113 (1): 21-27 APR 2009
- 2009, Franco, R: Sanchez-Olea, R: Reyes-Reyes, EM: Panayiotidis, MI. Environmental toxicity, oxidative stress and apoptosis: Menage a Trois. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 674 (1-2): 3-22 Sp. Iss. SI MAR 31 2009.
- 2009, Melo, PS: De Azevedo, MMM: Frungillo, L: Anazetti, MC: Marcato, PD: Duran, N. Nanocytotoxicity: Violacein and Violacein-Loaded Poly (D, L-lactide-co-glycolide) Nanoparticles Acting on Human Leukemic Cells. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY 5 (2): 192-201 APR 2009
- 2009, Oevermann, L: Scheitz, J: Starke, K: Kock, K: Kiefer, T: Dolken, G: Niessen, J: Greinacher, A: Siegmund, W: Zygmunt, M: Kroemer, HK: Jedlitschky, G: Ritter, CA. Hematopoietic stem cell differentiation affects expression and function of MRP4 (ABCC4), a transport protein for signaling molecules and drugs. INTERNATIONAL JOURNAL OF CANCER 124 (10): 2303-2311 MAY 15 2009.
- 2009, Doyle D. Notoriety to respectability: a short history of arsenic prior to its present day use in haematology BRITISH JOURNAL OF HAEMATOLOGY Volume: 145 Issue: 3 Pages: 309-317 Published: MAY 2009.
- 2009, Wang, W: Adachi, M: Zhang, R: Zhou, J: Zhu, DL. A Novel Combination Therapy With Arsenic Trioxide and Parthenolide Against Pancreatic Cancer Cells. PANCREAS 38 (4): E114-E123 MAY 2009
- 2009, Yazid, Samia: Solito, Egle: Christian, Helen: McArthur, Simon: Goulding, Nicolas: Flower, Roderick. Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. BIOCHEMICAL PHARMACOLOGY 77 (12): 1814-1826 JUN 15 2009
- 2009, Papila, C: Uzun, H: Balci, H: Zerdali, H: Sezgin, C: Can, G: Yanardag, H. Clinical significance and prognostic value of serum sHER-2/neu levels in patients with solid tumors. MEDICAL ONCOLOGY 26 (2): 151-156 JUN 2009.
- 2009, Pine, JK: Fusai, KG: Young, R: Sharma, D: Davidson, BR: Menon, KV: Rahman, SH. Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. EJSO 35 (6): 605-610 JUN 2009.
- 2009, Izdebska, M: Grzanka, A: Szczepanski, MA: Litwiniec, A. Selected mechanisms of the therapeutic effect of arsenic trioxide in cancer treatment. POSTEPY HIGIENY I MEDYCYNY DOSWIADCZALNEJ 62: 463-467 2008
- 2009, Izdebska, M: Grzanka, D: Gackowska, L: Zuryn, A: Grzanka, A. The influence of Trisenox on actin organization in HL-60 cells. CENTRAL EUROPEAN JOURNAL OF BIOLOGY 4 (3): 351-361 SEP 2009.
- 2009, Jantscheff P, Esser N, Graeser R, et al. Liposomal Gemcitabine (GemLip)-Efficient Drug Against Hormone-Refractory Du145 and PC-3 Prostate Cancer Xenografts. PROSTATE 69 (11): 1151-1163, AUG 1 2009.
- 2009, Wang, JZ: Loh, KP: Wang, Z: Yan, YL: Zhong, YL: Xu, QH: Ho, PC. Fluorescent Nanogel of Arsenic Sulfide Nanoclusters. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION 48 (34): 6282-6285 2009
- 2009, Rolfes, N: Lummen, G. The value of biphosphonates in the therapy of prostate cancer. UROLOGE 48 (9): 990-+ SEP 2009.
- 2009, Tsavaris N, Kavantzas N, Tsigritis K, et al. Evaluation of DNA ploidy in relation with established prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. BMC CANCER 9 JUL 31 2009.
- 2009, Blanka, MW: Ewa, NM: Marek, S. Safety of PLD in the treatment of the patients with recurrent ovarian cancer - clinical experience. GINEKOLOGIA POLSKA 80 (9): 682-686 SEP 2009.
- 2009, Maeda, H: Miyajima, N: Kano, S: Tsukiyama, T: Okumura, F: Fukuda, S: Hatakeyama, S. Ubiquitin-Conjugating Enzyme UBE2Q2 Suppresses Cell Proliferation and Is Down-Regulated in Recurrent Head and Neck Cancer. MOLECULAR CANCER RESEARCH 7 (9): 1553-1562 SEP 2009.
- 2009, Tel, H: Tel, H: Er, O. Hopelessness and Depression in Cancer Patients. NEUROLOGY PSYCHIATRY AND BRAIN RESEARCH 16 (1): 31-34 2009.
- 2009, Marra, M: Abbruzzese, A: Addeo, R: Del Prete, S: Tassone, P: Tonini, G: Tagliaferri, P: Santini, D: Caraglia, M. Cutting the Limits of Aminobisphosphonates: New Strategies for the Potentiation of their Anti-Tumour Effects. CURRENT CANCER DRUG TARGETS 9 (7): 791-800 NOV 2009.
- 2009, Wirtitsch, M: Roth, E: Bachleitner-Hofmann, T: Wessner, B: Sturlan, S. omega-3 and omega-6 Polyunsaturated Fatty Acids Enhance Arsenic Trioxide Efficacy in Arsenic Trioxide-Resistant Leukemic and Solid Tumor Cells. ONCOLOGY RESEARCH 18 (2-3): 83-94 2009
- 2009, Jia, YF: Zheng, Y: Ma, XL: Su, ZT: Wang, YS. The Enhancement of drug sensitivity of human AFP-producing gastric carcinoma cell line FU97 to arsenic trioxide Using AFP as targeting siRNA. 2009 3RD INTERNATIONAL CONFERENCE ON BIOINFORMATICS AND BIOMEDICAL ENGINEERING, VOLS 1-11 : 623-626 2009.
- 2008, Bamias A, Koutsoukou V, Terpos E, et al. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNF alpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy. GYNECOLOGIC ONCOLOGY, 108 (2): 421-427, FEB 2008 .
- 2008, Saito, F: Matsusaka, S: Takahashi, Y: Wakabayashi, I. Enhancement of nitric oxide synthase induction in alveolar macrophages by in vivo administration of docetaxel. EUROPEAN JOURNAL OF PHARMACOLOGY 580 (3): 425-430 FEB 12 2008
- 2008, Merritt, WM: Lin, YG: Spannuth, WA et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. JOURNAL OF THE NATIONAL CANCER INSTITUTE 100 (5): 359-372 MAR 5 2008.
- 2008, Werner S, Mendoza A, Hilger RA, et al. Preclinical studies of treosulfan demonstrate potent activity in Ewing's sarcoma. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 62 (1): 19–31, 2008.
- 2008, Wang, P: Meng, ZQ: Chen, Z: Lin, JH: Zhou, ZH: Chen, H: Wang, K: Shen, YH: Zhu, ZF: Zhao, GF: Fu, H: Liu, LM. Survival rate of pancreatic cancer in elderly patients. HEPATO-GASTROENTEROLOGY 55 (82-83): 681-686 MAR-APR 2008
- 2008, Han, YH: Kim, SZ: Kim, SH: Park, WH. Enhancement of arsenic trioxide-induced apoptosis in HeLa cells by diethyldithiocarbamate or buthionine sulfoximine. INTERNATIONAL JOURNAL OF ONCOLOGY 33 (1): 205-213 JUL 2008
- 2008, Zhao SG, Xu Z, Zhang J, et al. Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains JOURNAL OF CHEMOTHERAPY Volume: 20 Issue: 2 Pages: 253-262 Published: APR 2008
- 2008, Copley L, van der Watt P, Wirtz KW, et al. Photolon (TM), a chlorin e6 derivative, triggers ROS production and light-dependent cell death via necrosisINTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY Volume: 40 Issue: 2 Pages: 227-235 Published: 2008
- 2008, Kim EH, Yoon NJ, Kim SU, et al. Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. CANCER RESEARCH, 68 (1): 266-275, 2008
- 2008, Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancerSource: CANCER TREATMENT REVIEWS Volume: 34 Issue: 4 Pages: 378-390 Published: JUN 2008
- 2008, Bartosch-Harlid, A: Andersson, B: Aho, U: Nilsson, J: Andersson, R. Artificial neural networks in pancreatic disease. BRITISH JOURNAL OF SURGERY 95 (7): 817-826 JUL 2008
- 2008, Wu, TH. Effectiveness of Taiwanese traditional herbal diet for pain management in terminal cancer patients. ASIA PACIFIC JOURNAL OF CLINICAL NUTRITION Volume: 17 Issue: 1 Pages: 17 Published: 2008.
- 2008, Tang, SC. Predictive markers of tubulin-targeting agents in breast cancer CLINICAL BREAST CANCER Volume: 8 Issue: Pages: S79 Published: MAR 2008
- 2008, Katz MHG, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA-A CANCER JOURNAL FOR CLINICIANS Volume: 58 Issue: 2 Pages: 111-125 Published: MAR-APR 2008
- 2008, Simonaro CM, D'Angelo M, He XX, et al. Mechanism of glycosaminoglycan-mediated bone and joint disease - Implications for the mucopolysaccharidoses and other connective tissue diseasesAMERICAN JOURNAL OF PATHOLOGY Volume: 172 Issue: 1 Pages: 112-122 Published: JAN 2008
- 2008, Park JK, Yoon YB, Kim YT, et al. Survival and prognostic factors of unresectable pancreatic cancerJOURNAL OF CLINICAL GASTROENTEROLOGY Volume: 42 Issue: 1 Pages: 86-91 Published: JAN 2008
- 2008, Han YH, Kim SZ, Kim SH, et al. Induction of apoptosis in arsenic trioxide-treated lung cancer A549 cells by buthionine sulfoximine. MOLECULES AND CELLS Volume: 26 Issue: 2 Pages: 158-164 Published: AUG 31 2008.
- 2008, Kang YH, Lee SJ. The role of p38 MAPK and JNK in arsenic trioxide-induced mitochondrial cell death in human cervical cancer cells. JOURNAL OF CELLULAR PHYSIOLOGY Volume: 217 Issue: 1 Pages: 23-33 Published: OCT 2008.
- 2008, Park JH, Kim EJ, Jang HY, et al. Combination treatment with arsenic trioxide and sulindac enhances apoptotic cell death in lung cancer cells via activation of oxidative stress and mitogen-activated protein kinases. ONCOLOGY REPORTS Volume: 20 Issue: 2 Pages: 379-384 Published: AUG 2008.
- 2008, Han YH, Kim SZ, Kim SH, et al. Suppression of arsenic trioxide-induced apoptosis in HeLa cells by N-acetylcysteine. MOLECULES AND CELLS Volume: 26 Issue: 1 Pages: 18-25 Published: JUL 31 2008
- 2008, Zhao SG, Zhang J, Zhang X, et al. Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. MOLECULAR BIOLOGY REPORTS Volume: 35 Issue: 3 Pages: 421-429 Published: SEP 2008
- 2008, Wei YY, Liu D, Ge YQ, et al. Down-regulation of beta 1,4GalT V at protein level contributes to arsenic trioxide-induced glioma cell apoptosis. CANCER LETTERS Volume: 267 Issue: 1 Pages: 96-105 Published: AUG 18 2008
- 2008, Han YH, Kim SH, Kim SZ, et al. Apoptosis in arsenic trioxide-treated Calu-6 lung cells is correlated with the depletion of GSH levels rather than the changes of ROS levels. JOURNAL OF CELLULAR BIOCHEMISTRY Volume: 104 Issue: 3 Pages: 862-878 Published: JUN 1 2008
- 2008, Kang, YH: Lee, SJ. Role of p38 MAPK and JNK in enhanced cervical cancer cell killing by the combination of arsenic trioxide and ionizing radiation. ONCOLOGY REPORTS 20 (3): 637-643 SEP 2008.
- 2008, Wilson, C: Wilson, T: Johnston, PG: Longley, DB: Waugh, DJJ. Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. MOLECULAR CANCER THERAPEUTICS 7 (9): 2649-2661 SEP 2008
- 2008, Diaz, Z: Mann, KK: Marcoux, S: Kourelis, M: Colombo, M: Komarnitsky, PB: Miller, WH. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. LEUKEMIA 22 (10): 1853-1863 OCT 2008
- 2008, Saydam, BK: Goksel, G: Korkmaz, E: Zekioglu, O: Kapkac, M: Sanli, UA: Uslu, R: Sezgin, C. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey. MEDICAL PRINCIPLES AND PRACTICE 17 (6): 475-480 2008
- 2008, Karasulu, H. Yesim. Microemulsions as novel drug carriers: the formation, stability, applications and toxicity. EXPERT OPINION ON DRUG DELIVERY 5 (1): 119-135 JAN 2008
- 2008, Sahin, F: Celik, HA: Aydin, HH: Oktem, G: Omay, SB: Saydam, G. The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. HEMATOLOGY 13 (4): 215-223 AUG 2008
- 2008, Sahin, F: Celik, HA: Aydin, HH: Oktem, G: Omay, SB: Saydam, G. The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. HEMATOLOGY 13 (4): 215-223 AUG 2008
- 2008, Cui, X: Kobayashi, Y: Akashi, M: Okayasu, R. Metabolism and the Paradoxical Effects of Arsenic: Carcinogenesis and Anticancer. CURRENT MEDICINAL CHEMISTRY 15 (22): 2293-2304 SEP 2008
- 2008, Joy, J: Nair, CKK. Amelioration of cisplatin induced nephrotoxicity in Swiss albino mice by Rubia cordifolia extract. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS 4 (3): 111-115 JUL-SEP 2008
- 2008, Sahin, F: Celik, HA: Aydin, HH: Oktem, G: Omay, SB: Saydam, G. The interaction between taxoids and serine/threonine protein phosphatase activities during taxan-induced apoptosis of HL 60 leukemic cells. HEMATOLOGY 13 (4): 215-223 AUG 2008
- 2008, Quaglia, W: Piergentili, A: Del Bello, F: Farande, Y: Giannella, M: Pigini, M: Rafaiani, G: Carrieri, A: Amantini, C: Lucciarini, R: Santoni, G: Poggesi, E: Leonardi, A. Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 9.(1) From 1,4-Benzodioxane to 1,4-Dioxane Ring as a Promising Template of Novel alpha(1D)-Adrenoreceptor Antagonists, 5-HT1A Full Agonists, and Cytotoxic Agents. JOURNAL OF MEDICINAL CHEMISTRY 51 (20): 6359-6370 OCT 23 2008
- 2008, Wei, J: DeAngulo, G: Sun, W: Hussain, SF: Vasquez, H: Jordan, J: Weinberg, J: Wolff, J: Koshkina, N: Heimberger, AB. Topotecan enhances immune clearance of gliomas. CANCER IMMUNOLOGY IMMUNOTHERAPY 58 (2): 259-270 FEB 2008.
- 2008, Wilson, C: Purcell, C: Seaton, A: Oladipo, O: Maxwell, PJ: O'Sullivan, JM: Wilson, RH: Johnston, PG: Waugh, DJJ. Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-kappa B Transcription and Evasion of Apoptosis. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 327 (3): 746-759 DEC 2008.
- 2008, Yamamoto, M: Imagawa, DK: Katz, MHG. Multidisciplinary management of resectable adenocarcinoma of the pancreatic head. EXPERT REVIEW OF ANTICANCER THERAPY 8 (10): 1611-1621 OCT 2008.
- 2008, Jian OY, Xu XH, Chen JH, et al. Involvement of Protein Phosphatase 2A in Arsenic Trioxide-Induced Differentiation and Apoptosis of NB4 Cells. METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY 30 (6), 411-419, JUL-AUG 2008.
- 2008, Bae-Jump, VL: Zhou, CX: Boggess, JF: Gehrig, PA. Arsenic Trioxide (As2O3) Inhibits Expression of Estrogen Receptor-alpha Through Regulation of the Mitogen-activated Protein Kinase (MAPK) Pathway in Endometrial Cancer Cells. REPRODUCTIVE SCIENCES 15 (10): 1011-1017 DEC 2008
- 2008, Nakai, Y: Isayama, H: Kawabe, T: Tsujino, T: Yoshida, H: Sasaki, T: Tada, M: Arizumi, T: Yagioka, H: Kogure, H: Togawa, O: Ito, Y: Matsubara, S: Hirano, K: Sasahira, N: Omata, M. Efficacy and Safety of Metallic Stents in Patients With Unresectable Pancreatic Cancer Receiving Gemcitabine. PANCREAS 37 (4): 405-410 NOV 2008.
- 2008, Wilson, C: Scullin, P: Worthington, J: Seaton, A: Maxwell, P: O'Rourke, D: Johnston, PG: McKeown, SR: Wilson, RH: O'Sullivan, JM: Waugh, DJJ. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer. BRITISH JOURNAL OF CANCER 99 (12): 2054-2064 DEC 9 2008.
- 2008, Quaglia, W: Piergentili, A: Del Bello, F: Farande, Y: Giannella, M: Pigini, M: Rafaiani, G: Carrieri, A: Amantini, C: Lucciarini, R: Santoni, G: Poggesi, E: Leonardi, A. Structure-Activity Relationships in 1,4-Benzodioxan-Related Compounds. 9. From 1,4-Benzodioxane to 1,4-Dioxane Ring as a Promising Template of Novel alpha(1D)-Adrenoreceptor Antagonists, 5-HT1A Full Agonists, and Cytotoxic Agents. JOURNAL OF MEDICINAL CHEMISTRY 51 (20): 6359-6370 OCT 23 2008
- 2007, Park MT, Kang YH, Park IC, et al. Combination treatment with arsenic trioxide and phytosphingosine enhances apoptotic cell death in arsenic trioxide-resistant cancer cells. MOLECULAR CANCER THERAPEUTICS 6 (1): 82-92 JAN 2007.
- 2007, Zhou CX, Boggess JF, Bae-Jump V, et al. Induction of apoptosis and inhibition of telomerase activity by arsenic trioxide (AS(2)O(3)) in endometrial carcinoma cells. GYNECOLOGIC ONCOLOGY 105 (1): 218-222 APR 2007.
- 2007, de Paiva TF, Ribeiro HB, Campanholo CB, et al. Behcet's disease associated with superior vena cava syndrome without thrombosis. CLINICAL RHEUMATOLOGY 26 (5): 804-806 MAY 2007.
- 2007, Kalkner KM, Ullen A, Wersall P, et al. Temporary effect of arsenic trioxide treatment of refractory extragonadal germ cell cancer. ACTA ONCOLOGICA 46 (6): 862-863 2007.
- 2007, Yu J, Qian HL, Li YF, et al. Arsenic trioxide (As2O3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. GYNECOLOGIC ONCOLOGY 106 (2): 400-406 AUG 2007.
- 2007, Diaz Z, Laurenzana A, Mann KK, et al. Trolox enhances the anti-lymphoma effects of arsenic trioxide, while protecting against liver toxicity. LEUKEMIA 21 (10): 2117-2127 OCT 2007.
- 2007, Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. CANCER TREATMENT REVIEWS 33 (6): 542-564 OCT 2007
- 2007, Yu ZY, Liang YG, Xiao H, et al. Melissoidesin G, a diterpenoid purified from Isodon melissoides, induces leukemic-cell apoptosis through induction of redox imbalance and exhibits synergy with other anticancer agents. INTERNATIONAL JOURNAL OF CANCER 121 (9): 2084-2094 NOV 1 2007.
- 2007, Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. NEW ENGLAND JOURNAL OF MEDICINE 357 (15): 1496-1506 OCT 11 2007.
- 2007, Tachiwada T, Chen ZS, Che XF, et al. Isolation and characterization of arsenite-resistant human epidermoid carcinoma KB cells. ONCOLOGY REPORTS 18 (3): 721-727 SEP 2007.
- 2007, Privette LM, Gonzalez ME, Ding L, et al. Altered expression of the early mitotic checkpoint protein, CHFR, in breast cancers: Implications for tumor suppression CANCER RESEARCH 67 (13): 6064-6074 JUL 1 2007
- 2007, Derin D, Soydinc HO, Guney N, et al. Serum IL-8 and IL-12 levels in breast cancer. MEDICAL ONCOLOGY 24 (2): 163-168 2007.
- 2007, Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. JOURNAL OF CLINICAL ONCOLOGY 25 (19): 2811-2818 JUL 1 2007
- 2007, Zalatnai A. Novel therapeutic approaches in the treatment of advanced pancreatic carcinoma. CANCER TREATMENT REVIEWS 33 (3): 289-298 MAY 2007.
- 2007, Ai ZL, Lu WQ, Ton SX, et al. Arsenic trioxide-mediated growth inhibition in gallbladder carcinoma cells via down-regulation of Cyclin D1 transcription mediated by Sp1 transcription factor. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 360 (3): 684-689 AUG 31 2007.
- 2007, Karasulu HY, Karabulut B, Goker E, et al. Controlled release of methotrexate from W/O microemulsion and its in vitro antitumor activity. DRUG DELIVERY 14 (4): 225-233 2007
- 2007, Jiang MC, Luo SF, Li LT, et al. Synergic CSE1L/CAS, TNFR-1, and p53 apoptotic pathways in combined interferon-gamma/adriamycin-induced apoptosis of Hep G2 hepatoma cells. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 26 (1): 91-99 MAR 2007.
- 2007, Terauchi M, Kajiyama H, Shibata K, et al. Inhibition of APN/CD13 leads to suppressed progressive potential in ovarian carcinoma cells. BMC CANCER, 7: 140, 2007.
- 2007, Avci CB, Sahin F, Gunduz C, et al. Protein phosphatase 2A (PP2A) has a potential role in CAPE-induced apoptosis of CCRF-CEM cells via effecting human telomerase reverse transcriptase activity. HEMATOLOGY, 12 (6): 519-525, 2007.
- 2007, Merritt WM, Sood AK. Markers of angiogenesis in ovarian cancer Source: DISEASE MARKERS Volume: 23 Issue: 5-6 Pages: 419-431 Published: 2007
- 2007, Banerji, U: Kuciejewska, A: Ashley, S: Walsh, G: O'Brien, M: Johnston, S: Smith, I. Factors determining outcome after third line chemotherapy for metastatic breast cancer. BREAST 16 (4): 359-366 AUG 2007
- 2007, Youm YH, Yang H, Yoon YD, et al. Doxazosin-induced clusterin expression and apoptosis in prostate cancer cells. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS 25 (6): 483-488, 2007.
- 2007, Wei YS, Lan Y, Tanga RG, et al. Single nucleotide polymorphism and haplotype association of the interleukin-8 gene with nasopharyngeal carcinomaSource: CLINICAL IMMUNOLOGY Volume: 125 Issue: 3 Pages: 309-317 Published: DEC 2007
- 2007, Chechlinska A, Kaminska J, Markowska J, et al. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination. Source: INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS Volume: 22 Issue: 3 Pages: 172-180 Published: JUL-SEP 2007
- 2007, Alberti C. Apoptosis induction by quinazoline-derived alpha(1)-blockers in prostate cancer cells: biomolecular implications and clinical relevance. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 11 (1): 59-64, 2007.
- 2007, Li Q. Recent progress in the discovery of Akt inhibitors as anticancer agents. EXPERT OPINION ON THERAPEUTIC PATENTS 17 (9): 1077-1130, 2007.
- 2006, Festjens N, Kalai M, Smet J, Meeus A, Van Coster R, Saelens X, Vandenabeele P. Butylated hydroxyanisole is more than a reactive oxygen species scavenger. CELL DEATH AND DIFFERENTIATION 13 (1): 166-169 JAN 2006.
- 2006, Hicsonmez G. The effect of steroid on myeloid leukemic cells: The potential of short-course high-dose methylprednisolone treatment in inducing differentiation, apoptosis and in stimulating myelopoiesis. LEUKEMIA RESEARCH 30 (1): 60-68 JAN 2006.
- 2006, Garrison, JB: Kyprianou, N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. CANCER RESEARCH, 66 (1): 464-472 JAN 1 2006
- 2006, Slot, KA: de Boer-Brouwer, M: Houweling, M: Vaandrager, AB: Dorrington, JH: Teerds, KJ. Luteinizing hormone inhibits Fas-induced apoptosis in ovarian surface epithelial cell lines. JOURNAL OF ENDOCRINOLOGY 188 (2): 227-239 FEB 2006.
- 2006, Luo, LQ: Qiao, HQ: Meng, FQ: Dong, XS: Zhou, BG: Jiang, HC: Kanwar, JR: Krissansen, GW: Sun, XY. Arsenic trioxide synergizes with B7H3-mediated immunotherapy to eradicate hepatocellular. INTERNATIONAL JOURNAL OF CANCER 118 (7): 1823-1830 APR 1 2006.
- 2006, Ho, SY: Huang, PC: Guo, HR: Chang, WH: Chen, RJ: Wei, BL: Wu, WJ: Tai, C: Wang, YJ. Mechanisms of apoptosis induction and cell cycle regulation in irradiated leukemia U937 cells and enhancement by arsenic trioxide. RADIATION RESEARCH 165 (4): 390-399 APR 2006.
- 2006, Terek, MC: Karabulut, B: Selvi, N: Akman, L: Karasulu, Y: Ozguney, I: Sanli, AU: Uslu, R: Ozsaran, A. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 16 (2): 532-537 Mar-Apr 2006.
- 2006, Oktem G, Vatansever S, Ayla S, et al. Effect of apoptosis and response of extracellular matrix proteins after chemotherapy application on human breast cancer cell spheroids. ONCOLOGY REPORTS 15 (2): 335-340 FEB 2006.
- 2006, Loibl S, Bratengeier J, Farines V, et al. Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 - estrogen has an influence on e-NOS, but not on i-NOS. PATHOLOGY RESEARCH AND PRACTICE 202 (1): 1-7 2006.
- 2006, Garrison JB, Kyprianou N. Doxazosin induces apoptosis of benign and malignant prostate cells via a death receptor-mediated pathway. CANCER RESEARCH 66 (1): 464-472 JAN 1 2006.
- 2006, Bertram, J: Peacock, JW: Tan, C: Mui, ALF: Chung, SW: Gleave, ME: Dedhar, S: Cox, ME: Ong, CJ. Inhibition of the phosphatidylinositol 3 '-kinase pathway promotes autocrine Fas-induced death of phosphatase and tensin homologue-deficient prostate cancer cells. CANCER RESEARCH 66 (9): 4781-4788 MAY 1 2006.
- 2006, Krishna, J: Shah, ZA: Merchant, M: Klein, JB: Gozal, D. Urinary protein expression patterns in children with sleep-disordered breathing: Preliminary findings. SLEEP MEDICINE 7 (3): 221-227 APR 2006.
- 2006, Kim HR, Kim EJ, Yang SH, et al. Combination treatment with arsenic trioxide and sulindac augments their apoptotic potential in lung cancer cells through activation of caspase cascade and mitochondrial dysfunction. INTERNATIONAL JOURNAL OF ONCOLOGY 28 (6): 1401-1408 JUN 2006.
- 2006, Beer, TM: Tangen, CM: Nichols, CR: Margolin, KA: Dreicer, R: Stephenson, WT: Quinn, DI: Raghavan, D: Crawford, ED. Southwest oncology group Phase II trioxide in patients with refractory malignancies. CANCER 106 (12): 2624-2629 JUN 15 2006.
- 2006, Taylor, BF: McNeely, SC: Miller, HL: Lehmann, GM: McCabe, MJ: States, JC. p53 suppression of arsenite-induced mitotic catastrophe is mediated by p21(CIP1/WAF1). JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 318 (1): 142-151 JUL 2006
- 2006, Iacopino, F: Angelucci, C: Lama, G: Zelano, G: La Torre, G: D'Addessi, A: Giovannini, C: Bertaccini, A: Macaluso, MP: Martorana, G: Sica, G. Apoptosis-related gene expression in benign prostatic hyperplasia and prostate carcinoma. ANTICANCER RESEARCH 26 (3A): 1849-1854 MAY-JUN 2006.
- 2006, Askar, N Cirpan, T Toprak, E Karabulut, B Selvi, N Terek, MC Uslu, R Sanli, UA Goker, E. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 16 (4): 1552-1556 JUL-AUG 2006
- 2006, Bergstralh Dt, Tıng Jpy. Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination. CANCER TREATMENT REVIEWS 32 (3): 166-179 MAY 2006.
- 2006, Ueda, M Hung, YC: Chen, JT: Chiou, SH: Huang, HH: Lin, TY: Terai, Y: Chow, KC. Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. GYNECOLOGIC ONCOLOGY 102 (2): 173-181 AUG 2006
- 2006, Petrova, E.E., Valyakina, T.I., Simonova, M.A., Komaleva, R.L., Khaidukov, S.V., Makarov, E.A., Blokhin, D.Yu., Ivanov, P.K., Andronova, T.M., Nesmeyanov, V.A. Muramyl peptides augment cytotoxic effect of tumor necrosis factor-alpha in combination with cytotoxic drugs on tumor cells. INTERNATİONAL IMMUNOPHARMACOLOGY, 6 (9) pp. 1377-1386, 2006.
- 2006, Yang, J., Xiao, J., Li, R. Therapeutic effect of domestic-made topotecan in the treatment of advanced epithelial ovarian carcinoma JOURNAL OF Xİ'AN JİAOTONG UNİVERSİTY (MEDİCAL SCİENCES), 27 (3) pp. 307-308+313, 2006.
- 2006, Ai, Z., Lu, W., Qin, X. Arsenic trioxide induces gallbladder carcinoma cell apoptosis via downregulation of Bcl-2. Biochemical and Biophysical Research Communications, 348 (3) pp. 1075-1081, 2006.
- 2006, Oka N, Tanimoto S, Taue R, et al.Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. CANCER SCIENCE 97 (10): 1093-1098 OCT 2006
- 2006, De Souza AC, Kodach L, Gadelha FR, et al.A promising action of riboflavin as a mediator of leukaemia cell death. APOPTOSIS 11 (10): 1761-1771 OCT 2006
- 2006, McNeely SC, Xu XG, Taylor BF, et al.Exit from arsenite-induced mitotic arrest is p53 dependent. ENVIRONMENTAL HEALTH PERSPECTIVES 114 (9): 1401-1406 SEP 2006
- 2006, DeAngulo GR, Sun W, Heimberger AB. Synergistic effect of immunotherapy and chemotherapy in, cancers: Perspective in high grade glioma treatment. LETTERS IN DRUG DESIGN & DISCOVERY 3 (8): 513-523 OCT 2006
- 2006, Zhang JJ, Wang B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. GYNECOLOGIC ONCOLOGY 103 (1): 199-206 OCT 2006
- 2006, Luo LY, Huang J, Gou BD, et al.Induction of human promyelocytic into monocytes by arsenic leukemia HL-60 cell differentiation sulphide: Involvement of serine/threonine protein phosphatases. LEUKEMIA RESEARCH 30 (11): 1399-1405 NOV 2006
- 2006, Oktem G, Bilir A, Selvi N, et al.Chemotherapy influences inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) activity on 3D breast cancer cell line. ONCOLOGY RESEARCH 16 (4): 195-203 2006
- 2006, Campo GM, Avenoso A, Campo S, et al.Chondroitin sulphate: Antioxidant properties and beneficial effects. MINI-REVIEWS IN MEDICINAL CHEMISTRY 6 (12): 1311-1320 DEC 2006.
- 2006, Krishnan S, Rana V, Janjan NA, et al.Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. CANCER 107 (11): 2589-2596 DEC 1 2006
- 2006, Angelucci A, Valentini A, Millimaggi D, et al.Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways.ANTI-CANCER DRUGS 17 (10): 1141-1150 NOV 2006
- 2006, McNeely SC, Xu XG, Taylor BF, et al. Exit from arsenite-induced mitotic arrest is p53 dependent. ENVIRONMENTAL HEALTH PERSPECTIVES 114 (9): 1401-1406 SEP 2006.
- 2006, Zhang JJ, Wang B. Arsenic trioxide (As2O3) inhibits peritoneal invasion of ovarian carcinoma cells in vitro and in vivo. GYNECOLOGIC ONCOLOGY 103 (1): 199-206 OCT 2006.
- 2006, Oka N, Tanimoto S, Taue R, et al. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. CANCER SCIENCE 97 (10): 1093-1098 OCT 2006.
- 2006, Oka N, Tanimoto S, Taue R, et al. Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand. CANCER SCIENCE 97 (10): 1093-1098 OCT 2006.
- 2006, DeAngulo GR, Sun W, Heimberger AB. Synergistic effect of immunotherapy and chemotherapy in, cancers: Perspective in high grade glioma treatment. LETTERS IN DRUG DESIGN & DISCOVERY 3 (8): 513-523 OCT 2006.
- 2006, Angelucci A, Valentini A, Millimaggi D, et al. Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. ANTI-CANCER DRUGS 17 (10): 1141-1150 NOV 2006.
- 2006, Luo LY, Huang J, Gou BD, et al. Induction of human promyelocytic into monocytes by arsenic leukemia HL-60 cell differentiation sulphide: Involvement of serine/threonine protein phosphatases. LEUKEMIA RESEARCH 30 (11): 1399-1405 NOV 2006.
- 2006, Kushida S, Ohmae H, Kamma H, et al. Artificial cytokine storm combined with hyperthermia induces significant anti-tumor effect in mice inoculated with Lewis lung carcinoma and B16 melanoma cells. INTERNATIONAL JOURNAL OF HYPERTHERMIA 22 (8): 699-712 DEC 2006.
- 2006, Queiroz KCS, Assis CF, Medeiros VP, et al. Cytotoxicity effect of algal polysaccharides on HL60 cells. BIOCHEMISTRY-MOSCOW 71 (12): 1312-1315 DEC 2006.
- 2005, Badary OA, Abdel-Maksoud S, Ahmed WA, Owieda GH. Naringenin attenuates cisplatin nephrotoxicity in rats. LIFE SCIENCES 76 (18): 2125-2135 MAR 18 2005
- 2005, Wozniak A, Drewa G, Wozniak B, Schachtschabel DO, Mila-Kierzenkowska C, Drewa T, Olszewska-Slonina D, Soponska M. The effect of antitumor drugs on oxidative stress in B16 and S91 melanoma cells in vitro. MEDICAL SCIENCE MONITOR 11 (1): BR22-BR29 JAN 2005
- 2005, Wang Z, Yu D, Chen Y, Hao J. Proteomic analysis of nuclear matrix proteins during arsenic trioxide induced apoptosis in leukemia K562 cells. CHINESE MEDICAL JOURNAL 118 (2): 100-104 JAN 20 2005.
- 2005, Haghighi AB, Pourmand R, Nikseresht AR. Neuro-Behcet disease - A review. NEUROLOGIST 11 (2): 80-89 MAR 2005.
- 2005, Uslu R, Sanli UA, Dikmen Y, Karabulut B, Ozsaran A, Sezgin C, Muezzinoglu GG, Omay SB, Goker E. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 15 (2): 240-245 MAR-APR 2005
- 2005, Sato S, Hori Y, Yamate J, Saito T, Kurasaki M, Hatai A. Protective effect of dietary azuki bean (Vigna angularis) seed coats against renal interstitial fibrosis of rats induced by cisplatin. NUTRITION 21 (4): 504-511 APR 2005
- 2005, Abaan OD, Levenson A, Khan O, Furth PA, Uren A, Toretsky JA. PTPL1 is a direct transcriptional target of EWS-FLI1 and modulates Ewing's Sarcoma tumorigenesis. ONCOGENE 24 (16): 2715-2722 APR 14 2005
- 2005, Douer D, Tallman MS. Arsenic trioxide: New clinical experience with an old medication in hematologic malignancies. JOURNAL OF CLINICAL ONCOLOGY 23 (10): 2396-2410 APR 1 2005
- 2005, Hanta I, Ucar G, Kuleci S, Ozbek S, Kocabas A. Superior vena cava syndrome: a rare clinical manifestation of Behcet's disease. CLINICAL RHEUMATOLOGY 24 (3): 314-315 JUN 2005
- 2005, Sharma, S: Odunsi, K. Targeted therapy for epithelial ovarian cancer.EXPERT OPINION ON THERAPEUTIC TARGETS, 9 (3): 501-513 JUN 2005
- 2005, Gazitt Y, Akay C. Arsenic trioxide: An anti cancer missile with multiple warheads. HEMATOLOGY 10 (3): 205-213 JUN 2005.
- 2005, Gazitt Y, Akay C. Arsenic trioxide: An anti cancer missile with multiple warheads. HEMATOLOGY 10 (3): 205-213 JUN 2005.
- 2005, Engin AB, Ergun MA, Yurtcu E, Kan D, Sahin G. Effect of ionizing radiation on the pteridine metabolic pathway and evaluation of its cytotoxicity in exposed hospital staff. MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS 585 (1-2): 184-192 AUG 1 2005.
- 2005, Park, MJ: Lee, JY: Kwak, HJ: Park, CM: Lee, HC: Woo, SH: Jin, HO: Han, CJ: An, S: Lee, SH: Chung, HY: Park, IC: Hong, SI: Rhee, CH. Arsenic trioxide (As2O3) inhibits invasion of HT1080 human fibrosarcoma cells: Role of nuclear factor-kappa B and reactive oxygen species. JOURNAL OF CELLULAR BIOCHEMISTRY, 95 (5): 955-969 AUG 1 2005.
- 2005, Chiang CF, Son EL, Wu GJ. Oral treatment of the TRAMP mice with doxazosin suppresses prostate tumor growth and metastasis. PROSTATE 64 (4): 408-418 SEP 1 2005
- 2005, Kong, B: Huang, S: Wang, W: Ma, D: Qu, X: Jiang, J: Yang, X: Zhang, Y: Wang, B: Cui, B: Yang, Q. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 15 (5): 872-877 SEP-OCT 2005.
- 2005, Kong, B: Huang, S: Wang, W: Ma, D: Qu, X: Jiang, J: Yang, X: Zhang, Y: Wang, B: Cui, B: Yang, Q. Arsenic trioxide induces apoptosis in cisplatin-sensitive and -resistant ovarian cancer cell lines. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 15 (5): 872-877 SEP-OCT 2005.
- 2005, Katsiari CG, Kyttaris VC, Juang YT, Tsokos GC. Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. JOURNAL OF CLINICAL INVESTIGATION 115 (11): 3193-3204 NOV 2005.
- 2005, Fernando MA, Heaney AP. alpha(1)-adrenergic receptor antagonists: Novel therapy for pituitary adenomas. MOLECULAR ENDOCRINOLOGY 19 (12): 3085-3096 DEC 2005.
- 2005, Quaglia W, Santoni G, et al. Structure-activity relationships in 1,4-benzodioxan-related compounds. 8. {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha(1D)- and alpha(1B)-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. JOURNAL OF MEDICINAL CHEMISTRY 48 (24): 7750-7763 DEC 1 2005.
- 2005, Munoz-Castaneda JR, Montilla P, Munoz MC, Bujalance I, Muntane J, Tunez I. Effect of 17-beta-estradiol administration during adriamycin-induced cardiomyopathy in ovariectomized rat. EUROPEAN JOURNAL OF PHARMACOLOGY 523 (1-3): 86-92 OCT 31 2005.
- 2005, Bornstein, J: Sagi, S: Haj, A: Harroch, J: Fares, F. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line. GYNECOLOGIC ONCOLOGY, 99 (3): 726-729 DEC 2005
- 2005, Leung, KN: Mak, NK: Fung, MC. Cytokines in the differentiation therapy of leukemia: From laboratory investigations to clinical applications. CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 42 (5-6): 473-514 2005
- 2005, Quaglia, W et al. Structure-activity relationships in 1,4-benzodioxan-related compounds. 8. {2-[2-(4-chlorobenzyloxy)phenoxy]ethyl}-[2-(2,6-dimethoxyphenoxy)ethyl]amine (clopenphendioxan) as a tool to highlight the involvement of alpha(1D)- and alpha(1B)-adrenoreceptor subtypes in the regulation of human PC-3 prostate cancer cell apoptosis and proliferation. JOURNAL OF MEDICINAL CHEMISTRY 48 (24): 7750-7763 DEC 1 2005.
- 2005, Berezhnaya, NM: Vinnichuk, UD: Konovalenko, V: Vorobjova, LI: Belova, OB: Proskurnia, LA. The sensitivity of chemioresistant human tumor explants to lysis by activated and nonactivated autological lymphocytes: A pilot study. EXPERIMENTAL ONCOLOGY 27 (4): 303-307 DEC 2005.
- 2005, Haga N, Fujita N, Tsuruo T. Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. CANCER SCIENCE 96 (11): 825-833 NOV 2005.
- 2005, Gutierrez LS, Noria F, Finol H, et al. Fas ligand expression and its correlation with apoptosis and proliferation in Lobund-Wistar prostate carcinomas. PATHOBIOLOGY 72 (5): 260-268 2005.
- 2005, Ling, K.-S., Chen, G.-D., Tsai, H.-J., Lee, M.-S., Wang, P.-H., Liu, F.-S. Mechanisms involved in chemoresistance in ovarian cancer. Taiwanese Journal of Obstetrics and Gynecology 44 (3), pp. 209-217, 2005.
- 2005, De Groot, D.J.A., Timmer, T., Spierings, D.C.J., Le, T.K.P., De Jong, S., De Vries, E.G.E.. Indomethacin-induced activation of the death receptor-mediated apoptosis pathway circumvents acquired doxorubicin resistance in SCLC cells. British Journal of Cancer 92 (8), pp. 1459-1466, 2005.
- 2005, Gao, S., Liu, T., Liu, L., Yan, K. Induction of apoptosis of ovarian carcinoma cell strains with As 2O3 via G1 phase cell cycle arrest. Journal of Xi'an Jiaotong University (Medical Sciences) 26 (3), pp. 269-272, 2005.
- 2005, Wei, L., Wang, X.-W., Zuo, W.-S., Song, X.-R. Primary research on arsenic trioxide inhibiting human breast cancer cells growth and its mechanisms. National Medical Journal of China 85 (17), pp. 1209-1213, 2005.
- 2005, Wang, Z., Zhang, D., Gu, N., Lu, X., Yan, S. Preparation and evaluation of As2O3 nanoparticles for treatment of human liver cancer cells in vitro. Journal of Southeast University (English Edition) 21 (1), pp. 58-62, 2005.
- 2005, Öktem, G., Ayla, Ş., Tuna, S., Baka, M., Bilir, A. Effect of doxorubicin on a MCF-7 cell line multicellular tumor spheroid model: An electronmicroscopic study | [Doksorubisinin multisellüler spheroid hücre kültü rlerinde MCF-7 hücreleri üzerine etkisi: Elektronmikroskobik çalişma]. Turkiye Klinikleri Journal of Medical Sciences 25 (3), pp. 337-342, 2005.
- 2005, Sun, M.-H., Han, X.-C., Jia, M.-K., Jiang, W.-D., Wang, M., Zhang, H., Han, G., Jiang, Y. Expressions of inducible nitric oxide synthase and matrix metalloproteinase-9 and their effects on angiogenesis and progression of hepatocellular carcinoma. World Journal of Gastroenterology 11 (38), pp. 5931-5937, 2005.
- 2005, Padma, S.; Sowjanya, A. Pavani; Poli, Usha Rani; et al. Downregulation of calcineurin activity in cervical carcinoma. CANCER CELL INTERNATIONAL 5 (7) DOI: 10.1186/1475-2867-5-7, 2005.
- 2004, Duan L, Aoyagi M, Tamaki M, Yoshino Y, Morimoto T, Wakimoto H, Nagasaka Y, Hirakawa K, Ohno K, Yamamoto K. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. CLINICAL CANCER RESEARCH 10 (1): 234-243 Part 1, JAN 1 2004.
- 2004, Andreani A, Granaiola M, Leoni A, Locatelli A, Morigi R, Rambaldi M, Lenaz G, Fato R, Bergamini C. 2-[(E)-3-(6-chloroimidazo[2,1-b]thiazol-5-yl)prop-2-enyl]-5,6-dimethoxy-3-methyl-1,4-benzoquinone: a new inhibitor of NADH dehydrogenase with antitumor activity. ARKIVOC 76-84 Part 5, 2004.
- 2004, Cuello M, Coats AO, Darko I, Ettenberg SA, Gardner GJ, Nau MM, Liu JR, Birrer MJ, Lipkowitz S. N-(4-hydroxyphenyl) retinamide (4HPR) enhances TRAIL-mediated apoptosis through enhancement of a mitochondrial-dependent amplification loop in ovarian cancer cell lines. CELL DEATH AND DIFFERENTIATION 11 (5): 527-541 MAY 2004.
- 2004, Closset J, Ammar H, Nguyen VH, Cornet A, Reiter E. New features in the treatment of androgen-independent prostate cancer. CURRENT PHARMACEUTICAL DESIGN 10 (5): 513-522 2004.
- 2004, Karasulu HY, Karabulut B, Kantarci G, Ozguney I, Sezgin C, Sanli UA, Goker E. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. DRUG DELIVERY 11 (6): 345-350 NOV-DEC 2004.
- 2004, Ferreira CV, Bos CL, Versteeg HH, Justo GZ, Duran N, Peppelenbosch MP. Molecular mechanism of violacein-mediated human leukemia cell death. BLOOD 104 (5): 1459-1464 SEP 1 2004.
- 2004, Tahmatzopoulos A, Kyprianou N. Apoptotic impact of alpha-blockers on prostate cancer growth: A myth or an inviting reality? PROSTATE 59 (1): 91-100 APR 1 2004.
- 2004, Tahmatzopoulos A, Rowland RG, Kyprianou N. The role of alpha-blockers in the management of prostate cancer. EXPERT OPINION ON PHARMACOTHERAPY 5 (6): 1279-1285 JUN 2004.
- 2004, Shaw YJ, Yang YT, Garrison JB, Kyprianou N, Chen CS. Pharmacological exploitation of the alpha 1-adrenoreceptor antagonist doxazosin to develop a novel class of antitumor agents that block intracellular protein kinase B/Akt activation. JOURNAL OF MEDICINAL CHEMISTRY 47 (18): 4453-4462 AUG 26 2004.
- 2004, Kang YH, Yi MJ, Kim MJ, Park MT, Bae S, Kang CM, Cho CK, Park IC, Park MJ, Rhee CH, Hong SI, Chung HY, Lee YS, Lee SJ. Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: Reactive oxygen species-mediated poly(ADP-ribose) polymerise-1 activation signals apoptosis-inducing factor release from mitochondria. CANCER RESEARCH 64 (24): 8960-8967 DEC 15 2004.
- 2004, Rojewski MT, Korper S, Schrezenmeier H. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside. LEUKEMIA & LYMPHOMA 45 (12): 2387-2401 DEC 2004.
- 2004, Yang J, Li H, Chen YY, Wang XJ, Shi GY, Hu QS, Kang XL, Lu Y, Tang XM, Guo QS, Yi J. Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. FREE RADICAL BIOLOGY AND MEDICINE 37 (12): 2027-2041 DEC 15 2004.
- 2004, Karasulu HY, Karabulut B, Kantarci G, Ozguney I, Sezgin C, Sanli UA, Goker E. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. DRUG DELIVERY 11 (6): 345-350 NOV-DEC 2004.
- 2004, Woo SH, Park IC, Park MJ, An S, Lee HC, Jin HO, Park SA, Cho HY, Lee SJ, Gwak HS, Hong YJ, Hong SI, Rhee CH. Arsenic trioxide sensitizes CD95/Fas-induced apoptosis through ROS-mediated upregulation of CD95/Fas by NF-kappa B activation. INTERNATIONAL JOURNAL OF CANCER 112 (4): 596-606 NOV 20 2004.
- 2004, Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. INTERNATIONAL JOURNAL OF CANCER 112 (4): 707-712 NOV 20 2004.
- 2004, Li XQ, Ding XZ, Adrian TE. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. CANCER INVESTIGATION 22 (3): 389-400 2004.
- 2004, Hour TC, Huang CY, Lin CC, Chen J, Guan JY, Lee JM, Pu YS. Characterization of molecular events in a series of bladder urothelial carcinoma cell lines with progressive resistance to arsenic trioxide. ANTI-CANCER DRUGS 15 (8): 779-785 SEP 2004.
- 2004, Ning SC, Knox SJ. Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS 60 (1): 197-203 SEP 1 2004
- 2004, Moon Y, Park G, Kim Y, Kim M, Lim J, Pai SH, Lee EJ, Kang CS, Han K. Arsenic trioxide (As2O3) sensitivity of carcinoma cell lines and cancer cells from patients with carcinomatosis peritonei. ANNALS OF CLINICAL AND LABORATORY SCIENCE 34 (3): 271-276 SUM 2004
- 2004, Evens AM, Tallman MS, Gartenhaus RB. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. LEUKEMIA RESEARCH 28 (9): 891-900 SEP 2004.
- 2004, Wu XX, Ogawa O, Kakehi Y. Enhancement of arsenic trioxide-induced apoptosis in renal cell carcinoma cells by L-buthionine sulfoximine. INTERNATIONAL JOURNAL OF ONCOLOGY 24 (6): 1489-1497 JUN 2004.
- 2004, Sumitomo M, Asano T, Asakuma J, Asano T, Nanus DM, Hayakawa M. Chemosensitization of androgen-independent prostate cancer with neutral endopeptidase. CLINICAL CANCER RESEARCH 10 (1): 260-266 Part 1, JAN 1 2004.
- 2004, Parmar S, Rundhaugen LM, Boehlke L, Riley M, Nabhan C, Raji A, Frater JL, Tallman MS. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. LEUKEMIA RESEARCH 28 (9): 909-919 SEP 2004.
- 2004, Yalcin R, Erkan A, Ergun MA, Yurtcu E. The effect of clopidogrel on apoptosis - an in vivo study. CELL BIOLOGY INTERNATIONAL 28 (6): 477-481 2004.
- 2004, Biesalski, H.K., Lambert, C., Frank, J. Antioxidant micronutrients as additives in oncology | [Antioxidative Mikronährstoffe als Zusatzstoffe in der Onkologie] Onkologe 10 (3), pp. 230-243, 2004.
- 2004, Kedzior, J., Masaoka, M., Kurono, C., Spodnik, J.H., Hallmann, A., Majczak, A., Niemczyk, E., Trzonkowski, P., Myśliwski, A., Soji, T., Wakabayashi, T. Changes in physicochemical properties of microtubules lead to the formation of a single spherical structure of mitochondrial assembly enveloping nuclear chromatins. Journal of Electron Microscopy Volume 53, Issue 6, 2004, Pages 659-670.
- 2004, Yuste Chaves, M., Santos Durán, J.C., Sánchez Estella, J., Alonso San Pablo, M.T. Facial edema in superior vena cava syndrome | [Edema facial en síndrome de vena cava superior]. Medicina Cutanea Ibero-Latino-Americana 32 (6), pp. 254-258, 2004.
- 2004, Kim, H.R., Yang, S.H., Jeong, E.T. Inducing Apoptosis of NCI-H157 Human Lung Carcinoma Cells via Activation of Caspase Cascade by Combination Treatment with Arsenic Trioxide and Sulindac. Tuberculosis and Respiratory Diseases 56 (4), pp. 381-392, 2004.
- 2004, Meng, M., Jiang, J.-M., Yin, X.-Y., Zhu, J.-R. Effects of lipopolysaccharide with L-arginine on proliferation and apoptosis of human hepatocellular carcinoma cell line Bel-7402. World Chinese Journal of Digestology 12 (9), pp. 2053-2056, 2004.
- 2003, Biesalski HK, Frank J. Antioxidants in cancer therapy: Is there a rationale to recommend antioxidants during cancer therapy? BIOFACTORS 17 (1-4): 229-240 2003.
- 2003, Sheena N, Ajith TA, Janardhanan KK. Prevention of nephrotoxicity induced by the anticancer drug cisplatin, using Ganoderma lucidum, a medicinal mushroom occurring in South India. CURRENT SCIENCE 85 (4): 478-482 AUG 25 2003.
- 2003, Van Haaften-Day C, Russell P, Davies S, King NJC, Tattersall MHN. Expression of Fas and FasL in human serous ovarian epithelial tumors. HUMAN PATHOLOGY 34 (1): 74-79 JAN 2003.
- 2003, Kuwahara D, Tsutsumi K, Oyake D, Ohta T, Nishikawa H, Koizuka I. Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells. AURIS NASUS LARYNX 30: S85-S88 Suppl. S FEB 2003.
- 2003, Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. INTERNATIONAL JOURNAL OF ONCOLOGY 22 (2): 431-437 FEB 2003.
- 2003, Spierings DCJ, de Vries EGE, Vellenga E, de Jong S. Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. CELL DEATH AND DIFFERENTIATION 10 (7): 808-822 JUL 2003.
- 2003, Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ, Mor G. Epithelial ovarian cancer cells secrete functional Fas ligand. CANCER RESEARCH 63 (17): 5573-5581 SEP 1 2003.
- 2003, Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. INTERNATIONAL JOURNAL OF ONCOLOGY 22 (2): 431-437 FEB 2003.
- 2003, Frost P, Caliliw R, Belldegrun A, Bonavida B. Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. INTERNATIONAL JOURNAL OF ONCOLOGY 22 (2): 431-437 FEB 2003.
- 2003, Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ. IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: A gene therapy approach. MOLECULAR THERAPY. 7 (2): 185-192 FEB 2003.
- 2003, Nakanishi H, Mizutani Y, Kawauchi A, Ukimura O, Shiraishi T, Hatano M, Mizuno M, Yoshida J, Miki T. Significant antitumoral activity of cationic multilamellar liposomes containing human IFN-beta gene against human renal cell carcinoma. CLINICAL CANCER RESEARCH 9 (3): 1129-1135 MAR 2003.
- 2003, Nakanishi H, Mazda O, Satoh E, Asada H, Morioka H, Kishida T, Nakao M, Mizutani Y, Kawauchi A, Kita M, Imanishi J, Miki T. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. GENE THERAPY 10 (5): 434-442 MAR 2003.
- 2003, Mishima K, Nariai Y, Yoshimura Y. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: Sensitization for apoptosis by upregulation of FADD expression. INTERNATIONAL JOURNAL OF CANCER 105 (5): 593-600 JUL 10 2003.
- 2003, Nastiuk KL, Kim JW, Mann M, Krolewski JJ. Androgen regulation of FLICE-like inhibitory protein gene expression in the rat prostate JOURNAL OF CELLULAR PHYSIOLOGY 196 (2): 386-393 AUG 2003.
- 2003, Rajesh D, Howard SP. Perillyl alcohol mediated radiosensitization via augmentation of the Fas pathway in prostate cancer cells. PROSTATE 57 (1): 14-23 SEP 15 2003
- 2003, Ovali E, Ozdemir F, Aydin F, Kavgaci H, Tekelioglu Y, Buyukcelik A, Yilmaz. The effects of dexamethasone on leukemic cells derived from patients with AML. MJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22 (1): 85-89 MAR 2003.
- 2003, Melo PS, Justo GZ, de Azevedo MBM, Duran N, Haun M. Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells TOXICOLOGY 186 (3): 217-225 APR 22 2003.
- 2003, Anazetti MC, Melo PS, Duran N, Haun M. Comparative cytotoxicity of dimethylamide-crotonin in the promyelocytic leukemia cell line (HL60) and human peripheral blood mononuclear cells TOXICOLOGY 188 (2-3): 261-274 JUN 30 2003.
- 2003, Liu W, Akhand AA, Takeda K, Kawamoto Y, Itoigawa M, Kato M, Suzuki H, Ishikawa N, Nakashima I. Protein phosphatase 2A-linked and -unlinked caspase-dependent pathways for downregulation of Akt kinase triggered by 4-hydroxynonenal. CELL DEATH AND DIFFERENTIATION 10 (7): 772-781 JUL 2003.
- 2003, G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E, Buyukkececi F, Omay SB. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Saydam LEUKEMIA RESEARCH 27 (8): 709-717 AUG 2003.
- 2003, Freire ACG, Aoyama H, Haun M, Ferreira CV. Relationship between phosphatase activity and cytotoxic effect of two protein phosphatase inhibitors, okadaic acid and pervanadate, on human myeloid leukemia cell line. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 18 (5): 425-429 AUG 2003.
- 2003, Faulkner NE, Lane BR, Bock PJ, Markovitz DM. Protein phosphatase 2A enhances activation of human immunodeficiency virus type 1 by phorbol myristate acetate. JOURNAL OF VIROLOGY 77 (3): 2276-2281 FEB 2003.
- 2003, Ovali E, Ozdemir F, Aydin F, Kavgaci H, Tekelioglu Y, Buyukcelik A, Yilmaz. The effects of dexamethasone on leukemic cells derived from patients with AML. MJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22 (1): 85-89 MAR 2003.
- 2003, G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E, Buyukkececi F, Omay SB. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Saydam LEUKEMIA RESEARCH 27 (8): 709-717 AUG 2003.
- 2003, Duyndam MCA, Hulscher STM, van der Wall E, Pinedo HM, Boven E. Evidence for a role of p38 kinase in hypoxia-inducible factor 1-independent induction of vascular endothelial growth factor expression by sodium arsenite JOURNAL OF BIOLOGICAL CHEMISTRY 278 (9): 6885-6895 FEB 28 2003.
- 2003, Yu D, Wang ZH, Zhu LY, Ec C. Nuclear matrix associated protein PML: an arsenic trioxide apoptosis therapeutic target protein in HepG2 cells. CHINESE MEDICAL JOURNAL 116 (1): 93-98 JAN 2003.
- 2003, Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J. Use of arsenic trioxide (AS(2)O(3)) in the treatment of patients with acute promyelocytic leukemia - The M. D. Anderson experience CANCER 97 (9): 2218-2224 MAY 1 2003.
- 2003, Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide CANCER RESEARCH 63 (9): 2103-2108 MAY 1 2003.
- 2003, Ozsoz M, Erdem A, Kara P, Kerman K, Ozkan D. Electrochemical biosensor for the detection of interaction between arsenic trioxide and DNA based on guanine signal ELECTROANALYSIS 15 (7): 613-619 MAY 2003.
- 2003, Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells BLOOD 101 (12): 4990-4997 JUN 15 2003.
- 2003, Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, Bommert K, Dorken B. Inhibition of NF-kappa B essentially contributes to arsenic-induced apoptosis. BLOOD102 (3): 1028-1034 AUG 1 2003.
- 2003, Crispini A, Pucci D, Sessa S, Cataldi A, Napoli A, Valentini A, Ghedini M. Synthesis and characterization of new transition metal complexes containing DNA intercalators of the acridine family. NEW JOURNAL OF CHEMISTRY 27 (10): 1497-1503 2003.
- 2003, Wei HL, Su HX, Bai DC, Zhao HS, Ge G, Wang B, Yao XJ, Ma LF. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene. CHINESE MEDICAL JOURNAL 116 (11): 1644-1648 NOV 2003
- 2003, Hicsonmez G, Cetin M, Okur H, Erdemli E, Gurgey A. The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia LEUKEMIA & LYMPHOMA 44 (6): 1037-1042 2003.
- 2003, Liu WJ, Shen Y, Ding J. Protein phosphatase 2A: Its structure, function and activity regulation. ACTA BIOCHIMICA ET BIOPHYSICA SINICA 35 (2): 105-112 FEB 2003.
- 2003, Ovali E, Ozdemir F, Aydin F, Kavgaci H, Tekelioglu Y, Buyukcelik A, Yilmaz. The effects of dexamethasone on leukemic cells derived from patients with AML. MJOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH 22 (1): 85-89 MAR 2003.
- 2003, Hicsonmez G. Retinoic acid and steroid in acute promyelocytic leukemia.. LEUKEMIA 17 (6): 1203-1203 JUN 20.
- 2003, Hicsonmez G, Cetin M, Aslan D, Ozyurek E. The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor PEDIATRIC HEMATOLOGY AND ONCOLOGY 20 (5): 373-379 JUL-AUG 2003.
- 2003, G, Aydin HH, Sahin F, Selvi N, Oktem G, Terzioglu E, Buyukkececi F, Omay SB. Involvement of protein phosphatase 2A in interferon-alpha-2b-induced apoptosis in K562 human chronic myelogenous leukaemia cells. Saydam LEUKEMIA RESEARCH 27 (8): 709-717 AUG 2003.
- 2003, Yurtcu E, Ergun MA, Menevse A. Apoptotic effect of gossypol on human lymphocytes. CELL BIOLOGY INTERNATIONAL 27 (9): 791-794 2003.
- 2003, Jacquel A, Herrant M, Legros L, Belhacene N, Luciano F, Pages G, Hofman P, Auberger P. Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation towards the erythroid lineage. FASEB JOURNAL 17 (12): U424-U447 SEP 2003.
- 2003, Campo GM, D'Ascola A, Avenoso A, Campo S, Ferlazzo AM, Micali C, Zanghi L, Calatroni A. Glycosaminoglycans reduce oxidative damage induced by copper (Cu+2), iron (Fe+2) and hydrogen peroxide (H2O2) in human fibroblast cultures. GLYCOCONJUGATE JOURNAL 20 (2): 133-141 2003.
- 2003, Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W.E., Tsang, B.K.. Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reproductive Biology and Endocrinology Volume 1, 7 October 2003, 13p.
- 2003, Galvão Freire, A.C., Fernandes De Assis, C., Frick, A.O., Da Silva Melo, P., Haun, M., Aoyama, H., Durán, N., (...), Ferreira, C.V. Influence of protein phosphatase inhibitors on HL60 cells death induction by dehydrocrotonin. Leukemia Research 27 (9), pp. 823-829, 2003.
- 2003, Omay, S.B., Saydam, G., Aydin, H.H., Selvi, N., Öktem, G., Sanli, U.A., Tobu, M., Büyükkeçeci, F. Potential involvement of calcineurin in regulating the state of differentiation and apoptosis of HL-60 cells during methylprednisolone-treatment. Turkish Journal of Haematology 20 (3), pp. 143-151, 2003.
- 2003, Blower, P.J. Inorganic pharmaceuticals. Annual Reports on the Progress of Chemistry - Section A 99, pp. 589-614, 2003.
- 2002, Balbi G, Di Prisco L, Musone R, Menditto A, Cassese E, Balbi C, Cardone A. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY 23 (4): 347-349 2002.
- 2002, Alas S, Ng CP, Bonavida B. Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. CLINICAL CANCER RESEARCH 8 (3): 836-845 MAR 2002.
- 2002, Sato S, Yamate J, Saito T, Hosokawa T, Saito S, Kurasaki M. Protective effect of taurine against renal interstitial fibrosis of rats induced by cisplatin. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 365 (4): 277-283 APR 2002.
- 2002, Balbi G, Di Prisco L, Musone R, Menditto A, Cassese E, Balbi C, Cardone A. Second-line with paclitaxel and carboplatin for recurrent disease following first paclitaxel and platinum compounds in ovarian carcinoma. EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY 23 (4): 347-349 2002.
- 2002, Stewart JH, Nguyen DM, Chen GA, Schrump DS. Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway. JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY 123 (2): 295-302 FEB 2002.
- 2002, Cheng JQ, Jiang XX, Fraser M, Li M, Dan HC, Sun M, Tsang BK. Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. DRUG RESISTANCE UPDATES 5 (3-4): 131-146 JUN-AUG 2002.
- 2002, Chouaib S, Thiery J, Gati A, Guerra N, El Behi M, Dorothee G, Mami-Chouaib F, Bellet D, Caignard A. Tumor escape from killing: Role of killer inhibitory receptors and acquisition of tumor resistance to cell death. TISSUE ANTIGENS 60 (4): 273-281 OCT 2002.
- 2002, Crowston JG, Chang LH, Constable PH, Daniels JT, Akbar AN, Khaw PT. Apoptosis gene expression and death receptor signaling in mitomycin-C-treated human tenon capsule fibroblasts. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE 43 (3): 692-699 MAR 2002
- 2002, Morris GZ, Williams RL, Elliott MS, Beebe SJ. Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells. PROSTATE 52 (4): 319-329 SEP 1 2002.
- 2002, Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: Two complementary signals to overcome cross-resistance. ADVANCES IN CANCER RESEARCH, VOL 85 ADVANCES IN CANCER RESEARCH 85: 145-174 2002.
- 2002, Curtin JF, Cotter TG. Anisomycin activates JNK and sensitises DU 145 prostate carcinoma cells to Fas mediated apoptosis.BRITISH JOURNAL OF CANCER 87 (10): 1188-1194 NOV 4 2002.
- 2002, Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS. Downregulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis CANCER BIOLOGY & THERAPY 1 (4): 401-406 JUL-AUG 2002.
- 2002, Ghosh J, Myers CE. Molecular mechanisms of prostate cancer cell death triggered by inhibition of arachidonate 5-lipoxygenase: Involvement of Fas death receptor-mediated signals eicosanoids and other bioactive lipids in cancer, inflammation, and radiation injury, 5 ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 507: 415-420 2002.
- 2002, Erkan F, Kiyan E, Tunaci A. Pulmonary complications of Behcet's disease. CLINICS IN CHEST MEDICINE 23 (2): 493-+ JUN 2002.
- 2002, Kappes S, Kunz M, Klautke G, Terpe H, Gross G. Facial edemas in a 61-year old patient. HAUTARZT 53 (9): 625-628 SEP 2002.
- 2002, Yuksel S, Saydam G, Uslu R, Sanli UA, Terzioglu E, Buyukececi F, Omay SB. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation.LEUKEMIA RESEARCH 26 (4): 391-398 APR 2002.
- 2002, Benning CM, Kyprianou N. Quinazoline-derived alpha 1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha 1-adrenoceptor-independent action. CANCER RESEARCH 62 (2): 597-602 JAN 15 2002.
- 2002, Anglin IE, Glassman DT, Kyprianou N. Review - Induction of prostate apoptosis by alpha(1)-adrenoceptor antagonists: mechanistic significance of the quinazoline component. PROSTATE CANCER AND PROSTATIC DISEASES 5 (2): 88-95 2002.
- 2002, Safak Yuksel, Guray Saydam, Ruchan Uslu, Ulus Ali Sanli, Ender Terzioglu, Filiz Buyukececi, Serdar Bedii Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. LEUKEMİA RESEARCH Apr:26(4):391-398, 2002. (8,33).
- 2002, Rojewski MT, Baldus C, Knauf W, Thiel E, Schrezenmeier H. Dual effects of arsenic trioxide (AS(2)O(3)) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation. BRITISH JOURNAL OF HAEMATOLOGY 116 (3): 555-563 MAR 2002.
- 2002, Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH. Arsenic trioxide as a novel anticancer agent against human transitional carcinoma - characterizing its apoptotic pathway. ANTI-CANCER DRUGS 13 (3): 293-300 MAR 2002.
- 2002, Baj G, Arnulfo A, Deaglio S, Mallone R, Vigone A, De Cesaris MG, Surico N, Malavasi F, Ferrero E. Arsenic trioxide and breast cancer: Analysis of the apoptotic, differentiative and immunomodulatory effects BREAST CANCER RESEARCH AND TREATMENT 73 (1): 61-73 MAY 2002.
- 2002, Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS LETTERS 519 (1-3): 195-200 MAY 22 2002.
- 2002, Woo SH, Park IC, Park MJ, Lee HC, Lee SWJ, Chun YJ, Lee SH, Hong SI, Rhee CH. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. INTERNATIONAL JOURNAL OF ONCOLOGY 21 (1): 57-63 JUL 2002.
- 2002, Carre M, Carles G, Andre N, Douillard S, Ciccolini J, Briand C, Braguer D.Involvement of microtubules and mitochondria in the antagonism of arsenic trioxide on paclitaxel-induced apoptosis. BIOCHEMICAL PHARMACOLOGY 63 (10): 1831-1842 MAY 15 2002.
- 2002, Miller WH, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. CANCER RESEARCH 62 (14): 3893-3903 JUL 15 2002.
- 2002, Li XQ, Ding XZ, Adrian TE. Arsenic trioxide inhibits proliferation and induces apoptosis in pancreatic cancer cells. ANTICANCER RESEARCH 22 (4): 2205-2213 JUL-AUG 2002.
- 2002, Pu YS, Hour TC, Chen J, Huang CY, Guan JY, Lu SH.Cytotoxicity of arsenic trioxide to transitional carcinoma cells. UROLOGY 60 (2): 346-350 AUG 2002.
- 2002, Sezgin, C., Şanli, U.A., Uslu, R., Göker, E. Arsenic trioxide has additive cytotoxic effects on MCF-7 breast cancer cell line with taxanes. Turkish Journal of Medical Sciences 32 (6), pp. 439-444, 2002.
- 2001, Masuda H, Tanaka T, Tateishi M, Naito M, Tamai H. Detection and cytotoxicity of cisplatin-induced superoxide anion in monolayer cultures of a human ovarian cancer cell line. CANCER CHEMOTHERAPY AND PHARMACOLOGY 47: (2) 155-160 FEB 2001.
- 2001, Duan L, Aoyagi M, Tamaki M, Nakagawa K, Nagashima G, Nagasaka Y, Ohno K, Yamamoto K, Hirakawa K. Sensitization of human malignant glioma cell lines to tumor necrosis factor-induced apoptosis by cisplatin. JOURNAL OF NEURO-ONCOLOGY 52 (1): 23-36 MAR 2001.
- 2001, Hara M, Yoshida M, Nishijima H, Yokosuka M, Iigo M, Ohtani-Kaneko R, Shimada A, Hasegawa T, Akama Y, Hirata K. Melatonin, a pineal secretory product with antioxidant properties, protects against cisplatin-induced nephrotoxicity in rats. JOURNAL OF PINEAL RESEARCH 30 (3): 129-138 APR 2001.
- 2001, Troyano A, Fernandez C, Sancho P, de Blas E, Aller P. Effect of glutathione depletion on antitumor drug toxicity (apoptosis and necrosis) in U-937 human promonocytic cells - The role of intracellular oxidation. JOURNAL OF BIOLOGICAL CHEMISTRY 276 (50): 47107-47115 DEC 14 2001.
- 2001, Zagozdzon R, Golab J. Immunomodulation by anticancer chemotherapy: More is not always better (review). INTERNATIONAL JOURNAL OF ONCOLOGY 18: (2) 417-424 FEB 2001.
- 2001, Bellarosa D, Ciucci A, Bullo A, Nardelli F, Manzini S, Maggi CA, Goso C. Apoptotic events in a human ovarian cancer cell line exposed to anthracyclines. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 296: (2) 276-283 FEB 2001.
- 2001, Frost PA, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. JOURNAL OF IMMUNOLOGY 166: (5) 3564-3573 MAR 1 2001.
- 2001, Liu WH, Bodle E, Chen JY, Gao MX, Rosen GD, Broaddus VC. Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY 25 (1): 111-118 JUL 2001
- 2001, Wahl AF, Donaldson KL, Mixan BJ, Trail PA, Siegall CB. Selective tumor sensitization to taxanes with the MAB-drug conjugate CBR96-doxorubicin. INTERNATIONAL JOURNAL OF CANCER 93 (4): 590-600 AUG 15 2001.
- 2001, Yang RC, Xu DW, Zhang AJ, Gruber A. Immature dendritic cells kill ovarian carcinoma cells by a Fas/FasL pathway, enabling them to sensitize tumor-specific CTLs. INTERNATIONAL JOURNAL OF CANCER 94 (3): 407-413 NOV 1 2001.
- 2001, Poulaki V, Mitsiades CS, Mitsiades N. The role of Fas and FasL as mediators of anticancer chemotherapy. DRUG RESISTANCE UPDATES 4 (4): 233-242 AUG 2001.
- 2001, Coffey RNT, Watson RWG, Fitzpatrick JM. Signaling for the caspases: Their role in prostate cell apoptosis. JOURNAL OF UROLOGY 165: (1) 5-14 JAN 2001.
- 2001, Moingeon P. Cancer vaccines. VACCINE 19: (11-12) 1305-1326 JAN 8 2001.
- 2001, Frost PA, Butterfield LH, Dissette VB, Economou JS, Bonavida B. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures. JOURNAL OF IMMUNOLOGY 166: (5) 3564-3573 MAR 1 2001.
- 2001, Nesterov A, Lu XJ, Johnson M, Miller GJ, Ivashchenko Y, Kraft AS. Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. JOURNAL OF BIOLOGICAL CHEMISTRY 276 (14): 10767-10774 APR 6 2001.
- 2001, Mitsiades CS, Koutsilieris M. Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. EXPERT OPINION ON INVESTIGATIONAL DRUGS 10 (6): 1099-1115 JUN 2001.
- 2001, Coffey RNT, Watson RWG, Hegarty PK, Watson CL, Wolohan L, Brady HR, O'Keane C, Fitzpatrick JM. Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases. CANCER 92 (9): 2297-2308 NOV 1 2001.
- 2001, Rubinchik S, Wang D, Yu H, Fan F, Luo M, Norris JS, Dong JY. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression. MOLECULAR THERAPY 4 (5): 416-426 NOV 2001.
- 2001, Zisman A, Ng CP, Pantuck AJ, Bonavida B, Belldegrun AS. Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis. JOURNAL OF IMMUNOTHERAPY 24 (6): 459-471 NOV-DEC 2001.
- 2001, Poulaki V, Mitsiades CS, Mitsiades N. The role of Fas and FasL as mediators of anticancer chemotherapy. DRUG RESISTANCE UPDATES 4 (4): 233-242 AUG 2001.
- 2001, Erkan F, Gul A, Tasali E. Pulmonary manifestations of Behcet's disease. THORAX 56 (7): 572-578 JUL 2001.
- 2001, McMahon KA, Wilson NJ, Marks DC, Beecroft TL, Whitty GA, Hamilton JA, Csar XF. Colony-stimulating factor-1 (CSF-1) receptor-mediated macrophage differentiation in myeloid cells: a role for tyrosine 559-dependent protein phosphatase 2A (PP2A) activity. BIOCHEMICAL JOURNAL. 358: 431-436, Part 2 SEP 1 2001.
- 2001, Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. ONCOGENE 20 (49): 7146-7153 OCT 29 2001.
- 2001, Tallman MS. Arsenic trioxide: its role in acute promyelocytic leukemia and potential in other hematologic malignancies. BLOOD REVIEWS 15 (3): 133-142 SEP 2001.
- 2001, Deng Y, Xu HB, Huang KX, Yang XL, Xie CS, Wu J. Size effects of realgar particles on apoptosis in a human umbilical vein endothelial cell line: ECV-304. PHARMACOLOGICAL RESEARCH 44 (6): 513-518 DEC 2001.
- 2001, Duyndam MCA, Hulscher TM, Fontijn D, Pinedo HM, Boven E. Induction of vascular endothelial growth factor expression and hypoxia-inducible factor 1 alpha protein by the oxidative stressor arsenite. JOURNAL OF BIOLOGICAL CHEMISTRY 276 (51): 48066-48076 DEC 21 2001.
- 2001, Meinhold-Heerlein, I., Stenner-Liewen, F., Liewen, H., Kitada, S., Krajewska, M., Krajewski, S., Zapata, J.M., (...), Reed, J.C.. Expression and potential role of fas-associated phosphatase-1 in ovarian cancer. American Journal of Pathology 158 (4), pp. 1335-1344, 2001.
- 2000, Kovacic P, Osuna JA. Mechanisms of anti-cancer agents: Emphasis on oxidative stress and electron transfer. CURR PHARM DESIGN 6: (3) 277-309 FEB 2000.
- 2000, Somani SM, Husain K, Whitworth C, et al. Dose-dependent protection by lipoic acid against cisplatin-induced nephrotoxicity in rats: Antioxidant defense system. PHARMACOL TOXICOL 86: (5) 234-241 MAY 2000.
- 2000, Kuwahara D, Tsutsumi K, Kobayashi T, et al. Caspase-9 regulates cisplatin-induced apoptosis in human head and neck squamous cell carcinoma cells. CANCER LETT 148: (1) 65-71 JAN 1 2000.
- 2000, Fellenberg J, Mau H, Nedel S, et al. Drug-induced apoptosis in osteosarcoma cell lines is mediated by caspase activation independent of CD95-receptor/ligand interaction. J ORTHOPAED RES 18: (1) 10-17 JAN 2000.
- 2000, Bertoni F, Conconi A, Carobbio S, et al. Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines. INT J CANCER 86: (3) 450-450 MAY 1 2000.
- 2000, Li Q, Tsuruda K, Sugahara K, et al. Qualitative and quantitative characterization of Fas (CD95) expression and its role in primary human acute leukemia cells. LEUKEMIA RES 24: (5) 437-444 MAY 2000.
- 2000, Frost P, Bonavida B. Circumvention of tumor cell escape following specific immunotherapy. CANCER BIOTHER RADIO 15: (2) 141-152 APR 2000.
- 2000, Li JL, Sasaki H, Sheng YL, Schneiderman D, Xiao CW, Kotsuji F, Tsang BK. Apoptosis and chemoresistance in human ovarian cancer: Is Xiap a determinant? BIOLOGICAL SIGNALS AND RECEPTORS 9: (2) 122-130 MAR-APR 2000.
- 2000, Haeryfar SMM, Nagy E, Baral E, Krepart G, Lotocki R, Berczi I. Antiestrogens affect both pathways of killer cell-mediated oncolysis. ANTICANCER RESEARCH. 20: (3A) 1849-1853 MAY-JUN 2000.
- 2000, Gora-Tybor J, Lech-Maranda E, Blonski JZ, Robak T. 2-chlorodeoxyadenosine (2-CDA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells. PURINE AND PYRIMIDINE METABOLISM IN MAN X 486: 307-310 2000.
- 2000, Frost P, Bonavida B. Circumvention of tumor cell escape following specific immunotherapy. CANCER BIOTHER RADIO 15: (2) 141-152 APR 2000.
- 2000, Sinkovics JG, Horvath JC. Vaccination against human cancers. INT J ONCOL 16: (1) 81-96 JAN 2000.
- 2000, Cal C, Uslu R, Gunaydin G, et al. Doxazosin: a new cytotoxic agent for prostate cancer? BJU INT 85: (6) 672-675 APR 2000.
- 2000, Frost P, Bonavida B. Circumvention of tumor cell escape following specific immunotherapy. CANCER BIOTHER RADIO 15: (2) 141-152 APR 2000.
- 2000, Costa-Pereira AP, McKenna SL, Cotter TG. Activation of SAPK/JNK by camptothecin sensitizes androgen-independent prostate cancer cells to Fas-induced apoptosis. BRIT J CANCER 82: (11) 1827-1834 JUN 2000.
- 2000, Haeryfar SMM, Nagy E, Baral E, Krepart G, Lotocki R, Berczi I. Antiestrogens affect both pathways of killer cell-mediated oncolysis. ANTICANCER RESEARCH. 20: (3A) 1849-1853 MAY-JUN 2000.
- 2000, Radoja S, Frey AB. Cancer-induced defective cytotoxic T lymphocyte effector function: Another mechanism how antigenic tumors escape immune-mediated killing. MOLECULAR MEDICINE 6: (6) 465-479 JUN 2000.
- 2000, Hyer ML, Voelkel-Johnson C, Rubinchik S, Dong J, Norris JS. Intracellular Fas ligand expression causes Fas-mediated apoptosis in human prostate cancer cells resistant to monoclonal antibody-induced apoptosis. MOLECULAR THERAPY 2: (4) 348-358 OCT 2000.
- 2000, Hara I, Miyake H, Hara S, Arakawa S, Kamidono S. Differential involvement of the Fas receptor/ligand system in p53-dependent apoptosis in human prostate cancer cells. PROSTATE 45: (4) 341-349 DEC 1 2000
- 2000, Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. CLINICAL CANCER RESEARCH 6: (12) 4957-4964 DEC 2000.
- 2000, Akpolat T, Yildiz L, Akpolat I, Selcuk MB, Ozbek N, Yucel I. Small-cell carcinoma as a cause of superior vena cava syndrome in a patient with Behcet's disease. RESPIRATION 67: (5) 593-593 SEP-OCT 2000.
- 2000, Akpolat T, Danaci M, Belet U, Erkan ML, Akar H. MR imaging and MR angiography in vascular Behcet's disease. MAGNETIC RESONANCE IMAGING 18: (9) 1089-1096 NOV 2000.
- 2000, Cal C, Uslu R, Gunaydin G, et al. Doxazosin: a new cytotoxic agent for prostate cancer? BJU INT 85: (6) 672-675 APR 2000.
- 2000, Aydin HH, Selvi N, Saydam G, Tobu M, Uzunoglu S, Uslu R, Buyukkececi F, Omay SB. Up-regulation of serine/threonine protein phosphatase type 2A regulatory subunits during methylprednisolone-induced differentiation of leukaemic HL-60 cells. CLINICAL AND LABORATORY HAEMATOLOGY 22: (5) 271-274 OCT 2000.
- 2000, Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. CLINICAL CANCER RESEARCH 6: (12) 4957-4964 DEC 2000.
- 2000, Farah, E., Bitar, K., AbouJaoude, S., Slaba, S., Ghayad, E. Pseudo-Takayasu in Behcet's disease | [Pseudo-Takayasu dans la maladie de Behcet]. Journal Medical Libanais 48 (3), pp. 164-167, 2000.
- 2000, Anisimov, A.G., Bolotnikov, I.A., Chekmasova, A.A., Volkova, T.O. Interconnection of in vitro induced differentiation of cancer cell lines and their susceptibility to non-specific lysis by natural killer cells. Possible mechanisms. Tsitologiya 42 (10), pp. 932-936, 2000.
- 1999, Keane MM, Ettenberg SA, Nau MM, et al. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. CANCER RES 59: (3) 734-741 FEB 1 1999.
- 1999, Schneiderman D, Kim JM, Senterman M, et al. Sustained suppression of Fas ligand expression in cisplatin-resistant human ovarian surface epithelial cancer cells. APOPTOSIS 4: (4) 271-282 AUG 1999.
- 1999, Rubio CA, Jacobsson B, Castanos-Velez E. Cytotoxic intraepithelial lymphocytes in colorectal polyps and carcinomas. ANTICANCER RES 19: (4B) 3221-3227 JUL-AUG 1999.
- 1999, Mori S, Murakami-Mori K, Nakamura S, et al. Sensitization of AIDS Kaposi's sarcoma cells to Apo-2 ligand-induced apoptosis by actinomycin D. J IMMUNOL 162: (9) 5616-5623 MAY 1 1999.
- 1999, Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review). INT J ONCOL 15: (4) 793-802 OCT 1999.
- 1999, Hedlund TE, Meech SJ, Srikanth S, et al. Adenovirus-mediated expression of Fas ligand induces apoptosis of human prostate cancer cells. CELL DEATH DIFFER 6: (2) 175-182 FEB 1999.
- 1999, Li L, Zhu ZY, Joshi B, et al. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. II: In vivo efficacy and pharmacokinetic studies. ANTICANCER RES 19: (1A) 61-69 JAN-FEB 1999.
- 1999, Granziero L, Krajewski S, Farness P, et al. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. EUR J IMMUNOL 29: (4) 1127-1138 APR 1999.
- 1999, Shishova YV, Yurchenko OV, Khromyak VN, et al. Cisplatin resistance associated with hypersensitivity to CD95-mediated apoptosis in epidermoid carcinoma cell KB/DDP5 subline. EXP ONCOL 21: (2) 141-145 JUN 1999.
- 1999, Frost PJ, Belldegrun A, Bonavida B. Sensitization of immunoresistant prostate carcinoma cell lines to Fas/Fas ligand-mediated killing by cytotoxic lymphocytes: Independence of de novo protein synthesis PROSTATE 41: (1) 20-30 SEP 15 1999.
- 1999, Bruckheimer EM, Gjertsen BT, McDonnell TJ. Implications of cell death regulation in the pathogenesis and treatment of prostate cancer. SEMIN ONCOL 26: (4) 382-398 AUG 1999.
- 1999, Hedlund TE, Duke RC, Miller GJ. Three-dimensional spheroid cultures of human prostate cancer cell lines. PROSTATE 41: (3) 154-165 NOV 1 1999.
- 1999, Bonavida B, Ng CP, Jazirehi A, et al. Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: The trail to non-toxic cancer therapeutics (Review). INT J ONCOL 15: (4) 793-802 OCT 1999.
- 1999, Petrylak DP. Chemotherapy for advanced hormone refractory prostate cancer. UROLOGY 54: (6A) 30-35 Suppl. S DEC 1999.
- 1999, Houman H, Lamloum M, Ben Ghorbel I, et al. Vena cava thrombosis in Behcet's disease. Analysis of a series of 10 cases. ANN MED INTERNE 150: (8) 587-590 DEC 1999.
- 1999, Mushika, M., Shibata, K., Miwa, T., Kaneda, T. Expression of FAS-antigen in human ovarian tumors. Acta Obstetrica et Gynaecologica Japonica 51 (10), pp. 845-849, 1999.
- 1999, Mizutani, Y., Yoshida, O.. Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells. Journal of Infection and Chemotherapy 5 (3), pp. 139-143, 1999.
- 1999, Mizutani, Y., Yoshida, O. Effect of anticancer agents on Fas-mediated cytotoxicity against bladder cancer cells. Journal of Infection and Chemotherapy 5 (3), pp. 139-143, 1999.
- 1999, Erkan, F. Pulmonary involvement in Behçet disease. Current Opinion in Pulmonary Medicine 5 (5), pp. 314-318. 1999.
- 1998, Li QD, Bostick-Bruton F, Reed E. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. ANTICANCER RES 18: (4A) 2283-2287 JUL-AUG 1998.
- 1998, Husain K, Morris C, Whitworth C, et al. Protection by ebselen against cisplatin-induced nephrotoxicity: Antioxidant system MOL CELL BIOCHEM 178: (1-2) 127-133 JAN 1998.
- 1998, De Vos K, Goossens V, Boone E, et al. The 55-kDa tumor necrosis factor receptor induces clustering of mitochondria through its membrane-proximal region J BIOL CHEM 273: (16) 9673-9680 APR 17 1998.
- 1998, Esposti MD. Inhibitors of NADH-ubiquinone reductase: an overview.BBA-BIOENERGETICS 1364: (2) 222-235 MAY 6 1998.
- 1998, McGahon AJ, Pereira APC, Daly L, et al. Chemotherapeutic drug-induced apoptosis in human leukaemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. BRIT J HAEMATOL 101: (3) 539-547 JUN 1998.
- 1998, Solary E, Micheau O, Dimanche-Boitrel MT, et al. Role of the Fas/Fas-L system in the immune response to tumors and the resistance to cytotoxic drugs. B CANCER 85: (8) 685-694 AUG 1998.
- 1998, Chekhun VF, Shishova YV, Yurchenko OV, et al. Synergistic cytotoxic effect of cisplatin and monoclonal anti-Fas IPO-4 antibodies on human epidermoid carcinoma cell line KB. EXP ONCOL 20: (3-4) 210-216 SEP-DEC 1998.
- 1998, Li QD, Bostick-Bruton F, Reed E. Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line. ANTICANCER RES 18: (4A) 2283-2287 JUL-AUG 1998.
- 1998, Hedlund TE, Duke RC, Schleicher MS, et al. Fas-mediated apoptosis in seven human prostate cancer cell lines: Correlation with tumor stage PROSTATE 36: (2) 92-101 JUL 1 1998.
- 1997, Bonavida B, Safrit J, Morimoto H, et al. Cross-resistance of tumor cells to chemotherapy and immunotherapy: Approaches to reverse resistance and implications in gene therapy (review). ONCOL REP 4: 201-205 Suppl. 1 JAN-FEB 1997.
- 1997, Okina H, Kataoka A, Sugiyama T, et al. Establishment and characterization of ovarian endometrioid adenocarcinoma cell line in nude mice and analyses of the immunohistochemical property among the original, recurred, and heterotransplanted tumor INT J ONCOL 10: (2) 311-316 FEB 1997.
- 1997, Miyajima A, Nakashima J, Yoshioka K, et al. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. BRIT J CANCER 76: (2) 206-210 JUL 1997.
- 1997, Asschert JGW, Vellenga E, Hollema H, et al. Expression of macrophage colony-stimulating factor (M-CSF), interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), interleukin-11 (IL-11) and tumour necrosis factor-alpha (TNF-alpha) in p53-characterised human ovarian carcinomas. EUR J CANCER 33: (13) 2246-2251 NOV 1997 .
- 1997, Uslu R, Borsellino N, Frost P, et al. Chemosensitization of human prostate carcinoma cell lines to anti-Fas-mediated cytotoxicity and apoptosis CLIN CANCER RES 3: (6) 963-972 JUN 1997.
- 1997, Frost P, Ng CP, Belldegrun A, et al. Immunosensitization of prostate carcinoma cell lines for lymphocytes (CTL, TIL, LAK)-mediated apoptosis via the Fas-Fas-ligand pathway of cytotoxicity. CELL IMMUNOL 180: (1) 70-83 AUG 25 1997 Bonavida B. Oncology Reports 4: 201, 1997.
- 1997, Williams BA, Makrigiannis AP, Blay J, et al. Treatment of the P815 murine mastocytoma with cisplatin or etoposide up-regulates cell-surface Fas (CD95) expression and increases sensitivity to anti-Fas antibody-mediated cytotoxicity and to lysis by anti-CD3-activated killer-T cells. INT J CANCER 73: (3) 416-423 NOV 4 1997 Rubia CA. Apoptosis 2: 489, 1997.
- 1997, Rubio CA. Intraepithelial lymphocytes vs. colorectal neoplastic cells: Who is winning the apoptotic battle? APOPTOSIS 2: (6) 489-493 DEC 1997.
- 1997, Millan Palomino, J.C., Gómez Zubeldia, M.A., Arbués Lacadena, J. Free radicals, estrogens, and cancer | [Radicales libres, estrógenos y cáncer] Toko-Ginecologia Practica 56 (622), pp. 321-330,1997
- 1996, Dorward AM, Singh G. Energetic characteristics of cisplatin resistant ovarian carcinoma cells. ANTICANCER RES 16: (1) 443-447 JAN-FEB 1996.
- 1996, Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis GYNECOL ONCOL 62: (2) 282-291 AUG 1996.
- 1996, Uslu R, Jewett A, Bonavida B. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis GYNECOL ONCOL 62: (2) 282-291 AUG 1996.
Books (16 entries)- Rüçhan Uslu. Meme Kanseri Hastaları İçin El Kitabı. 2013, Meta Basım, İzmir.
- Rüçhan Uslu. Kolon ve Rektum. Pratik Klinik Onkoloji kitabı, ed: Doç. Dr. Feyyaz Özdemir 1. baskı, 2012, Ege Basım/İstanbul.
- Rüçhan Uslu. Metastatik Meme Kanserinde Sistemik Tedavi. Meme Hastalıkları Kitabı, ed: Prof. Dr. Vahit Özmen, 2012, Güneş Tıp Kitabevi/Ankara.
- Rüçhan Uslu. Meme Kanseri Cerrahisine Bağlı Lenfödem, ed: Doç. Dr. Sibel Eyigör, Prof. Dr. Rüçhan Uslu 1. baskı, Temmuz 2011, Ege Üniversitesi Tıp Fakültesi Halk Kitapları Sağlık Serisi 5.
- Rüçhan Uslu. Kemoterapi Uygulama Rehberi (Solid Tümörler) 2007, Meta Basım, İzmir.
- Rüçhan Uslu, Bülent Karabulut, Derya Bıçaklı. Onkoloji Hastaları için Kemoterapi El Kitabı. 2007, Meta Basım, İzmir
- Rüçhan Uslu, Özlem Uğur, Çiçek Fadıloğlu. Onkoloji Hastanız ve Siz. 2007, Meta Basım, İzmir
- Bülent Karabulut, Rüçhan Uslu. Kanser Epidemiyolojisi, Kanserde Palyatif Bakım Nerede? Ne Zaman?. Kanser ve Palyatif Bakım, ed: Meltem Uyar, Rüçhan USLU, Yasemin Kuzeyli Yıldırım, sayfa: 3-15, 2006. Meta Basım, İzmir.
- Burçak Karaca, Rüçhan Uslu. Kanser Hastalığında Palyatif Bakım Hizmetlerinin Organizasyonu. Kanser ve Palyatif Bakım, ed: Meltem Uyar, Rüçhan USLU, Yasemin Kuzeyli Yıldırım, sayfa: 3-15, 2006. Meta Basım, İzmir.
- Rüçhan Uslu, Cem Bilgen, Mustafa Esassolak. Baş ve Boyun Kanserleri. Onkoloji El Kitabı, ed: Adnan Aydıner, Erkan Topuz, sayfa: 81-115, 2006, Turgut Yayıncılık, İstanbul.
- Rüçhan Uslu, Cem Bilgen, Mustafa Esassolak. Ürogenital Kanserler. Onkoloji El Kitabı, ed: Adnan Aydıner, Erkan Topuz, sayfa: 351-381, 2006, Turgut Yayıncılık, İstanbul.
- Rüçhan Uslu. Baş-boyun melanomları kemoterapisi. Baş-Boyun Kanserleri, ed: Kayıhan Engin, Levent Erişen, sayfa: 605-621, 2003
- Rüçhan Uslu, Çağ Çal. İleri evre prostat kanserinde destek tedavisi. Prostat Kanserinde Tedavi, ed: Çağ Çal, İbrahim Cüreklibatur, sayfa: 191-205, 2003. Yelken Basım, İstanbul.
- Erdem Göker, Ulus A. Şanlı, Rüçhan Uslu. Maligniteye bağlı gastrointestinal sistem komplikasyonları. Gastrointestinal Sistem Acil Hastalıkları, ed: Hakan Yüceyar, sayfa: 379-385, 2001.
- 2000, Erdem Göker, Ulus A. Şanlı, Rüçhan Uslu, Mesut Aytimur. Akciğer kanserlerinde kemoterapi. Akciğer kanserleri tanı ve tedavi, ed: Prof. Dr. Ayfer Haydaroğlu sayfa 223-235, Ege Üniversitesi Kanserle Savaş Uygulama ve Araştırma Merkezi Kitabevi.
- Benjamin Bonavida, Hermes Garban, Ruchan Uslu, Hideki Morimoto, and Yoichi Mizutani. Cytokine-drug interactions and the potential for integrated therapies. In: Ovarian Cancer 5, F. Sharp, A.D. Blackett, J.S. Berek, and R.C. Bast, eds. Isis Medical Media, Oxford, UK, pp: 373-384, 1998

Finished Research Projects (14 entries)- 2011, Ege Üniversitesi, No:2011-T-00009, Trabectedin\'in Meme Kanseri Hücre Kültürlerindeki Apoptotik ve Epigenetik Etkilerinin Araştırılması
- 2011, Ege Üniversitesi, No:2011-D-00007, AtT-20 kortikotrop adenom hücre hattında gossipolün (AT-101) hücre proliferasyonu ve hormon sentezi üzerine olan inhibisyon etkisinin moleküler hedeflerinin araştırılması
- 2011, Ege Üniversitesi, No:2011-D-00006, AtT-20 pitüiter kortikotrop adenom hücre hattında gossipol ve retinoik asidin apopitoz, hormon salınımı ve sitokin profili üzerine sinerjistik etkisi
- Ege Üniversitesi, Metastatik Kolorektal Adenokarsinomalı Hastalarda Kapesitabin, Oksaliplatin ve Bevasizumab ile Kombine Başlangıç Tedavisi Sonrasında, İdame Tedavisi Olarak Bevasizumab ve Kepasitabin’in Etkililik ve Güvenliliğinin Değerlendirildiği Randomize Açık Faz III Ulusal Çalışma, ML21440, Proje Sorumlusu, 2007.
- Ege Üniversitesi, ErbB2'yi Aşırı Eksprese Eden Enflamatuvar Meme Kanserinde Pazopanib İle Lapatinibin Kombinasyonu İle Lapatinib Monoterapisinin Karşılaştırıldığı Randomize, Çok Merkezli, Faz III Çalışma, VEG108838, Proje Sorumlusu, 2007.
- Ege Üniversitesi, İlerlemiş Hastalık için Daha Önce Kemoterapiyle Tedavi Edilmemiş Metastatik veya Lokal olarak Tekrarlayan Mide Kanseri Hastalarında Sisplatin (CDDP) ve Dosetaksel Kombinasyonu veya 5-Florourasil (5-FU) ve CDDP ve Dosetaksel ile CDDP ve 5-FU Kombinasyonunu Karşılaştıran Açık, Randomize, Çok Merkezli Faz II/III Çalışması, RP 56976-V-325, Araştırıcı, 2002.
- Ege Üniversitesi, HER 2 Ekspresyonu Aşırı Yüksek Metastatik Meme Kanseri Olan, Post Menapozal, Hormon Reseptörü Pozitif (ER + ve/veya PR +) Hastalara Birinci Basamak ve İkinci Basamak Tedavi Olarak Uygulanan Herceptin (Trastuzumab) ve Oral Aromataz İnhibitörü Arimidex (Anastrozol) Kombinasyonunun Etkinlik ve Güvenilirliğinin Tek Başına Uygulanan Arimidex ile Karşılaştıran Randomize, Kontrollü, Açık Çalışma, BO16216D/H2223g, Proje Sorumlusu, 2002.
- Ege Üniversitesi, Daha Önce Bir Kemoterapi Rejimi Almış Metastatik veya Lokal Nüks Yapmış Meme Kanseri Olan Kadınlarda Dosetaksel + LY335979 Tedavisini Karşılaştıran Bir Randomize, Plasebo Kontrollü, Çift Kör Faz 2 Çalışması, B3T-MC-JTAJ, Araştırıcı, 2001.
- Ege Üniversitesi, Evre III Kolon Kanserinde Adjuvant Tedavi Olarak Campto+İnfüzyonel 5 FU/FA Kombinasyon Şeması İle Sadece İnfüzyonel 5-FU/FA Şemasının Karşılaştırıldığı Açık İşaretli, Çok Merkezli, Randomize, FAZ III Çalışma, RP 64174A V-307, Araştırıcı, 2000.
- Ege Üniversitesi, Daha Önce Kemoterapi Almamış Metastatik Veya Rekürran Mide Kanseri Hastalarında CPT-11’in Sisplatin (CDDP) İle Kombinasyonu veya CPT-11’in 5-FU İle Kombinasyonunun, CDDP’nin 5-FU İle Kombinasyonuyla Karşılaştırması Yapılan Açık, Randomize, Çok Merkezli, Faz II/III Çalışması, RP64174A V-306, Araştırıcı, 2000.
- Ege Üniversitesi, Glioblastoma Multiforme Ve Anaplastik Astrositoma Relapsı Bulunan Hastaların Tedavisinde Temodal (SCH 52365) Kullanımı ile İlgili Bir Faz III Çalışma, M96-087, Araştırıcı, 2000.
- Ege Üniversitesi, Over Kanserinde Paclitaxel Tedavisi ve IL-8, Ege Üniversitesi Araştırma Projesi, Proje Yürütücüsü, 1999.
- Ege Üniversitesi, Metastatik Meme Kanserinde Ilk Sıra Tedavi Olarak Gemsitabin / Epirubisin / Paklitaksel ( GET ) Kombinasyonu Ile 5 – Flurourasil / Epirubisin Siklofosfamid ( FEC ) Kombinasyonunu Karşılaştıran Faz III Çalışması, Araştırıcı, 1999.
- Ege Üniversitesi, Avrupa Adjuvan Kolon Kanseri çalışması, standart leukovorin ile modüle edilmiş 5-FU Bolusuna göre Tomudex in değeri / PETACC-1 1694IL/0022, Araştırıcı,1998.
Memberships of Professional Associations (12 entries)- American Association for Cancer Research (AACR)
- American Society of Clinical Oncology (ASCO)
- Anadolu Tıbbi Onkoloji Derneği
- Ege Yüksek Öğretim Derneği
- European Society of Medical Oncology (ESMO)
- Meme Hastalıkları Derneği
- Palyatif Bakım Derneği
- Tıbbi Onkoloji Derneği
- Türkiye AIDS’: le Savaş Derneği
- Türkiye Hematoloji Derneği
- Türkiye Hepatit’:le Savaş Derneği
- Türkiye İmmünoloji Derneği
Granted Scholarships (1 entries)- 1993, Yüksek Öğretim Kurumu Yurt Dışı Eğitim Bursu
Granted Prizes (13 entries)- 2012, 4. Tıbbi Onkoloji Kongresi 21-25 Mart 2012, Antalya “Poster Ödülü”
- 2012, XI. Ulusal Histoloji ve Embryoloji Kongresi, 16-19 Mayıs 2012, Denizli “Bilimsel Yayın Dalında Üçüncülük Ödülü”.
- 2010, En İyi Bildiri Ödülü, 7. Ulusal Tıbbi Onkoloji Kongresi, ANTALYA
- 2009, Prof Dr Lale Atahan Onkolojide Yenilikler Ödülü, XVI. Ege Onkoloji Günleri, İZMİR
- 2009, En İyi Bildiri Ödülü, 6. Ulusal Tıbbi Onkoloji Kongresi, ANTALYA
- 2008, Poster Bildirisi İkincilik Ödülü, II. Multidisipliner Kanser Araştırma Sempozyumu, BURSA
- 2008, En İyi Çalışma Ödülü, 5. Ulusal Tıbbi Onkoloji Kongresi, ANTALYA
- 2006, Sözlü Bildiri Ödülü, I. Tıbbi Onkoloji Kongresi, Antalya.
- 1999, Roche Tıp Araştırma Ödülü (Birinci)-Onkoloji
- 1999, En iyi sözel sunu ödülü, 13. Ulusal Kanser Kongresi, ANTALYA
- 1999, En iyi poster ödülü, 13. Ulusal Kanser Kongresi, ANTALYA
- 1998, En iyi poster ödülü, 26. Ulusal Hematoloji Kongresi, ANKARA
- 1995, Outstanding Poster Ödülü, 86th Annual Meeting of the American Association for Cancer Research,Canada
Student's Completed Thesis (7 entries)- Doktora, 2012, Uzm. Dr. Gülcan Bulut, Tez Danışmanı: Prof. Dr. Rüçhan Uslu. AT-101/ Trastuzumab Kombinasyonunun Meme Kanseri Hücre Hatlarındaki Etkilerinin Araştırılması, 2012.
- Doktora, 2011, Dr. Cenk Gökalp, Tez Danışmanı: Prof. Dr. Rüçhan Uslu. Prostat Kanseri Hücre Hatlarında Zoledronik Asit Uygulamasının Sitotoksik ve Anti-Anjiogenik Etkilerinin Araştırılması. İç Hastalıkları Uzmanlık Tezi İzmir, 2011.
- Doktora, 2011, Dr. Hakan Çamyar, Tez Danışmanı: Prof. Dr. Rüçhan Uslu. MCF-7 ve MDA-231 Meme Kanseri Hücre Hatlarında Docetaxel-Octreotid Kombinasyon Tedavisinin Olası Sinerjistik Sitotoksik/Apoptotik Etkilerinin Araştırılması. İç Hastalıkları Uzma...
- Doktora, 2011, Uzm. Dr. Yalçın Çırak, Tez Danışmanı: Prof. Dr. Rüçhan Uslu. Prostat Kanseri Hücre Hatlarında Protein Fosfataz İnhibitörleri ve Zoledronik Asit Uygulamasının Additif/Sinerjistik Antitümoral Etkileri. Onkoloji Uzmanlık Tezi, İzmir, 2...
- Doktora, 2007, Dr. Ercüment Cengiz, Tez Danışmanı: Doç. Dr. Rüçhan Uslu. Prostat Kanseri Hücre Hatlarında Dosetaksel ve Zoledronik Asit Uygulanmasının Additif/Sinerjistik Antitümoral Etkileri. Onkoloji Uzmanlık Tezi, İzmir, 2007.
- Doktora, 2007, Dr. Özcan Hüdaverdi, Tez Danışmanı: Doç. Dr. Rüçhan Uslu. Lokal İleri Evre Nazofarinks Kanseri Tedavisinde c-erb B-2 ve topoizomeraz 2 alfa’nın Prediktif Değeri. İç Hastalıkları Uzmanlık Tezi İzmir, 2007.
- Doktora, 2004, Dr. Serkan Ocakçı, Tez Danışmanı: Doç. Dr. Rüçhan Uslu. Meme Kanserinde Adjuvan Ardışık Adriablastin(A) Ve Siklofosfamid-5 Flourourasil-Metotreksat(CMF) Tedavisinin Etkinliği. İç Hastalıkları Uzmanlık Tezi, İzmir, 2004.